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SUMMARY.
Denture stomatitis is characterised by erythema and oedema of the palatal mucosa 
beneath an upper denture. It is common, affecting approximately 50% of denture 
wearers. The recurrence rate is high and the repeated failure of current methods 
of treatment of denture stomatitis results in the prescribing of repeated courses of 
antifungal medication.
The aims of this study were to evaluate the use of itraconazole in the 
treatment of denture stomatitis and to determine by molecular typing of C. 
albicans species isolated before and after treatment whether there had been a 
recurrence of infection with the same strain, selection of particular strains or 
infection with new strains of C. albicans. Forty patients with long-standing 
Candida-associated denture stomatitis were enrolled in a single blind clinical trial 
to compare the new cyclodextrin solution of itraconazole and itraconazole 
capsules in the management of denture stomatitis. The trial design also 
encompassed determination of the safety of itraconazole, itraconazole sensitivity 
of yeasts isolated from the mouths of patients before and after treatment and 
measurement of itraconazole levels achieved in blood and saliva. Strain 
differentiation of C. albicans isolates was achieved by extracting genomic DNA 
from selected stored yeast isolates. The DNA was digested with the restriction 
enzyme EcoRl then hybridised with the C. albicans -specific 27A probe.
A pilot study was conducted to evaluate the use of an electro-optical 
instrument, the Erythema meter, as a means of objectively measuring erythema of 
the palatal mucosa. A series of non-clinical and clinical investigations were carried 
out. Erythema meter readings were taken from 40 patients with healthy palatal 
mucosa, 20 denture wearers and 20 non-denture wearers. Readings were also 
taken from 20 denture stomatitis patients who were then enrolled in a pilot clinical 
trial comparing fluconazole and itraconazole capsules in the management of 
denture stomatitis.
As a result of the preliminary investigations the Erythema meter was 
found to be a sensitive and reproducible means of measuring palatal erythema. It 
was quick and easy to use and was well tolerated by patients. Fluconazole and
itraconazole capsules were found to have similar efficacy in the management of 
denture stomatitis.
In the main clinical trial patients were randomly assigned to take either the 
cyclodextrin solution of itraconazole or itraconazole capsules at a dose of 1 OOmg 
twice daily for 15 days. Of the 40 patients enrolled in the clinical trial, two 
patients from each treatment group failed to complete the course of medication. 
Results from the remaining patients indicated that both the cyclodextrin solution 
of itraconazole and itraconazole capsules showed similar efficacy in the 
management of denture stomatitis, in terms of reduction in erythema and 
mycological response. However, a high incidence of gastro-intestinal side-effects 
was reported by patients in the cyclodextrin group suggesting that, since the 
response to treatment was similar with both preparations, the itraconazole 
capsules would be preferred to the cyclodextrin solution of itraconazole for the 
treatment of denture stomatitis. The multifactorial aetiology of denture stomatitis 
was highlighted by the results of the trial leading to the conclusions that 
maintenance of good denture hygiene, the provision of new dentures and the 
cessation of smoking are all important factors in ensuring a long-term resolution 
of the condition. Denture stomatitis patients should also be routinely screened for 
underlying haematinic deficiencies and diabetes mellitus.
The molecular typing of C. albicans revealed that the strain of C. albicans 
present six months after treatment commenced is likely to be the same as the 
strain isolated at baseline in any given patient. This implies that recurrence of 
denture stomatitis is due to re-colonisation by the original infecting strain, rather 
than re-infection with a different strain. A wide variety of genotypes of 
C. albicans were isolated in this study, suggesting that no one particular virulent 
strain of C. albicans is associated with denture stomatitis.
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CHAPTER ONE
INTRODUCTION AND REVIEW OF THE
LITERATURE
1
■1.1. GENERAL INTRODUCTION.
Cawi/ufa-associated denture stomatitis is one of several clinical types of candidal 
infection affecting the oral cavity (Table 1.1). In many cases of oral candidosis 
there is an underlying predisposing factor, which may be local or systemic 
(Samaranayake, 1990). Management of these infections requires treatment of the 
underlying factor in addition to that of the infection itself Many of the antifungal 
drugs used in the past have been toxic agents which could only be prescribed for 
topical application. These included nystatin and amphotericin B (Budtz-Jorgensen, 
1990b). In recent years the new triazole antifungals, notably fluconazole and 
itraconazole have become available (Odds, 1993a; Karyotakis and Anaissie,
1994). These drugs can be prescribed for systemic use and compliance is far 
better. They have been used widely and successfully for managing oral candidosis 
in immunocompromised patients, for example those with HIV infection (Just- 
Niibling et al., 1991; Blatchford, 1990) or bone marrow transplant recipients 
(Goodman et al., 1992). However, their role in the management of oral candidosis 
in immunocompetent hosts has not been fully researched.
In this thesis, the role of fluconazole and itraconazole in the overall 
management of patients suffering from Cam/rdor-associated denture stomatitis has 
been examined.
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Table 1.1.
Classification of oral candidosis.
Pseudomembranous 
Erythematous 
Hyperplastic 
Mucocutaneous 
Ctfra/r'tffa-associated lesions: 
Denture stomatitis 
Angular cheilitis 
Median rhomboid glossitis
(after Samaranayake, 1990; Scully et al., 1995)
1.2. THE BIOLOGY OF CANDIDA SPECIES.
1.2.1. Taxonomy.
Fungi are eukaryotes and have a membrane surrounding their nucleus. Their cells 
are much larger than bacteria and their molecular processes closely resemble those 
of plants and animals. However, unlike mammalian cells, fungi possess a rigid cell 
wall surrounding their plasma membrane. Fungi that exist predominantly in the 
form of independent single cells are usually called yeasts. Although most fungi are 
capable of sexual reproduction, some species are not known to mate sexually and 
are called deuteromycetes or hyphomycetes (previously fungi imperfecti) (Odds, 
1996). The genus Candida falls into this class. It comprises more than 150 species 
(Odds, 1988). C. albicans, C. tropicalis and C. glabrata are the species most 
frequently isolated from medical specimens. The other pathogenic Candida 
species are C. parapsilosis, C. stellatoidea, C. guillermondii, C. krusei and C. 
pseudotropicalis. C. stellatoidea is differentiated from C. albicans by its inability 
to assimilate sucrose. The ability to form pseudohyphae is a distinguishing feature 
of Candida species within the class of Deuteromycetes. C. glabrata is the only 
Candida species incapable of this (Shepherd, 1990).
1.2.2. Fungal Structure and Growth.
Typically, fungi grow as either ovoid yeast cells or as thin filamentous hyphal 
elements. A mass of hyphal filaments is called a mycelium. Yeasts reproduce by
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budding. Different morphological forms of C. albicans, including budding yeast 
cells, pseudohyphae, true hyphae and chlamydospores, are exhibited under 
different environmental conditions. For example, yeast cell growth is favoured at 
temperatures below 33°C. Bud formation occurs at the polar region of these 
ovoid cells distal to the birth scar. At higher temperatures and neutral pH mycelial 
growth is favoured and the conversion of a yeast cell to a hyphal cell occurs via a 
germ tube. The germ tube develops into a true hyphal cell when the first septum is 
formed l-2pm from the mother cell. Pseudohyphae are long branching filaments 
of elongated yeast cells formed by polar budding and constricted at the site of 
emergence with a septum. Candida produce pseudohyphae in both in vitro and in 
vivo conditions (Shepherd, 1990). Round, thick walled chlamydospores develop 
from hyphae under certain conditions. Chlamydospore formation is a property 
peculiar to C. albicans and to very rare isolates of C. tropicalis and C. 
stellatoidea (Silverman et al., 1990). Their function is uncertain.
The various components of the cell wall of C. albicans play an important 
role in the pathogenesis and serodiagnosis of the organism (Odds, 1988). 
Transmission electron microscopy studies have shown the wall to be composed of 
at least five distinct layers, made up of mannoproteins, (3 glucans and chitin. These 
layers alter during germ tube formation and growth. Mannoprotein forms the 
outermost layer but is also distributed throughout the wall. This forms the major 
antigenic component of the wall and two serotypes of C. albicans can be 
distinguished. In addition to the outermost mannoprotein layer, there is a fibrillar 
layer contained within a fuzzy coat. This layer is believed to be important in the 
overall virulence of C. albicans by affecting adherence and phagocytosis. P-
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glucans form the major structural elements of the cell wall. Chitin is located 
primarily in the bud scars in C. albicans, but there is also a layer close to the 
plasma membrane and chitin is also distributed all over the cell surface. Mycelial 
cells contain three times more chitin than yeast cells. Receptors on the C. albicans 
cell surface which bind complement fragments consequently enhance the 
pathogenicity of the organism, because the phagocytic uptake of the yeast by 
human polymorphonuclear leucocytes is impaired (Shepherd, 1990). Other 
pathogenic Candida species have layered cell wall structures and compositions 
resembling that of C. albicans (Odds, 1988).
The majority of yeasts will grow on simple media containing a source of 
carbon (glucose) and nitrogen (either ammonium or nitrate). Biotin is an 
additional growth factor required for C. albicans. Candida species can grow over 
the temperature range 20-40°C and within the pH range 2-8 (Shepherd, 1990).
1.2.3. Oral Carriage of Candida species.
The oral prevalence of C. albicans and other Candida species in healthy adults 
ranges from 3% to 47% (Samaranayake et al., 1986a). However, these figures are 
dependent on isolation techniques and time of sampling (Cumming et al., 1990; 
Olsen and Stenderup, 1990). C. albicans is the most dominant species, followed 
by C. tropicalis, C. glabrata, C. parapsilosis and C. krusei (Stenderup, 1990). 
Although C. albicans mainly colonises the dorsum of the tongue, the fitting 
surface of maxillary dentures in the edentulous and the gingival crevice in the
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dentate are likely to be the primary reservoirs for oral yeasts (Cumming et al., 
1990).
Candida carriage is more common in females than males (Scully et al.,
1995). A significant increase in the prevalence of oral yeasts has been found in the 
warmer summer months (Gergely and Uri, 1966). Candida carriage is also subject 
to diurnal variation, counts being highest in the morning. When dentures, which 
tend to act as a reservoir for Candida, are worn overnight, the early morning 
Candida count is high whereas if dentures are not worn at night, the early 
morning Candida count will be the lowest (Scully et al., 1995).
Several other factors have been reported to influence the establishment of 
Candida species in the oral environment (Arendorf and Walker, 1980; 
Samaranayake and MacFarlane, 1981b; Oliver and Shillitoe, 1984). For example, 
acidic saliva or a reduction in salivary flow, nutritional factors such as iron, folate 
and Vitamin B12 deficiencies, smoking and alterations to the normal oral flora by 
antibiotic therapy for example, may lead to increases in the carriage of C. albicans 
(Samaranayake, 1990). Non-secretion of blood group antigens in saliva and 
people of blood group O are more likely to be carriers (Mason et al., 1988). 
Hospitalisation is also associated with an increase in carrier rates (Cumming et al., 
1990).
1.2.4. Culture Methods.
Pathogenic fungi can grow well on many of the media used for the isolation of 
bacteria from clinical specimens. However, they may grow slowly and without
distinguishing features and so media which specifically promote the growth of 
fungi have been developed (Mackenzie, 1996). The most commonly used medium 
for primary isolation of pathogenic Candida species is Sabouraud’s dextrose agar 
or malt extract agar. Positive cultures will show cream-coloured, smooth or 
rough, convex colonies after 48 hours incubation at 37°C under aerobic 
conditions. C. albicans grows very poorly under anaerobic conditions, appearing 
as characteristic star-shaped colonies. Although coliforms can sometimes grow on 
Sabouraud’s agar, the growth of many commensal oral bacteria is suppressed by 
the pH of this medium (pH 6). Bacterial growth can be further suppressed by the 
addition of antibiotics such as chloramphenicol, penicillin, streptomycin and 
ciprofloxacin (Silverman et al., 1990). Whilst Sabouraud’s agar permits the 
isolation of several different genera, the colonies are very similar in appearance 
and their subsequent investigation requires considerable investigative time in the 
laboratory (Beighton et al., 1995).
Several media which allow differential isolation of yeast species through 
visual differences in colouration have been developed (Nickerson, 1953; 1954; 
Pagano et al., 1958; Costa and Branco, 1964; Odds and Bernaerts, 1994). For 
example, Nickerson’s medium (1953; 1954) relies on the reduction of complex 
bismuth salts to give light- and dark- coloured colonies. However, it does not 
adequately differentiate yeast species from each other or from bacteria (Schnell, 
1982).
C. albicans isolates give pale-coloured colonies and other yeast species 
appear with varying degrees of pink, red and mauve colouration on Pagano-Levin 
medium. This is the result of the reduction of triphenyltetrazolium chloride
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incorporated into Sabouraud’s agar (Pagano et al., 1958). Pagano-Levin has been 
found to be as sensitive as Sabouraud’s agar in detecting yeast isolates but was 
superior to the latter in detecting multiple yeast species within a single sample 
(Yamane and Saitoh, 1985; Samaranayake et al., 1987). In practice it has been 
found to yield a high rate of false-positive and false-negative results when used to 
differentiate species (Sinski et al., 1975). Furthermore, high concentrations of 
tetrazolium chloride may inhibit C. albicans and C. glabrata, and so it has been 
suggested that both Pagano-Levin and Sabouraud’s agar be used for primary 
isolation and enumeration of yeasts (Silverman et al., 1990).
A phosphomolybdate agar on which C. albicans appears green and other 
species give white or blue colonies was devised by Costa and Branco (1964). 
Bump and Kuntz (1968) confirmed the efficacy of this medium.
CHROMagar® Candida is a chromogenic medium for presumptive 
identification of C. albicans, C. krusei and C. tropicalis and the differentiation of 
these species from other yeasts on the basis of strongly contrasted colony colours 
produced by reactions of species-specific enzymes with a proprietary chromogenic 
mix (Odds and Bernaerts, 1994). Studies have indicated that the recovery of 
different species on Sabouraud’s dextrose agar and CHROMagar® Candida plates 
is not significantly different (Odds and Bernaerts, 1994). C. albicans is the only 
species to give a green colour when grown on this medium and C. tropicalis gives 
dark grey colonies with a brown-purple halo formation in the agar (Odds and 
Bernaerts, 1994; Freydiere and Gille, 1994; Beighton et al., 1995). However, C. 
glabrata was found to vary in colour from purple to pale pink which may lead to 
confusion with C. parapsilosis (Beighton et al., 1995). This difficulty with the
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correct identification of C. glabrata was also noted by Houang et al. (1997) who 
used CHROMagar® Candida to identify yeasts from a series of genital specimens. 
These workers found C. glabrata colonies to vary in colour from white or yellow 
through to different hues of pink or brown, although the most common were 
glossy pink-purple colonies with a paler edge. In contrast, Pfaller et al. (1996) 
reported satisfactory identification of C. glabrata by CHROMagar® Candida 
when they found nine out of ten stock isolates of this species to show dark pink 
colonies with pale edges. CHROMagar® Candida is capable of detecting mixed 
cultures (Pfaller et al., 1996) and retards the growth of most bacteria (Odds and 
Bernaert, 1994) but cannot be used satisfactorily if stored at 4°C for more than 14 
days (Beighton et al., 1995). Isolates grow well when subcultured from 
CHROMagar® to Sabouraud’s agar, indicating that viability is not lost by growth 
in the presence of the chromophore contained in this medium (Odds and Bernaert, 
1994).
1.2.5. Identification Methods.
The production of hyphal outgrowths (germ tubes) from blastospores when 
incubated at 37°C in serum for 2-3 hours is a rapid method of identifying C. 
albicans (Odds, 1988). The formation of germ tubes is influenced by a wide range 
of factors such as temperature, inoculum size, composition of the medium and the 
strain of Candida (Mackenzie, 1962). Although other media have been suggested, 
serum is the medium of choice for germ tube formation (Silverman et al., 1990). 
Rarely, germ tube tests can give inaccurate results (Odds, 1988). For example, 
there have been reports of C. albicans isolates not forming germ tubes whilst
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some C. tropicalis and C. stellatoidea isolates do (Silverman et al., 1990). 
Additional physiological tests for proper speciation should be carried out on any 
isolates with atypical morphology which form germ tubes in serum (Odds, 1988).
Chlamydospore formation is a property peculiar to C. albicans and to very 
rare isolates of C. tropicalis and C. stellatoidea. Although a variety of media has 
been used to induce chlamydospore formation in C. albicans, the most popular is 
corn meal Tween 80 agar. After 1-2 days at room temperature chlamydospore 
growth could be observed by direct microscopy in regions with low oxygen 
tension (Silverman et al., 1990).
Final and certain identification of a yeast isolate to species level requires a 
knowledge of its physiological properties (Odds, 1988). Hence, carbon and 
nitrogen yeast assimilation tests are used to assess the ability of a particular yeast 
isolate to assimilate a specific carbohydrate as its sole carbon source. 
Auxanography is one of the main methods by which assimilation properties may 
be determined. Sugar solutions, contained in wells cut in a gel or impregnated 
onto paper discs, diffuse into the surrounding gel which contains the necessary 
nutrients, with the exception of carbon. If the well or disc contains a sugar which 
the yeast species can assimilate a circular zone of growth around the wells or disc 
will be observed. Alternatively, another method involves observation of the 
growth of Candida in tubes containing a liquid basal medium (yeast nitrogen 
base) to which different carbon sources are added. This method has higher 
sensitivity and specificity than auxanography and modifications of it are used in 
rapid commercial systems for the identification of Candida species. These 
methods are also used in tests for assimilation of nitrogen sources, but the basal
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media must be free of nitrogen and include glucose as a carbon source. 
Carbohydrate fermentation is a less sensitive and less dependable test for 
differentiating Catidida species than the carbohydrate assimilation test (Silverman 
etal., 1990).
Commercial systems for yeast identification, offering a high accuracy of 
identification in comparison to traditional methods, have enhanced the speed and 
ease of yeast identification in routine clinical laboratories (Odds, 1988). Most of 
these commercial kits rely mainly on physiological tests but identifications based 
on physiological evidence alone cannot be assumed to be correct and morphology 
testing should remain an integral part of any identification process (Odds, 1988).
The API 20C yeast identification system (bioMerieux, Marcy FEtoile, 
France) is faster and provides more reliable results than the classic identification 
methods (Buesching et al., 1979; Land etal., 1979). It is the most popular and 
widely used of the commercial kits (Odds, 1988). However, as the API 20C 
system is time-consuming to set up and interpretation of the results may be 
difficult, the Auxacolour system (Sanofi Diagnostics Pasteur, Marnes-la- 
Coquette, France) has been suggested as a quicker, simpler alternative for the 
routine identification of germ tube negative isolates (Davey et al., 1995). Other 
systems recommended as alternatives to API 20C include ATB 32C (bioMerieux, 
Spain) and AMS-YBC (Vitek System, bioMerieux, Spain) (Guttierez etal.,
1994).
Candida species have been differentiated according to their heat-sensitive 
antigenic components or by the use of agglutination tests with species-specific
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antisera to distinguish C. krusei, C. guillermondii and C. pseudotropicalis 
(Silverman et al., 1990).
1.2.6. Typing Methods.
C. albicans strains can be grouped, according to the antigenic characteristics of 
their cell walls, into one of two serotypes, A and B, by simple slide agglutination. 
Although commercial versions of this test have been developed, it offers poor 
discrimination and has been surpassed by other simple and superior typing 
methods (Silverman et al., 1990).
Biotyping enables C. albicans strains to be typed according to their 
different biochemical characteristics (Silverman et al., 1990). The API ZYM 
system has been shown to be both a rapid and reproducible method of biotyping. 
The API 20 C carbon assimilation profile has also been used for the successful 
biotyping of C. albicans strains. However, a highly discriminatory system has 
been developed using a combination biotyping system comprising the API ZYM, 
API 20C system and a plate test for boric acid (Silverman et al., 1990).
Other typing methods include resistogram typing, immunoblotting, colony 
morphotyping and electrophoretic karyotyping (Silverman et al., 1990).
It has been suggested that DNA typing is one of the methods with the 
greatest potential for discrimination (Merz,1990). DNA fingerprinting was first 
applied to yeasts by Scherer and Stevens (1987) who examined 17 isolates of C. 
albicans, 10 C. tropicalis, 7 C. parapsilosis, 1 C. krusei and 1 C.
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pseudotropicalis. Methods of typing C. albicans isolated from infected patients 
are useful in determining whether a new episode of the disease is caused by 
reinfection or relapse, whether commensally carried strains are the source of 
infection and whether there are particular strains adapted to particular body niches 
(Magee et al., 1992). Mathaba et al. (1995) determined the genotypic 
relationships of individual C. albicans isolates by hybridisation of a C. albicans- 
specific moderately repetitive sequence, 27A, to iscoRI-digested C. albicans 
chromosomal DNA. They concluded that denture stomatitis was due to the 
overgrowth of commensal strains in the oral cavities of patients and that no one 
particular virulent strain of C. albicans is associated with denture stomatitis. 
Furthermore, in five of the 18 patients studied, C. albicans isolates were obtained 
from a secondary infection which occurred after antifungal therapy. It was 
concluded that this was due either to the re-emergence of the original infecting 
strain or the emergence of a new strain from an exogenous source, or both. The 
type of antifungal therapy used in this study was not specified.
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1.3. DENTURE STOMATITIS.
1.3.1. Historical aspects.
One of the first to describe the condition now recognised as denture stomatitis 
was McKenzie in 1918. He noted the red and swollen mucous membrane of 
patients who wore a plate on the roof of the mouth. He also considered that this 
was a form of infection which was very common among denture wearers where 
the utmost cleanliness was not observed.
The term ‘denture sore mouth’ was first used by Cahn in 1936, who was 
also probably the first to consider that the condition was associated with a yeast 
infection. Cawson (1963) suggested that ‘denture sore mouth’ was a misnomer as 
the degree of soreness complained of by patients was variable and the severity of 
symptoms was not related to the degree of inflammation. In 1965 Cawson re­
iterated that despite the inflammatory changes, soreness is usually absent and 
because of this suggested ‘denture stomatitis’ as a better alternative. Lehner 
(1965) went one stage further and introduced the term chronic atrophic 
candidiasis. This he described as being a more clinicopathologically precise term, 
taking its place among the other varieties of oral candidiasis but also, he argued, 
having the advantage of including candidal angular cheilitis with or without the 
palatal involvement. However, Holmstrup and Axell (1990) proposed that the 
value of using the term ‘atrophic’ to describe red areas was limited, as redness 
may be caused not only by reduced epithelial thickness (ie atrophy) but also by 
increased vascularity (ie. erythema). Nairn (1975) acknowledged the various
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synonyms describing inflammation beneath a denture and suggested denture- 
related candidiasis as an appropriate term. When Candida species are involved, 
the more common terms "Candida-associated denture stomatitis’ (Budtz- 
Jorgensen et a l 1988), ‘denture-induced candidosis’ or ‘chronic erythematous 
candidosis’ (Samaranayake and Yaacob, 1990) are used. A further variation was 
introduced by Walker et al. (1981) when they referred to ‘denture -induced 
stomatitis’ in their study to evaluate two agents in the treatment of this condition. 
Other terms of historical interest include ‘chronic denture palatitis’ (Pryor 1936), 
‘stomatitis venenata’ (Fisher 1956), ‘rubber sore mouth’ (Lyon and Chick, 1957), 
‘denture sore mouth syndrome’ and ‘stomatitis prothetica’ or ‘stomatopathia 
prothetica’ ( Nater et al., 1978).
The concept that denture stomatitis is multifactorial in aetiology was 
becoming apparent even from the earliest papers (Cahn,1936; Bartels, 1937; Lyon 
and Chick, 1957). Early treatment regimens involved leaving dentures out at night 
and soaking them in a mild hypochlorite solution (Cahn, 1936). The use of 
therapeutic agents such as Gentian violet (Cahn, 1936) and sodium-caprylate jelly 
(Lyon and Chick, 1957) has also been recorded.
1.3.2. Classification and Clinical Features.
1.3.2.1. Classification.
Classification of denture stomatitis has generally been based on the clinical 
appearance of the inflamed mucosa beneath maxillary dentures. The most widely
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used classification is that of Newton (1962) who described three forms of the 
disease:
1) pinpoint hyperaemic foci
2) diffuse hyperaemia of the denture-supporting tissues
3) papillary hyperplasia.
The same changes were described in a slightly different way by Budtz- 
Jorgensen and Bertram (1970a):
1) simple localised inflammation
2) simple diffuse (generalised) inflammation
3) granular inflammation (papillary hyperplasia).
In a one year follow-up study, Bergendal (1982) concentrated only on the 
diffuse and papillary varieties of denture stomatitis respectively, referring to these
as:
1) atrophic denture stomatitis
2) hyperplastic denture stomatitis.
I.3.2.2. Clinical Features.
Denture stomatitis (Fig. 1.1) is characterised by chronic erythema and oedema of 
part or all of the palatal mucosa that comes into contact with a denture (Budtz-
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Figure 1.1. Denture stomatitis.
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Jorgensen, 1990a). Most authors agree that denture stomatitis affects only the 
palatal mucosa beneath an upper denture (Budtz- Jorgensen and Bertram, 1970a; 
Nairn, 1975) although some state that the condition does, on rare occasions, 
occur beneath the lower denture (Newton, 1962; Ritchie et al., 1969). Neill 
(1965) observed inflammation of the lower denture-bearing mucosa beneath 
partial lower dentures only and stated that it was very rare to see the tissues 
beneath a complete lower denture affected by this condition.
Arendorf and Walker (1987) found that the condition is usually 
symptomless although severe aching and burning pain has been noted in patients 
with reduced salivary secretion, for example those with Sjogren’s syndrome or 
advanced cancer (Pollack et al., 1964). Other oral complaints that have been 
related to denture stomatitis include mucosal bleeding and swelling, halitosis or an 
unpleasant taste or dryness in the mouth. It has been estimated that between 28% 
and 70% of patients with denture stomatitis have oral complaints (Ritchie et 
al., 1969; Budtz-Jorgensen and Bertram, 1970a; Kotilainen, 1972; Budtz- 
Jorgensen, 1974; Olsen, 1975a; Dorey etal., 1985).
Denture stomatitis has a frequent association with angular cheilitis 
(Fig. 1.2) which is present in 33-82.6% of patients with denture stomatitis (Chick, 
1962; Cawson 1965; Makila, 1969; Ritchie et al., 1969; Davenport, 1970; 
Russotto, 1980; Bergendal and Isacsson, 1983). Although Candida-associated 
denture stomatitis has been proposed as an important aetiological factor of 
angular cheilitis (Cawson, 1963; Nairn, 1975; Rose, 1968), the condition is also 
found in dentate, non denture-wearing patients (Ohman et al., 1986). It is 
generally accepted that angular cheilitis has a multifactorial aetiology (Davenport,
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Figure 1.2. Angular cheilitis.
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1970) which includes nutritional deficiencies, such as iron deficiency anaemia 
(Rose, 1968; Makila, 1969; Burton and Thomson, 1972; Murphy and Bissada, 
1979), vitamin B12 deficiency (Makila, 1969) or folic acid deficiency (Rose,
1971). In a study by Ohman et al. (1986), the aetiological role of lower serum 
iron and transferrin could not be confirmed. Shuttleworth and Gibbs (1960) and 
Cawson (1963) emphasised the aetiological importance of microbial infection, 
particularly with C. albicans, which is frequently present in angular cheilitis 
lesions. MacFarlane and Helnarska (1976) and Dahlen etal. (1982) pointed out 
the association of organisms other than yeasts, namely S. aureus and y3 
haemolytic streptococci. The roles of S. aureus and C. albicans in angular 
cheilitis are not clear, although Cawson (1963) and Nairn (1975) found that 
lesions heal rapidly after antifungal therapy. Furthermore, they suggested that 
topical application of antifungals to the angles of the mouth is unnecessary if 
denture stomatitis is adequately treated. Prior to this, Lyon and Chick (1957) had 
already stated that angular cheilitis resolved when the associated denture sore 
mouth was successfully treated. The association of angular cheilitis with poorly 
designed or faulty dentures, in particular a loss of the vertical dimension, has been 
reported by some workers (Ritchie and Fletcher, 1973). However, other studies 
(Cawson, 1963; Turrell, 1968; Ohman et al., 1986) suggest that neither loss of 
the vertical dimension nor the condition of the dentures seem to be significant 
factors in the aetiology of angular cheilitis.
Other pathology occasionally associated with denture stomatitis includes 
median rhomboid glossitis (Arendorf and Walker, 1984), pseudomembranous 
candidosis and chronic hyperplastic candidosis (Bergendal and Isacsson, 1983).
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1.3.3. Epidemiology.
1.3.3.1. Prevalence.
The prevalence of denture stomatitis depends on the population examined and the 
diagnostic criteria used (MacEntee, 1985). As a result, the prevalence of denture 
stomatitis has been reported to vary from 9% to 97% (Budtz- Jorgensen et al., 
1975; Manderson and Ettinger, 1975; Smith and Sheiham, 1979; MacEntee,
1985).
In studies using randomised samples, chosen to be representative of the 
elderly population as a whole ( Love et al., 1967; Budtz-Jorgensen et al., 1975; 
Smith and Sheiham, 1979; Mikkonen et al., 1984; Ambjornsen, 1985; Hand and 
Whitehill, 1986), the prevalence of denture stomatitis ranges from 16.3% to 65%.
Studies in the U.K. by Hoad-Reddick et a/.(1987) and Tobias (1988) 
found the prevalence of denture stomatitis to be relatively lower, with values of 
7.3% and 9% respectively. In these studies, the samples comprised the 
institutionalised elderly and those living at home (Hoad-Reddick et al., 1987) or 
elderly living in sheltered accommodation (Tobias, 1988). In an earlier study, 
Smith and Sheiham (1979) found denture stomatitis in 20.5% of the elderly 
population. Numerous studies have been carried out on those living in institutions 
such as nursing homes and hospitals (Manderson and Ettinger, 1975; Palmquist et 
al., 1984; Vigild, 1987; Schou et al., 1987; Kaplan and Moskona, 1990; 
Pietrokovski et al., 1990; Cumming et al., 1990; Jorge et al., 1991; Wilkieson et 
al., 1991). From these studies it appears that the prevalence of denture stomatitis 
in the institutionalised elderly ranges from 19% (Pietrokovski et al., 1990 ) to
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54% (Cumming et al., 1990). Lastly, in studies involving dental hospital patients, 
Nyquist (1952) reported the prevalence of denture stomatitis as 27% and Budtz- 
Jorgensen (1972) found the condition present in 75% of female and 55% of male 
dental hospital patients.
1.3.3.2. Age Distribution.
Epidemiological studies into denture stomatitis have produced variable results 
when relating the prevalence of the condition to age. Kaplan and Moskona (1990) 
found denture stomatitis to be increasingly common with increasing age.
However, Love et a/.(1967), Mikkonen et al. (1984), Palmquist et al. (1984) and 
Vigild (1987) all recorded that denture stomatitis occurs less frequently with 
increasing age. Furthermore, some studies have reported that the prevalence of 
denture stomatitis is unrelated to age (Ambjornsen, 1985; Cumming et al., 1990; 
Jorge et al., 1991).
1.3.3.3. Sex Distribution.
Most investigators have concluded that denture stomatitis is more common in 
females (Nyquist, 1952; Budtz-Jorgensen, 1972; Mikkonen et al., 1984; Jorge *7 
al., 1991) although some studies have found no difference in prevalence between 
males and females (Wilkieson etal., 1991; Ambjornsen, 1985; Palmquist e ta l, 
1984; Vigild, 1987). No studies have found denture stomatitis to be more 
prevalent in males. The high proportion of women to men sufferers is most likely
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because of the higher incidence of edentulism among women and because of the 
tendency for women to seek dental treatment more often than men (Dorey et al., 
1985).
I.3.3.4. Colonisation Patterns.
Yeasts are most commonly isolated from the midline of the dorsum of the tongue 
in healthy dentate carriers (Arendorf and Walker, 1980). On the insertion of a 
denture, however, the density of candidal colonisation in all intraoral sites 
increases, by comparison with dentate individuals (Arendorf and Walker, 1979). 
Using various sampling techniques, it has been found that the denture fitting 
surface and the underlying mucosa are more densely colonised by yeasts in 
denture stomatitis patients than in denture wearers with healthy palatal mucosa 
(Budtz-Jorgensen and Bertram, 1970a; Davenport, 1970; Budtz-Jorgensen, 1976; 
Arendorf and Walker, 1979; Bergendal et al., 1979; Axell et al., 1985) and higher 
numbers of yeasts are isolated from the fitting surface of dentures than from the 
palatal mucosa (Budtz-Jorgensen, 1990). Furthermore, impressions of the maxilla 
taken in Sabouraud’s medium revealed that inflamed sites of the oral mucosa had 
greater numbers of yeast colonies than other areas (Budtz-Jorgensen and Bertram, 
1970a).
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1.3.4. Aetiology and Predisposing Factors.
I.3.4.I. Denture Trauma.
It is generally accepted that Newton’s (1962) Type I denture stomatitis is caused 
by trauma alone (Budtz-Jorgensen and Bertram, 1970a). Other forms of denture 
stomatitis are considered to have a multifactorial aetiology (Budtz-Jorgensen,
1974), of which trauma from ill-fitting dentures is just one aspect. The factors 
generally considered to be of particular significance in the aetiology of denture 
stomatitis are summarised in Table 1.2.
Several workers (Nyquist, 1952; Newton, 1962; Bergman et al., 1964; 
Turrell, 1966; Bastiaan, 1976) have suggested that denture trauma, resulting from 
problems such as instability, an unbalanced occlusion or ill-fitting dentures, plays 
an important role in the aetiology of denture stomatitis. Nyquist (1952) examined 
1090 complete denture wearers and demonstrated that the incidence of denture 
stomatitis increased in direct proportion to an increase in the number of traumatic 
denture factors.
However, Cawson (1963) drew attention to what he felt was a high 
incidence of denture stomatitis (24% of 1090 denture wearers) in Nyquist’s study 
population and the fact that he had not considered the lower denture-bearing area. 
Cawson (1963) postulated that denture trauma was not a causative factor in 
denture stomatitis but a predisposing factor which made the tissues more prone to 
infection. Incidentally, although the lower denture-bearing area was included in 
Cawson’s 1963 study, no inflammatory changes were noted here.
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Nyquist also reported a significant resolution of denture stomatitis 
following adjustment of the dentures, although other workers (Cawson, 1963; 
Bergman et al., 1964; Bastiaan, 1976) found that the provision of new dentures 
with satisfactory stablity and occlusion did not always result in the resolution of 
denture stomatitis. Bastiaan (1976) carried out a similar study to Nyquist (1952) 
and found that denture trauma was more prevalent in denture stomatitis patients 
than in healthy denture wearers.
Table 1.2. Factors of significance in the aetiology of denture 
stomatitis:
• trauma from an ill-fitting denture, including continuous denture 
wearing
• poor denture hygiene
• candidal infection
• systemic factors
• dietary factors
•  allergy to denture base materials
(after Arendorf and Walker, 1987; Lombardi and Budtz-Jorgensen, 1993)
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Aware that the exact role of trauma as an aetiological factor in denture 
stomatitis was still unclear, Bastiaan (1976) considered some of the other factors 
implicated. As a result he found patients with denture stomatitis to have poorer 
denture hygiene and a higher incidence of candidal colonisation compared with 
controls. He also found that a greater number of the denture stomatitis patients 
wore their dentures continuously. This finding was in contrast to Neill (1965) 
who, like Nyquist (1952), found no significant difference in the incidence of 
denture stomatitis amongst those who wore their dentures continuously and those 
who left them out at night. Several other studies have failed to show any 
relationship between denture stomatitis and denture wearing habits (Budtz- 
Jorgensen and Bertram, 1970a; Bergman etal., 1971; Wilkieson etal., 1991).
Bergendal (1982) acknowledges the conflicting evidence as to whether the 
wearing of dentures at night contributes to the development of denture stomatitis 
(Budtz-Jorgensen and Bertram, 1970a; Bergman et al., 1971; Arendorf and 
Walker, 1979; Ettinger, 1975). However, from his one year follow-up study of 
denture stomatitis, he concludes that the wearing of dentures at night does 
significantly increase the development of the condition because of the prolonged 
exposure of the mucosa to the denture plaque.
Most recent authors consider continuous denture wearing to be a factor in 
the aetiology of denture stomatitis (Arendorf and Walker, 1987). For example, 
Oksala (1990) found that continuous denture wearing provoked denture 
stomatitis by enhancing local mucosal trauma, whilst removal of dentures leads to 
resolution of the infection (Turrell, 1966). Williamson (1972) demonstrated that
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patients who wore their dentures at night had much higher early morning Candida 
counts in saliva than those who left their dentures out at night.
Miner (1973) suggested that denture trauma may be the result of micro­
roughness on the surface of the denture rather than macroscopic defects. In 1981, 
Harrison reviewed the use of temporary soft linings as a means of protecting the 
denture-bearing mucosa from mechanical trauma. More recently, Lombardi and 
Budtz-Jorgensen (1993) suggested that one aspect of treatment of denture 
stomatitis should include the smoothing of rough areas on the fitting surface of 
dentures or the relining of dentures with a soft tissue conditioner.
Budtz-Jorgensen and Bertram (1970a) and Bastiaan (1976) not only 
assessed the dentures but also the ability of the alveolar ridges to offer good 
retention and stability for dentures. Both studies found that alveolar mucosa 
which provides poor support for dentures, for example, a displaceable ridge, was 
more likely to have an associated denture stomatitis.
There have been several other suggestions as to why the presence of a 
denture in the mouth is a prerequisite for the development of denture stomatitis 
(Budtz-Jorgensen, 1990a). For example, Newton (1962) compared denture 
stomatitis to the ‘sweat retention syndrome’. He suggested that occlusion of the 
palatal minor salivary gland duct orifices by a denture, resulting in lateral spread 
of saliva into the tissues, may be responsible for the clinical features of denture 
stomatitis. Ritchie et al. (1969) disputed this theory, observing that denture 
stomatitis did not start at the back, as described by Newton (1962), but seemed to 
start anteriorly and then spread posteriorly and onto the ridge. Ritchie et al.
28
(1969), like Cawson (1963), also recognised that denture trauma may predispose 
the tissues to denture stomatitis by reducing their resistance to infection.
This idea was taken further by Riber and Kaaber (1976; 1978) who found 
that the barrier properties of oral mucosa are affected by denture wearing and that 
permeability is considerably increased when the mucosa becomes inflamed.
This concept of denture trauma as a predisposing factor to candidal 
infection was further enhanced when Samaranayake et al. (1980) showed that the 
adhesion of Candida to acrylic strips was enhanced by coating the strips with 
serum and reduced by coating them with mixed saliva. As a result, they suggested 
that denture trauma may result in an inflammatory exudate which would enhance 
the adhesion and colonisation of Candida to the denture fitting surface.
Other workers (Nater et al., 1978; Bergendal, 1982) have found no 
difference between the denture trauma present in patients with denture stomatitis 
and that seen in patients with healthy palatal mucosa. Also, some studies (Vigild, 
1987; Jorge et al., 1991) have been unable to demonstrate any significant 
correlation between trauma from dentures and denture stomatitis.
I.3.4.2. Denture Cleanliness.
Fisher (1956) was one of the earliest to propose that poor denture hygiene might 
predispose to denture stomatitis. Although Nyquist (1953) reported no such 
relationship, several workers since then (Love et al., 1967; McKendrick, 1968; 
Budtz-Jorgensen and Bertram, 1970a, Bergendal, 1982) have found a relationship
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between lack of denture cleanliness and denture stomatitis. Furthermore, Van 
Reenen (1973) suggested that bacteria may play a causative role in denture 
stomatitis and Abelson (1981) suggested that denture plaque was probably of 
more significance in the aetiology of denture stomatitis than ill-fitting or traumatic 
dentures.
Tarbet (1982) reported a quantitative approach to assessing the 
relationship among denture plaque levels, Candida species counts and mucosal 
irritation scores. He found a significant correlation between plaque levels and 
erythema scores but also found a significant correlation between Candida counts 
and erythema scores. As a result, it was concluded that plaque and yeasts operate 
as two independent factors which influence mucosal erythema.
Budtz-Jorgensen et al. (1983a) analysed one week old denture plaque 
from semi-quantitative cultures. They found that the rate of plaque formation was 
ten times higher in stomatitis patients than in controls with clinically healthy 
palatal mucosae. However, it was not clear whether the difference in microbial 
counts between patients and controls was the cause or the effect of the disease. 
The authors considered the possibility that inflammatory exudate of the palatal 
mucosa may augment the rate of plaque growth on the dentures.
Light and electron microscopic examinations, both in patients with denture 
stomatitis and in those with healthy mucosa, have shown that denture plaque is 
composed mainly of bacteria (Theilade and Budtz-Jorgensen, 1980). The plaque is 
attached to the acrylic surface by a pellicle which appears to be different from the 
acquired pellicle which forms on enamel (Edgerton and Levine, 1992). In patients 
with denture stomatitis the pellicle was found to contain serum products,
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degradation products and G albicans cell components that were not detected in 
pellicle from healthy patients.
Theilade and Budtz-Jorgensen (1980) found no substantive difference 
between the denture plaque of patients with denture stomatitis and those with 
healthy palatal mucosa.
Budtz-Jorgensen et al. (1981) found a predominance of cocci and rods 
when they studied the microbiology of denture plaque in a group of denture 
wearers with healthy palatal mucosae, using pieces of sand-blasted self-adhesive 
tape stuck to the fitting surface of maxillary dentures. Radford and Radford 
(1993) also found a predominance of coccoid- and rod-shaped bacteria, yet only a 
small number of yeast cells, when using a scanning electron microscope to 
examine denture plaque from denture stomatitis patients. This finding compares 
well with microbial culture studies (Theilade and Budtz-Jorgensen, 1988; Harding 
et al., 1991) which found yeasts to comprise only a very small proportion of the 
total cultivable flora in patients with denture stomatitis. However, an earlier 
scanning electron microscope study (Catalan et al., 1987) and a transmission 
electron microscope based study, looking at denture stomatitis patients only 
(Frank and Steuer, 1985), both reported regularly finding yeast cells in denture 
stomatitis patients. Frank and Steuer (1985) did note a difference between thick 
plaque, which was composed predominantly of bacteria, and thin plaque deposits, 
which had a predominance of yeasts.
Some studies (Frank and Steuer, 1985; Walter and Frank, 1985) have 
shown that the intercellular spaces of the palatal epithelium harbour bacteria and
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yeasts and that renewal of denture plaque occurs by proliferation of organisms 
from this site (Walter et al., 1986).
Frank and Steuer (1985) often observed micro-organisms between the 
yeast layer and the pellicle and suggested that bacteria may be important in the 
attachment of yeasts to various surfaces in the mouth. Furthermore, using an 
agglutination assay, Bagg and Silverwood (1986) found that some common oral 
bacteria will bind to C. albicans, hence possibly acting as a bridge in the 
attachment of Candida to the oral mucosa.
Although bacteria are generally far more numerous in denture plaque than 
yeasts (Theilade and Budtz-Jorgensen, 1980; Budtz-Jorgensen et al., 1983a; 
Theilade and Budtz-Jorgensen, 1988) the role of bacteria in the aetiology of 
denture stomatitis has received little attention.
Microbiological studies indicate that it is the quantity rather than the 
composition of denture plaque that determines the development of denture 
stomatitis (Budtz-Jorgensen and Theilade, 1983; Budtz-Jorgensen et al., 1983a; 
Theilade et al., 1983; Theilade and Budtz-Jorgensen, 1988). Epidemiological 
studies (Palmquist, 1984; Vigild, 1987; Schou et al., 1987) have shown that 
denture stomatitis patients have significantly greater quantities of denture plaque 
than those with healthy palatal mucosa. It has also been noted that when plaque 
accumulation is prevented, mucosal health improves ( Lombardi and Budtz- 
Jorgensen, 1993).
However, qualitative studies by other workers (Koopmans et al., 1988) 
have found differences between the bacterial flora of patients with denture
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stomatitis and healthy controls. For example, there were fewer cocci in the 
bacterial flora of the former group but higher percentages of obligate anaerobic 
bacteria in both denture and palatal plaque. Invasion of the epithelial and sub- 
epithelial tissues by bacteria has been demonstrated (Van Reenen, 1973). 
However, smears from the palate and dentures of denture stomatitis patients 
showed leucocytes in association with yeasts more frequently than with bacteria 
(Budtz-Jorgensen et al., 1975), suggesting that yeasts rather than bacteria are 
responsible for eliciting the inflammatory response.
I.3.4.3. Candidal Infection.
Yeast infection is assumed to be a major aetiological factor in denture stomatitis, 
mainly because of the fact that denture stomatitis usually resolves following 
antifungal therapy (Cawson, 1963; Budtz-Jorgensen, 1974, Quinn, 1985).
High salivary yeast counts are much more common in complete denture 
wearers than in dentate subjects (Parvinen, 1984). Yeasts are demonstrable in 78- 
100% of patients with denture stomatitis (Olsen, 1974). However, in 
microbiological studies of patients with denture stomatitis, yeast counts usually 
constituted less than 1% of the total microbial counts, although there was a 
tenfold increase of the yeast counts in denture plaque obtained from denture 
stomatitis patients compared with healthy controls (Budtz-Jorgensen and 
Theilade, 1983; Budtz-Jorgensen et al., 1983a).
Cahn (1936) recognised the opportunistic nature of yeast organisms. He 
suggested that alterations to the environment, as a result of wearing a denture,
A
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could be sufficient to change a harmless yeast into a pathogen. Cahn’s proposal 
that C. albicans was responsible for denture stomatitis was backed up by Bartels 
(1937) who confirmed the presence of these organisms by culturing swabs from 
Cahn’s patients.
Subsequent investigators have been able to demonstrate that yeasts can be 
cultured far more frequently from the mouths of patients with denture stomatitis 
than from those with healthy palatal mucosa (Lyon and Chick, 1957; Cawson, 
1963; Turrell, 1966; Budtz-Jorgensen and Bertram, 1970a; Bergendal et al.,
1979; Palmquist et al., 1984; Cumming et al., 1990; Nanetti et al., 1993) and 
also that yeasts could be more often isolated from dentures than from mucosal 
surfaces (Wilkieson et al., 1991; Bergendal et al., 1979; Palmquist et al., 1984). 
The occurrence in smears of candidal hyphae, believed to be an indication of 
infection (Winner, 1969), has also been shown to be more frequent in populations 
with denture stomatitis than those without (Arendorf and Walker, 1987).
In a random sample of the elderly Danish population, Budtz-Jorgensen et 
al. (1975) showed that yeasts could be isolated from the mouths of 93% of those 
with denture stomatitis. However, among denture wearers with healthy palatal 
mucosa, they found a yeast carriage rate of 86%.
Sampling techniques throughout the published studies on denture 
stomatitis have been as diverse as the results produced (Cumming et al., 1990). 
Methods of quantifying yeasts include impression cultures (Bahn et al., 1962), 
imprint cultures (Davenport, 1970), saliva cultures (Oliver and Shillitoe, 1984) 
and oral rinse cultures (Samaranayake et al., 1986a).
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Recovery rates of yeasts depend on the technique used. For example, 
swabbing of mucosal surfaces has been reported to produce inferior recovery 
rates in comparison to culture of salivary samples (Lilienthal, 1950). Arendorf and 
Walker (1979) compared different techniques for detecting and quantifying yeasts 
in dentate individuals and in denture wearers, both with healthy palatal mucosa 
and with denture stomatitis. As a result, they suggested that imprint cultures were 
more sensitive than other techniques for detecting candidal carriers. Furthermore, 
they suggested that quantitative imprint cultures may be useful in differentiating 
between carrier and disease states. Wilkieson et al. (1991) have challenged this 
suggestion.
Samaranayake et al.( 1986a), in a study comparing the imprint culture with 
the concentrated oral rinse technique, recommended the latter as the most 
sensitive method when screening for the oral carriage of yeasts, coliforms or S. 
aureus.
No difference has been found between the yeast flora isolated from 
patients with denture stomatitis and that of controls (Turrell, 1966; Budtz- 
Jorgensen et a/., 1975; Budtz-Jorgensen et al., 1983a). C. albicans is the most 
frequently isolated species in both health and disease (Cawson, 1963; Budtz- 
Jorgensen and Bertram, 1970a; Davenport, 1970; Olsen, 1974; Budtz-Jorgensen 
et al., 1975; Bergendal et al., 1979; Arendorf and Walker, 1979; Budtz- 
Jorgensen et al., 1983a; Tamamoto et al., 1986; Shimizu et al., 1987; Schou et al., 
1987).
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Wilkieson et al. (1991) agreed with the majority of workers when they 
found C. albicans to be the organism most frequently isolated in their study group 
as a whole. However, they also found C. glabrata to be the predominant species 
in patients with denture stomatitis.
In contrast to the majority, Cumming et al (1990) found C. glabrata to 
be the commonest species isolated in their study population.
C. albicans appears to be isolated in pure culture more often than in 
combination with other species (Budtz-Jorgensen and Bertram, 1970a; Olsen, 
1974; Wilkieson et al., 1991). However, unless specific culture media are used it 
is difficult to identify mixed growth (Samaranayake et al., 1987).
Budtz-Jorgensen (1971a) suggested that some candidal species, such as C. 
albicans or C. tropicalis, might be more pathogenic than others. The virulence of 
candidal species is thought to be dependent on a number of factors (Ruechel, 
1990). One of the most important of these factors is adherence and C. albicans 
has been shown to adhere more readily than other species to both mucosal and 
acrylic surfaces (Critchley and Douglas, 1985).
McCourtie and Douglas (1984) compared the adherence to acrylic and 
buccal epithelial cells of strains of C. albicans isolated from active infections and 
from asymptomatic carriers. Growth in media containing high concentrations of 
sucrose and galactose increased the adherence of infective strains many times, 
whilst only small increases in carrier strains were observed.
It has been shown that a number of different strains of C. albicans are 
involved in denture stomatitis (McCreight et al., 1984; Watkinson et al., 1985).
These studies failed to produce conclusive evidence that a particular strain was 
involved in the aetiology.
However, Shakir et al. (1983) found C. albicans serotype A to cause 
palatal candidosis more frequently in rats than serotype B. This confirmed earlier 
clinical indications of the greater role played by serotype A in denture stomatitis 
(Martin and Lamb, 1982). There is also experimental evidence from animal and in 
vitro models that certain strains of C. albicans are more virulent than others 
(Holbrook et al., 1983; McCourtie and Douglas, 1984).
A number of studies have indicated that the pathogenesis of denture 
stomatitis is associated with the presence of C. albicans in its hyphal form 
(Cawson, 1965; Budtz-Jorgensen and Bertram, 1970a; Davenport, 1970). 
Evidence from an experimental model in monkeys appears to support this view 
(Budtz-Jorgensen, 1971b). Furthermore, using light microscopy, Allison and 
Douglas (1973) demonstrated microcolonies of Candida with hyphae projecting 
from the fitting surface of temporary soft lining materials, from patients with 
denture stomatitis.
Conversely, abundant hyphae have often been demonstrated in denture 
wearers with healthy mucosa (Budtz-Jorgensen et al., 1975; Olsen and Birkeland, 
1977; Arendorf and Walker, 1979) and blastospores have occasionally been 
found to be the only morphological form present in patients with denture 
stomatitis (Olsen and Birkeland, 1977; Arendorf and Walker, 1979). Shepherd 
(1985) produced evidence that either yeast or mycelial forms of Candida are
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capable of producing disease. Rebora et al. (1973) found mycelial forms to be 
rare in experimental infection of human skin.
Holbrook et al. (1983), in experimental oral infection of mice, showed that 
a virulent strain of C. albicans produced few, short pseudohyphae whilst an 
attenuated strain produced abundant, long pseudohyphae.
It has been suggested that the morphological form of C. albicans depends 
on the local environmental conditions, such as the pH (Budtz-Jorgensen, 
197lb; 1990a). Denture plaque in patients with denture stomatitis is more acidic 
than in healthy controls (Olsen and Birkeland, 1977; Samaranayake et al., 1983), 
particularly following sucrose rinses (Olsen and Birkeland, 1975; 1977). No 
relationship could be demonstrated between the pH of resting denture plaque and 
the occurrence of hyphae (Olsen and Birkeland, 1975; 1977).
Palatal candidosis has been induced by the inoculation of C. albicans 
beneath acrylic plates in monkeys (Budtz-Jorgensen, 197lb; 1973; 1975; Olsen and 
Haanaes, 1977) and Wistar rats (Olsen and Bondevik, 1978; Shakir et 
al., 1981; 1986a). As gnotobiotic rats were not used, it is not clear whether the 
denture stomatitis was due to the Candida species alone or whether bacteria were 
involved (Arendorf and Walker, 1987).
An erythematous response, with a histological appearance similar to that 
of denture stomatitis in man, was produced in monkeys (Budtz-Jorgensen, 
1971b). However, this resolved spontaneously after two to three weeks and could 
only be sustained by repeated inoculation and use of topical tetracycline. In one
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animal wearing a plate, but with no candidal inoculum beneath it, localised 
erythema occurred around the orifices of the palatal minor salivary glands.
The two studies using rat models (Olsen and Bondevik, 1978; Shakir et al., 1981) 
divided the animals into four experimental groups:
• untreated animals
• animals wearing a plate with no candidal inoculum
• animals wearing a plate with candidal inoculum
• inoculated animals not wearing a plate.
Olsen and Bondevik (1978) reported the most severe inflammation in the plate 
plus inoculum group. Sporadic inflammation was seen in the other experimental 
animals but C. albicans was isolated from many of the animals prior to the study 
which complicates the interpretation of the results.
In the study by Shakir et al. (1981) no yeasts were isolated from the rats 
prior to the start of the study. Consequently, they found that inflammation 
occurred only in the animals wearing a plate with C. albicans serotype A 
inoculated beneath it. This began as localised inflammation and spread to involve 
the whole of the area covered by the plate. The inflammatory response resolved 
when the plates were removed but Candida organisms persisted in the mouths of 
the rats (Shakir et al., 1981 ;1986a). When the plates were subsequently re­
inserted without a further inoculum, the inflammation returned (Shakir et al., 
1986a). This was interpreted as indicating that the plate caused conversion of the 
IC. albicans to its more pathogenic form (hyphae).
The studies by Shakir et al. (1981; 1986a) demonstrated hyphal invasion of 
the mucosa. Other studies have not demonstrated this invasion (Budtz-Jorgensen, 
1971b; Olsen and Bondevik, 1978).
A few studies have been unable to show a relationship between candidal 
growth and denture stomatitis (Nater et al., 1978; Bergendal and Isacsson, 1983). 
Nater et al. (1978) used an unusual method of isolating Candida species which 
may have accounted for their findings. An unspecified culture medium was cast in 
the form of the upper denture and then applied to the palatal mucosa. Bergendal 
and Isacsson (1983) also used an indirect method.
Monaco and Pickett (1981) denied the involvement of Candida species in 
the hyperplastic form of denture stomatitis, basing their conclusion on the absence 
of hyphal invasion alone.
Evidence in favour of C albicans as a primary aetiological factor in 
denture stomatitis is seen in the response of the condition to antifungal agents 
(Quinn, 1985). However, nystatin and chlorhexidine have been shown to inhibit 
bacterial populations as well as yeasts (Budtz-Jorgensen and Loe, 1972; Van 
Reenen, 1973), and penicillin, with a known ability to enhance, directly or 
indirectly, fungal growth (Seelig, 1966), has been used successfully to treat 
denture stomatitis (Van Reenen, 1973). As a result, there is difficulty in 
distinguishing the role of yeasts and bacteria in denture plaque (Arendorf and 
Walker, 1987).
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1.3.4.4. Systemic Factors.
Systemic diseases frequently reported in association with denture stomatitis 
include diabetes mellitus, immunodeficiency states, anaemia, hypoparathyroidism, 
nephritis, mercury intoxication, bullous pemphigoid, kidney and urinary tract 
disease (Budtz- Jorgensen and Bertram, 1970a; Budtz-Jorgensen, 1978; Nater et 
al., 1978; Bergendal, 1982).
Some studies have shown that candidal carriage is more prevalent among 
diabetic patients compared to non-diabetic individuals (Tapper-Jones et a/., 1981; 
Lamey et al., 1988). In an earlier study, Peters et al. (1966) could find no increase 
in the prevalence of candidal carriage, nor in the density of growth of C. albicans, 
in diabetic patients compared with controls.
In relation to their ability or inability to secete blood group antigens, 
Lamey et al. (1988) found no significant difference in the prevalence of oral 
candidal carriage and infection between diabetic patients and non-diabetics.
Knight and Fletcher (1971) showed that saliva from diabetics can promote 
the growth of C. albicans and this finding was correlated with the salivary glucose 
level.
Odds et al. (1978) claimed that candidal carriage rate among diabetics was 
dependent upon glycaemic control. However, such a relationship has been denied 
by more recent investigators (Tapper-Jones et al., 1981; Fisher et al., 1987; 
Lamey et al., 1988; Aly et al., 1991).
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Some workers have found that diabetic denture wearers have increased 
yeast counts when compared to diabetic dentate patients (Tapper-Jones et al., 
1981; Fisher et al., 1987). Despite this, Phelan and Levin (1986) demonstrated no 
significant increase in the prevalence of denture stomatitis in those with either 
diabetes mellitus or elevated plasma glucose levels.
It is generally accepted that the use of broad spectrum antibiotics and, to a 
lesser extent, corticosteroids may predispose to the development of oral 
candidosis (Odds, 1988; Samaranayake, 1990). Knight and Fletcher (1971) 
produced evidence that antibiotics promote the growth of C. albicans by 
inhibiting bacteria and thus removing the competition for salivary glucose. 
McKendrick et al. (1967) found no relationship between the administration of 
tetracycline, used in the treatment of chronic bronchitis, and the prevalence or 
relative numbers of oral Candida. Furthermore, McKendrick (1968) could find no 
significant relationship between tetracycline administration and the occurrence of 
denture stomatitis. One study (Budtz-Jorgensen, 1975) has produced 
experimental evidence using an animal model to suggest that corticosteroids may 
exacerbate denture stomatitis.
The anamnestic data indicating the possible association between the 
presence of kidney and urinary tract diseases and denture stomatitis (Bergendal, 
1982), suggested that repeated and prolonged treatment with antibiotics and 
sulphonamides may be a predisposing factor.
The carriage rate of Candida species has been reported to be elevated in 
patients taking psychopharmacological drugs (Budtz-Jorgensen, 1990a). Lucas 
(1993) found that Candida species and S. aureus were isolated more frequently in
complete maxillary denture wearers undergoing treatment with psychotropic 
drugs. Palatal inflammation was also present more frequently in these patients 
than in controls. However, other factors predisposing to denture stomatitis such 
as a poor standard of denture hygiene, cigarette smoking and high sugar 
consumption were also more commonly seen in the psychiatric patients.
1.3.4.5. Dietary Factors.
There is evidence that nutritional factors such as deficiencies of iron, folic acid 
and vitamins may increase the susceptibility of individuals to denture stomatitis 
(Budtz-Jorgensen, 1990a). In a study of a large group of denture wearers, 
Ettinger (1973) found the dietary intake of one third of those investigated to be 
both quantitatively and qualitatively unsatisfactory. Furthermore, Field et al. 
(1995) point out that since oral changes appear to precede many of the systemic 
indicators of nutritional deficiency, at least in the case of Vitamin B12, early 
recognition of these oral changes may lead to early diagnosis and the institution of 
therapy which may prevent more serious sequelae.
Cawson (1963) was the first to describe an apparent relationship between 
iron deficiency and oral candidosis. Rose (1968) also reported the frequent 
existence of iron deficiency in denture stomatitis patients. However, Jenkins et al. 
(1977) were unable to find any differences in iron, folic acid and vitamin B12 
deficiency between patients with denture stomatitis and controls.
Samaranayake and MacFarlane (1981a), in a retrospective study, found 
cases of iron, folate and vitamin B12 deficiency in association with denture
stomatitis. Correction of the deficiencies had little or no effect on the incidence of 
denture stomatitis.
Joynson et al. (1972) and Fletcher et al. (1975) demonstrated that iron 
deficiency appears to exert its effects through impairments in lymphocyte 
function, although Fletcher et al. (1975) found impairments in lymphocyte 
function in iron deficient patients both with and without oral lesions. Once iron 
levels were returned to normal, cell-mediated immunity to C. albicans was 
restored (Joynson et al., 1972).
Rennie et al. (1984) suggested that iron deficiency may produce an 
impairment of iron-dependent enzyme systems thereby affecting the metabolism 
and the kinetics of the rapidly dividing oral epithelial cells. As a result the 
epithelial surface may be more conducive to the adhesion, growth and invasion of 
Candida (Rennie et al., 1982).
Saliva from iron-deficient patients has been shown to support the growth 
of C. albicans in vitro more readily than did saliva from controls (Fletcher et al.
1975).
Jennings and MacDonald (1990) found that denture stomatitis developed 
in patients with haematological abnormalities when candidal colonisation was less 
dense than in patients with normal haematological values.
There is evidence to suggest that a high intake of sugars in the diet is 
associated with oral candidosis (Shuttleworth and Gibbs, 1960; Olsen and 
Birkeland, 1976; Samaranayake and MacFarlane, 1981a, b). Olsen and Birkeland 
(1976) found that sucrose rinses could not only aggravate existing denture
stomatitits but also initiate denture stomatitits in denture wearers with previously 
healthy oral mucosa.
In vitro studies have suggested that glucose promotes the growth of 
Candida species in saliva (Knight and Fletcher, 1971; Samaranayake et al., 
1986b). The rapid decline in pH associated with this growth may be involved in 
the pathogenesis of oral candidosis (Samaranayake et al., 1986b). For example, 
reduced pH levels may potentiate candidal virulence by enhancing its growth, 
multiplication and adherence to host tissues whilst activating the acidic proteases 
and phospholipases of the yeast. Furthermore, the direct cytotoxic effect of the 
acidic metabolites may exacerbate the host inflammatory response (Samaranayake 
and MacFarlane, 1985).
Other studies (Samaranayake et al., 1980; McCourtie and Douglas, 1984) 
have shown that sugar substrate appears to enhance the ability of C. albicans to 
adhere to both acrylic and to buccal epithelial cells.
1.3.4.6. Xerostomia.
The protective role of saliva against candidal infection, through its mechanical 
washing effect and antifungal properties, is widely recognised 
(Samaranayake, 1990).
C. albicans may be found in significantly greater numbers in the mouths of 
patients with Sjogren’s Syndrome compared to healthy individuals (MacFarlane 
and Mason, 1974). Suppressed salivary flow in monkeys caused aggravation of
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inflammation produced by inoculating C. albicans beneath acrylic palatal plates 
(Olsen and Hanaaes, 1977). Knight and Fletcher (1971) demonstrated the 
inhibition of the growth of C. albicans by unsterilised human saliva whilst 
Samaranayake et al. (1980) found that pre-coating strips of acrylic with mixed 
human saliva reduced the adhesion of C. albicans.
However, although xerostomia may increase the severity of the symptoms 
associated with denture stomatitis, there is no direct evidence that drug-induced 
xerostomia predisposes to yeast infection in denture wearers (Budtz-Jorgensen,
1990a).
1.3.4.7. Tobacco Smoking.
Arendorf and Walker (1980) claimed that smoking increased the rate of oral 
candidal carriage. Conversely, however, Oliver and Shillitoe (1984) claimed that 
smoking had no effect on the oral candidal carriage rate.
Two epidemiological studies have indicated that tobacco smoking is 
associated with a significantly increased prevalence of denture stomatitis (Hand 
and Whitehill, 1986; Cumming et al., 1990).
Arendorf et al. (1983) found tobacco smoking and denture wearing to be 
important factors in the aetiology of candidal leukoplakia. Approximately one 
third of patients with this condition also had denture stomatitis.
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1.3.4.8. Allergic Reactions to Denture Base Materials.
Early studies (Rattner, 1936; Bradford, 1948) recorded allergic and 
primary irritant reactions to denture base materials as possible aetiological factors 
in denture stomatitis. However, Fisher (1956) showed that what had originally 
been regarded as a positive patch test to the patients’ dentures was actually due to 
a non-specific traumatic event.
Neill (1965) and Turrell (1966) suggested that the allergic reaction may be 
attributed to substances absorbed by the denture during wear. A report by 
Danielewicz (1971) appears to support this view, however, the effects of plaque 
and its components have not been taken into account (Arendorf and Walker, 
1987).
Nater et al. (1978) carried out patch tests on the palatal mucosa and skin 
of the back of patients with denture stomatitis, using denture wearers with healthy 
palatal mucosa as controls. Although several constituents of denture base 
materials were used as allergens, no significant differences between the two 
groups were found in the patch test results.
Occasional reports of a true allergic reaction have occurred (Giunta et al., 
1979; Walker, 1982). However, it is now generally accepted that true allergy to 
denture base materials or its constituents is rare (Arendorf and Walker, 1987).
1.3.5. Pathogenesis and Host Resistance.
1.3.5.1. Histopathology and Tissue Invasion.
Biopsy specimens from the palatal mucosa of denture stomatitis patients have 
been examined by several investigators (Budtz-Jorgensen, 1970; Wictorin, 1975; 
Bergendal and Isacsson, 1983; Morimoto et al., 1987). Their findings have been 
quite consistent and the main features are summarised in Table 1.3.
The histological appearance of the granular type of denture stomatitis is 
similar to that of the generalised simple form, except for the presence of papillary 
projections in the former (Budtz-Jorgensen, 1970; Bergendal and Isacsson, 1983; 
Morimoto et al, 1987). These projections consisted of either markedly 
hyperplastic epithelium with a narrow core of connective tissue or hyperplastic 
connective tissue with a covering epithelium of almost normal thickness 
(Bergendal and Isacsson, 1983). The crypts between the papillae harboured 
microbial plaque and debris.
Budtz- Jorgensen (1970) could find no qualitative differences in the 
histopathological appearance between denture stomatitis caused by trauma and 
that caused by candidal infection. However, pronounced intraepithelial leucocyte 
infiltration and the occurrence of leucocytes in smears were much more 
pronounced in the Carafafo-associated lesions. It was also shown that these 
histological changes could be reversed by appropriate treatment. The persistence 
of subepithelial inflammation in biopsies taken from the granular form of denture 
stomatitis could be explained by the difficulty of removing the microbial plaque 
and debris from the deep epithelial crypts.
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Table 1.3.
Main histopathological features of denture stomatitis.
• Absence of keratin layer or parakeratosis.
• Epithelial hyperplasia with deeply penetrating rete pegs, alternating with areas 
of epithelial atrophy.
• Intracellular and intercellular oedema within the epithelium.
• Leucocyte infiltration.
• Chronic inflammation of the lamina propria, usually extending into the 
epithelial layers.
• No evidence of hyphae or blastospores invading the epithelium.
(after Budtz-Jorgensen, 1970; Wictorin et al., 1975; Bergendal and Isacsson, 
1983; Morimoto et al., 1987).
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The inflammatory cell infiltrate in denture stomatitis has been found to be 
similar to that seen in chronic marginal periodontitis and chronic apical 
periodontitis. It consists mainly of T lymphocytes, plasma cells and macrophages 
(Johannessen etal., 1986).
Ostlund (1958) found a moderate increase in the number of mitoses seen 
in denture stomatitis biopsies compared to normal mucosa. In contrast, Van 
Mens et al. (1975) found a significantly lower mitotic index in the palatal 
epithelium of denture stomatitis patients compared to denture wearers with 
healthy palatal mucosa. Although palatal epithelial thickness and the number of 
mitotic figures was initially reduced when palatal candidosis was experimentally 
induced in rats (Shakir et al., 1986b), both epithelial thickness and mitotic activity 
later showed a sharp increase.
In humans, epithelial thickness alternates with areas of extreme atrophy 
(Ostlund, 1958; Budtz-Jorgensen, 1970; Wictorin et al., 1975; Bergendal and 
Isacsson, 1983; Morimoto et al., 1987).
Tissue invasion by yeasts in oral candidosis is usually limited to the 
superficial keratotic or parakeratotic layers (Jepsen and Winther, 1965; Cawson,
1966). Several studies have demonstrated that Candida species seldom invade the 
tissues in denture stomatitis and that relatively few yeast cells are revealed in 
mucosal smears (Cawson, 1966; Budtz-Jorgensen, 1970; Davenport, 1970; 
Bergendal and Isacsson, 1983). Budtz-Jorgensen (1990c) has suggested that the 
keratotic epithelium with deeply penetrating rete pegs and alternating areas of 
atrophy (Budtz-Jorgensen, 1970; Bergendal and Isacsson, 1983) may be a poor 
substrate for the keratophilic yeast cells. He also points out that because
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pseudohyphae are abundant in smears from the mucosal surface and fitting 
denture surface, this indicates that yeast growth is limited to host detritus and the 
microbial plaque between the mucosa and the denture. Furthermore, in 
experimentally induced denture stomatitis in monkeys and rats, intraepithelial 
invasion by hyphae was an inconsistent finding even when yeast proliferation was 
enhanced by treatment with broad-spectrum antibiotics (Budtz-Jorgensen, 1971b; 
Olsen and Hanaaes, 1977; Shakir etal., 1981).
1.3.5.2. Hypersensitivity.
Eglitis et al. (1981) suggested that the inflammatory response seen in Newton’s 
Type III denture stomatitis (Newton, 1962) arises from a local disturbance of the 
host-parasite relationship which enables an endogenous yeast to cause disease. 
Also concentrating on hyperplastic denture stomatitis, Johannessen et al. (1986) 
used various immunological techniques to demonstrate the presence of IgG, IgA, 
IgM, complement factors, T-lymphocytes and macrophages in the inflammatory 
cell infiltrate. They concluded that denture stomatitis is a complex inflammatory 
lesion with elements of both humoral and cell-mediated immune responses. The 
immunofluorescent technique used in this study failed to demonstrate Candida 
antigens in the epithelium. However, Johannessen et al. (1986) agreed with the 
suggestion of Budtz-Jorgensen et al. (1983a) that it is likely that these antigens 
are present in the tissues and play an important role in the initiation and 
maintenance of the disease. The extent to which bacterial or candidal antigens 
contribute to the inflammation has not yet been ascertained (Budtz-Jorgensen, 
1990a).
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Evidence that a delayed type hypersensitivity reaction against C. albicans 
contributes to the inflammatory reaction in denture stomatitis has been provided 
by Budtz-Jorgensen (1971b). In this study, re-inoculation of C. albicans beneath 
an acrylic plate in monkeys produced a recurrence of inflammation, with 
histological evidence of a delayed hypersensitivity reaction to the yeast. In the 
same experimental model, the cellular response was studied directly by observing 
in vitro leucocyte migration and was seen to reach its peak at the same time as the 
inflammation resolved (Budtz-Jorgensen, 1973; 1975). When this immune 
response was suppressed by immunosuppressive drugs, thrush-like lesions 
developed and hyphal invasion of the superficial epithelial layers occurred (Budtz- 
Jorgensen, 1973; 1975). This inflammation persisted until after the 
immunosuppressant had been discontinued. The cellular immune response was 
suppressed by the drug and did not occur until the drug was stopped. The 
humoral response in these animals was early and strong but failed to clear the 
infection (Budtz-Jorgensen, 1973). A similar picture was observed in monkeys 
treated with corticosteroids, which also suppressed the cell-mediated immune 
response (Budtz-Jorgensen (1975).
It is known that cellular immunity is important in combatting systemic 
fungal infections, whereas humoral immunity may be less important (Folb and 
Trounce, 1970).
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1.3.5.3. Virulence Factors.
There is no single virulence factor of Candida species which is predominantly 
responsible for the establishment of candidosis (Ruechel, 1990).
Dobias (1964) suggested that C. albicans may produce an endotoxin. 
However, other workers (Chattaway et al., 1971; Cutler et al., 1972) have found 
insufficient levels of endotoxin in vivo to produce toxic effects. Odds (1988) 
stated that it was unlikely that an opportunistic pathogen would produce a 
potently bioactive toxin and remain opportunistic.
Secretory lipases of C. albicans and, to a lesser extent, other Candida 
species have been studied as possible virulence factors (Ruechel, 1990). Pugh and 
Cawson (1977) have shown histochemically that phospholipases are concentrated 
at the tips of fungal hyphae and localised to where invasion is occurring in chick 
embryonic membranes, although their role is still to be determined. Samaranayake 
et al. (1984a) showed that phospholipase production by C. albicans was limited 
to acidic growth conditions and was inversely related to the concentration of 
glucose or galactose in the media.
Price and Cawson (1977) differentiated the lipolytic activity of C. albicans 
into phospolipase A and lysophospholipase. Although these enzyme activities 
were found in most C. albicans strains, Samaranayake et al. (1984b) failed to 
demonstrate phospholipase activity in organisms known to be less virulent than C. 
albicans, such as C. glabrata, C. tropicalis and C. parapsilosis. Furthermore, 
Williamson et al. (1986) found significant differences between the phospholipase 
activity of different clinical isolates of C. albicans.
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Evidence linking lipolytic activity with virulence of fungi has been 
provided by Barrett-Bee et al. (1985) and Ibrahim et al. (1995).
Extracellular proteinases which can degrade the salivary proteins have 
been implicated in the pathogenicity of C. albicans (Borg and Ruechel, 1988).
The ability of acid proteinases to cleave IgAl, IgA2 and secretory IgA has been 
demonstrated (Budtz-Jorgensen, 1990c). The low pH necessary for activation of 
these acidic enzymes is found in denture plaque, particularly after sugar intake 
(Olsen and Birkeland, 1976). Furthermore, Theilade and Budtz-Jorgensen (1988) 
found that this cleavage of salivary antibacterial immunoglobulins by the various 
Candida proteinases may enhance the pathogenic potential of the bacterial 
components of denture plaque.
The variable ability of different Candida species to secrete extracellular 
proteinases largely reflects the virulence of these opportunistic organisms 
(Ruechel, 1990). For example, virtually all isolates of the more virulent species, C. 
albicans and C. tropicalis secrete proteinases (MacDonald, 1984). In contrast, 
the extracellular proteolytic activity of C. parapsilosis is expressed under in vitro 
conditions only (Ruechel et a/., 1986) and Reinholdt et al. (1987) found C. 
glabrata to have only weak proteolytic actvity.
In a study relating the germ tube formation and proteinase activity of C. 
albicans to the virulence of this organism for mice, Okamoto et al. (1993) found 
that clinical isolates from patients with denture stomatitis were lethal for mice, 
regardless of their proteinase activity. However, the overall results from this study 
led these workers to conclude that the virulence of C. albicans is partly due to 
proteinase activity.
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Evidence against proteinase as a virulence factor has also been reported 
(King et al., 1980; MacDonald and Odds, 1983; Cutler, 1991).
Candida species adhere to a variety of surfaces, including acrylic 
(Samaranayake et al., 1980; Samaranayake and MacFarlane, 1980; Minagi et al., 
1986). Some investigators have suggested a relationship between the adherence of 
C. albicans to acrylic and epithelial surfaces and its ability to colonise and cause 
disease (Kennedy et al., 1988; Soli, 1992). Hyphal forms of the organism tend to 
adhere more strongly than yeast forms (Samaranayake and MacFarlane, 1982; 
Tronchin et al., 1988). Adherence also varies with environmental conditions, for 
example, it is promoted by sugars (Minagi et al., 1985; Rotrosen et al., 1986). 
Other factors which contribute to adherence are listed in Table 1.4.
Table 1.4. Factors affecting adhesion of yeasts.
• Yeast cell attributes: medium/cultivation, phenotype, germ tubes/hyphae,
extracellular polymeric material, floccular/fibrillar 
surface layers, mannan, chitin, hydrophobicity, 
cellular lipids.
• Host cell attributes: cell source, mucosal size and viability, fibronectin,
fibrin, sex hormones, yeast carriers versus patients 
with overt candidosis.
• Environmental factors: cations, pH, sugars, saliva, humoral antibody and
serum, antibacterial drugs, bacteria, lectins.
(after Olsen, 1990; Scully era/., 1995).
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C. albicans frequently exhibits variant colonial forms when grown in vitro 
(Shepherd, 1990). Studies have linked switching in vitro with virulence in vivo 
(Soli, 1988). Mechanisms to explain the relationship of colony switching to 
pathogenicity of C. albicans are not yet known (Nelson et al., 1991). However, 
the pathogenic mechanisms which may be potentiated by switching include 
enhanced adhesion of different phenotypes to each other and to epithelial cells 
(Kennedy et al., 1988), avoidance of elimination by neutrophils (Kolotila and 
Diamond, 1990) or enhanced potential for C. albicans cells to adapt rapidly to 
new microniches (Soli et al., 1991). Furthermore, switching may enhance tissue 
penetration, secretion of enzymes such as proteinases and phospholipases and the 
capacity to escape antifungal treatment (Shepherd, 1990).
1.3.5.4. Host Defences.
Scully et al. (1995) divided host oral defences against Candidal infection into 
immune and non-immune factors. As non-immune factors they included iron, 
lysozyme, salivary histidine-rich polypeptides, lactoferrin, lactoperoxidase and 
salivary glycoproteins.
Immune factors, such as phagocytosis and cell-mediated and humoral 
immunity, provide a second line of defence against candidal infection (Budtz- 
Jorgensen, 1990a). C. albicans is primarily controlled by phagocytosis (Ashman 
and Papadimitriou, 1990; 1992). Conditions where candidal phagocytosis and/or 
killing by polymorphonuclear leucocytes or monocytes is depressed are often 
associated with serious candidal infections (Odds, 1988). Similarly, infections with
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Candida species are consistently seen where there is depressed cell-mediated 
imune function (Scully et al., 1995).
Although patients with denture stomatitis do not have any serious cell- 
mediated immune defects, they may be deficient in migration-inhibition factor and 
may have overactive suppressor T cells or other T lymphocyte or phagocyte 
defects (Iacopino and Wathen, 1992).
Secretory IgA is the major humoral factor which defends against yeast 
organisms by aggregation or by prevention of adherence (Challacombe, 1990).
1.3.6. Diagnosis of Denture Stomatitis.
1.3.6.1. Clinical Findings.
The characteristic presenting signs of denture stomatitis are chronic erythema and 
oedema of the mucosa that contacts the fitting surface of the denture (Budtz- 
Jorgensen, 1990a). Lesions are often free of symptoms and the presenting 
complaint is commonly associated with angular cheilitis (Odds, 1988).
There are no reliable clinical criteria which can distinguish between a 
( 'andida-associated-, bacterial induced-, or trauma-induced- denture stomatitis 
and an allergic reaction to the denture base material (Budtz-Jorgensen, 1990a; b; 
c). Therefore, Budtz-Jorgensen (1990a) stated that in order to establish a 
diagnosis it is necessary to carry out a mycological examination.
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1.3.6.2. Microbiological Investigations.
Scully et al. (1995) have suggested that the detection of yeasts in a clinical 
specimen should start with direct microscopic examination of smears of the lesion. 
Although valuable in many situations, smears have been shown to be less sensitive 
than culture techniques (Silverman et al., 1990).
A sterile cotton-tipped swab rubbed over the lesional tissue or over all 
surfaces irrespective of clinical signs, and subsequently cultured in the laboratory, 
is a useful method to detect the presence or absence of Candida spp.. However, 
this will not provide a quantitative estimate (Silverman et al., 1990). Odds (1982) 
found that C. albicans can remain viable for at least 24 hours on a moist swab.
Discrimination between candidal carriage and frank oral candidosis can be 
made using the imprint culture technique (Arendorf and Walker, 1979). Sterile 
plastic foam pads dipped in Sabouraud’s broth are placed directly onto the clinical 
surface and then directly onto a suitable culture medium. According to Arendorf 
and Walker (1979), colony counts in excess of 30CFU cm2 of mucosa in the 
dentate and 49CFU cm'2 in denture wearers may suggest a candidal infection.
The concentrated oral rinse technique was first described by McKendrick 
et al. (1967) and later modified by Samaranayake et al. (1986a). This method is 
more simple to perform than the imprint culture technique, especially if multiple 
sites are involved. It also removes the risk of inhalation of the sterile foam pads 
(Silverman et al., 1990). Samaranayake et al. (1986a) found that although the 
imprint culture technique and the concentrated oral rinse method had comparable 
sensitivity, the latter was superior in quantifying yeast, coliform and S. aureus.
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The impression culture technique (Bahn et al., 1962), although useful in 
quantifying the relative distribution of yeasts on various oral surfaces, is purely a 
research tool (Silverman et al., 1990).
No single method of detecting oral Candida species is sensitive enough 
(Silverman et al. 1990) and the choice of method should depend on whether a 
semi-quantitative or a quantitative estimate of candidal carriage is required.
1.3.7. Management of Denture Stomatitis.
1.3.7.1. Denture Hygiene Advice.
Denture hygiene is an important factor in the treatment of denture stomatitis 
(Thomas and Webb, 1995). Several surveys have revealed that a large number of 
people do not know how to clean their dentures satisfactorily, and this has been 
attributed to a lack of advice or to failure to follow the advice given (Neill, 1968; 
Polyzois, 1983; Jagger and Harrison, 1995).
Odds (1988) states that denture stomatitis may be managed by antifungal 
therapy in combination with strict denture disinfection and advice to patients not 
to wear their dentures at night. Furthermore, as dentures act as a reservoir of 
infection, the risk of relapse following antifungal therapy is reduced if patients 
maintain meticulous oral and denture hygiene and continue to remove their 
dentures at night (Budtz-Jorgensen, 1990a).
Walker et al. (1981) found that both the yeast concentration on the 
denture-fitting surface and palatal inflammation were as effectively reduced with
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mechanical removal of plaque alone, as with a combination of plaque removal, 
both mechanically and using a proprietary peroxide denture cleaner, and 
amphotericin B.
The importance of good oral hygiene was further supported when Berge 
et ai (1987) found that professional plaque control resulted in an improvement of 
the mucosal state, whilst withdrawal lead to recurrence of the denture stomatitis 
(Lombardi and Budtz-Jorgensen, 1993).
It has been suggested that mechanical methods of denture cleansing, such 
as scrubbing dentures after meals and massaging the denture-bearing mucosa with 
a soft toothbrush, should be introduced to denture wearers with and without 
denture stomatitis (Lombardi and Budtz-Jorgensen, 1993). However, some 
studies have shown no relationship between the frequency of brushing and the 
amount of denture plaque (Schou et al., 1987) nor the frequency of denture 
brushing and the prevalence of denture stomatitis (Nyquist, 1953; Mikkonen et 
cil., 1984).
In addition to the mechanical removal of plaque from the denture fitting 
surface and mucosa, numerous solutions, pastes and powders are available for the 
chemical cleansing of dentures (Jagger and Harrison, 1995). The most common of 
these consist of alkaline hypochlorite or alkaline peroxide (Abelson, 1985). Acids 
(Lambert and Kolstad, 1986) and enzymes (Budtz-Jorgensen, 1977) have also 
been used with some success.
In their review of the treatment of denture stomatitis, Lombardi and 
Budtz-Jorgensen (1993) stated that alkaline peroxides had no significant effect on
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either denture plaque accumulation or palatal inflammation, whereas hypochlorites 
removed plaque efficiently but had the disadvantage of having a harmful effect on 
certain denture base materials, such as soft lining materials and metals.
Lambert and Kolstad (1986) and Iacopino and Wathen (1992) found that 
C. albicans was eliminated from dentures using a denture soak containing benzoic 
acid. Granata and Staffanou (1991) found that this compound showed no harmful 
effects on soft as well as hard denture lining materials, a further advantage.
The use of enzymes which may disrupt the plaque matrix is based on the 
assumption that denture plaque is similar to dental plaque, consisting of mutan, 
dextran and salivary glycoprotein (Budtz-Jorgensen and Kelstrup, 1977; Connor 
et a!., 1977; Budtz-Jorgensen et al., 1983b). Enzymes have been shown to be 
effective at removing established plaque from dentures (Budtz-Jorgensen and 
Kelstrup, 1977; Connor et al., 1977; Odma, 1992) but also help to reduce the 
formation of denture plaque (Budtz-Jorgensen et al., 1983b).
Antibacterial substances used in the treatment of denture stomatitis include 
chlorhexidine and Listerine antiseptic (Lombardi and Budtz-Jorgensen, 1993).
Chlorhexidine has been used as a denture disinfectant and as a topical 
medicament (Budtz-Jorgensen and Loe, 1972; Olsen, 1975a; 1975b; 1975c; 
Budtz-Jorgensen and Knudsen, 1978; Lai et al., 1992 ). It has been shown to 
reduce both the clinical signs of denture stomatitis (Budtz-Jorgensen and Loe, 
1972; Olsen, 1975b; Lai et al., 1992) and yeast colonisation of the palate and 
denture surface (Budtz-Jorgensen and Loe, 1972; Olsen, 1975a; Lai et al., 1992). 
However, once chlorhexidine therapy was terminated, the inflammation recurred
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and this was followed by increased yeast colonisation (Budtz-Jorgensen and Loe, 
1972; Olsen,1975a; b; Lai etal., 1992). Prolonged use of a 0.2% chlorhexidine 
solution as an overnight denture soaking agent prevented both clinical and 
mycological relapse (Olsen, 1975c).
Brushing dentures with a 1% chlorhexidine gel proved more effective in 
preventing plaque formation than a commercial alkaline peroxide soaking agent 
(Steradent). However, the use of chlorhexidine gel was no more effective than 
brushing with a placebo gel (Budtz-Jorgensen and Knudsen, 1978).
Olsen (1975a; b) found a combination of chlorhexidine and amphotericin 
B to be effective in the treatment of denture stomatitis, although a pronounced 14 
day relapse rate in all study groups was also reported. In vitro testing has 
indicated that combining nystatin and chlorhexidine reduces the anti-candidal 
effect of both agents, possibly as a result of salt formation (McCourtie et al.,
1986; Barkvoll and Attramandal, 1989).
McCourtie et al. (1986) suggested that chlorhexidine may exert a 
beneficial effect by reducing the adhesion of Candida species to acrylic resin.
Listerine antiseptic has been found to be effective against microorganisms 
isolated from the dentures of hospitalised patients (DePaola et a/., 1984). Studies 
by the same group of workers also found Listerine to be as effective as nystatin in 
reducing inflammation and yeast colonisation in denture stomatitis patients 
(DePaola et al., 1986) and as effective as a commercial soft denture relining 
product (Coe Comfort) at reducing inflammation (DePaola et al., 1990). Plaque
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scores were not reduced in either of these studies, neither were patients assessed 
after the cessation of treatment to determine the incidence of relapse.
Although there have been few reports concerning the effects of denture 
treatment solutions on denture base materials (Aldana et al., 1994), most of these 
have indicated that disinfecting solutions have deleterious effects on acrylic resins 
(Burns et al., 1976) and soft linings (Davenport et al.; 1986; Harrison et al., 
1989).
Aldana et al. (1994) suggested that light-activated resins may be the 
materials of choice for denture stomatitis patients, as they demonstrated less 
overall degradation from the candidal treatment modalities investigated in their
study.
Staining of the denture base material is a frequent complication when 
chlorhexidine is used as a denture disinfectant (Olsen, 1975b). Furthermore, little 
is known about the possible effects of chlorhexidine on the denture-bearing 
mucosa (Lombardi and Budtz-Jorgensen, 1993).
Jagger and Harrison (1995) recommended alkaline hypochlorite as the 
most effective denture cleansing agent. They also suggested that it was suitable 
for use when dentures were lined with temporary soft lining materials. 
Furthermore, they advised that the problem of corrosion of metal based dentures 
by alkaline hypochlorite can be overcome by reducing the soaking time from 
twenty minutes to ten, followed by thorough rinsing and soaking in water.
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Alternatively, Stafford et al. (1986) found a significant reduction in 
( 'andida colonisation, without any significant dimensional changes to the 
dentures, if they were allowed to dry in air for 8 hours overnight.
Sterilization of dentures by microwaves has been recommended (Rohrer 
and Bulard, 1985). Thomas and Webb (1995) found that dimensional changes in 
dentures were almost negligible after 6 minutes microwaving at 350 watts. 
However, they stated that investigations were continuing as regards the effect that 
this level of radiation has on microorganisms.
1.3.7.2. Prosthodontic Treatment.
I he removal of denture trauma, by providing new, well-fitting dentures with good 
occlusion, has been advocated by some workers as a successful method of 
treating denture stomatitis (Budtz-Jorgensen and Bertram, 1970a, Davenport, 
1970, Bastiaan, 1976; Graham et al., 1991). However, as denture stomatitis has a 
multifactorial aetiology (Lombardi and Budtz-Jorgensen, 1993), several 
investigators have found that more successful treatment regimes reflect this 
(Ritchie et al., 1969, Arikan etal., 1995; Salonen et al., 1996). For example, 
Ritchie et al (1969) concluded that although denture stomatitis may be resolved 
by new, well-fitting, stable, non-traumatic dentures, most patients also require 
treatment with antimycotic drugs This conclusion was confirmed when Budtz- 
Jorgensen and Bertram (1970b) found that although prosthodontic treatment 
alone did result in reduced inflammation in Candida-induced denture stomatitis, it 
did not eliminate hyphal structures Furthermore, Arikan et al. (1995) found a
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combination of fluconazole and chlorhexidine to have a greater fungicidal effect 
and result in greater improvement of palatal inflammation, than either treatment 
with fluconazole or the provision of new dentures alone. However, the beneficial 
effects of prosthodontic treatment seen in patients with Newton’s Type I 
(Newton, 1962) denture stomatitis, indicated that the provision of new dentures 
without antifimgal therapy could provide a successful means of treating this form 
of denture stomatitis (Arikan eta/., 1995).
In the case of Newton’s Type III denture stomatitis (Newton, 1962), 
although the renewal of dentures results in healing to some extent (Salonen,
1994), again, the best results are obtained by combining antifungal therapy with 
the provision of new dentures (Salonen et al., 1996).
The use of tissue conditioning materials (Budtz-Jorgensen and Bertram, 
1970b; Olsson and Bergman, 1971; Zakhari and McMurry, 1977) and hard 
laboratory relines (Olsson and Bergman, 1971) have been shown to reduce the 
severity of and, in some cases, resolve palatal inflammation among patients with 
denture stomatitis Although the internal denture base acrylic which has been 
penetrated by yeasts is removed prior to placing a soft liner (Iacopino and 
^athen, 1992), the lining material itself should be replaced frequently, as these 
materials do not inhibit candidal growth (Bums et a l , 1976). In fact, an increased 
incidence of denture stomatitis has been reported in association with soft linings 
fMakila, 1976).
This problem may be reduced by the incorporation of antimycotic agents 
into soft denture reline materials (Quinn, 1985; C arter et a/., 1986). Truhlar et al.
(1994) acknowledge that more research is required in this area, but advise that the
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incorporation of a single dose of antimycotic agent into the reline material of a 
denture that allows release of the agent over a two week period, provides a 
promising treatment modality for the management of denture stomatitis.
Budtz-Jorgensen and Kaaber (1986) showed that glazing of the denture 
fitting surface was effective in reducing plaque formation and palatal erythema in 
denture stomatitis patients. However, the glazing system tested was not 
particularly durable.
I.3.7.3. Identification and Correction of Underlying Systemic Factors.
Denture stomatitis rarely occurs without at least one predisposing factor that 
lowers patient resistance (Iacopino and Wathen, 1992). Estimates of haemaglobin, 
lymphocyte and white blood cell counts, corrected whole blood folate, vitamin 
B12 and serum ferritin can all be important (Scully et al., 1995).
It is well known that uncontrolled diabetics are predisposed to oral 
candidosis (Samaranayake, 1990) and an assessment of the random blood glucose 
level should be included in investigations. There have been isolated reports of two 
patients with persistent denture stomatitis (Cawson, 1965) and another with 
angular cheilitis (Burman et al., 1956) whose lesions resolved after correction of 
the diabetic state (Samaranayake, 1990).
In the treatment of fungal infection, attention to the underlying cause will 
avoid the need for prolonged or repeated courses of treatment. However,
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intermittent or prolonged topical therapy may be necessary where the underlying 
cause is unavoidable or incurable (Scully et al., 1995).
I.3.7.4. Antifungal Therapy.
Antifungal therapy may be indicated in cases of Carafofa-associated denture 
stomatitis (Lombardi and Budtz-Jorgensen, 1993). Until relatively recently, 
topical nystatin, amphotericin B and miconazole were the mainstay of treatment 
for oral candidosis (Budtz-Jorgensen, 1990a). Although these drugs have been 
shown to be effective in producing an initial improvement in denture stomatitis, 
recurrence rates are high and treatment regimens tend to be prolonged (Cawson, 
1963; Nairn, 1975; Bergendal and Isacsson, 1980; Bergendal, 1982; Martin et al., 
1986; Lamb and Douglas, 1988). The systemic triazoles, fluconazole and 
itraconazole, have provided potentially important additional agents for treatment 
of this infection (Odds, 1993a; Karyotakis and Anaissie, 1994).
Nystatin (Mycostatin) is a specific polyene antifungal drug which has been 
used in clinical practice since 1950. The polyene mechanism of action involves an 
effect on the fungal plasma membranes, leading to augmented permeability 
(Lombardi and Budtz-Jorgensen, 1993). It is effective against candidiasis and, in 
particular, denture stomatitis (Cawson, 1963). Nystatin is insoluble and toxic 
when given parenterally and so it is limited to topical use (Scully et al., 1995) as a 
suspension, ointment or troche (Iacopino and Wathen, 1992). The treatment 
regimen consists of oral rinses kept in the mouth for five minutes, three or four 
times a day for two to three weeks (Iacopino and Wathen, 1992; Lombardi and
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Budtz-Jorgensen, 1993). Nystatin has a bitter taste which may lead to poor 
patient compliance and nausea has occasionally been reported (Lombardi and 
Budtz-Jorgensen, 1993).
Amphotericin B is also a polyene antifungal, discovered a few years after 
nystatin (Lombardi and Budtz-Jorgensen, 1993). Amphotericin B binds to the 
membrane sterols of fungal cells, causing impairment of their barrier function and 
loss of cell constituents (Warnock, 1991). Amphotericin B is not absorbed by the 
gut, but has been used intravenously for systemic candidosis. However, it does 
possess adverse side-effects such as nausea and nephrotoxicity (Lombardi and 
Budtz-Jorgensen, 1993). The use of amphotericin B in oral candidosis is usually 
limited to topical application (Epstein, 1990; Lai et al., 1992). Amphotericin B 
has been widely used in the treatment of denture stomatitis (Walker et al., 1981), 
either in the form of tablets, to be dissolved orally with the denture removed, or as 
an ointment applied to the fitting surface of the denture for three to four weeks 
(Lombardi and Budtz-Jorgensen, 1993). Although most of the major fungal 
pathogens of man are sensitive to amphotericin B (Scully et al., 1995), occasional 
strains of C. albicans which are resistant to amphotericin B are now being 
reported (Conly et al., 1992). Earlier, Ritchie et al. (1969) claimed to have 
demonstrated resistance of C. albicans to both amphotericin B and nystatin. 
However, Martin et al.{ 1986) tested C. albicans isolates from 500 cases of 
denture stomatitis and found no resistance to nystatin.
A number of studies have investigated the efficacy of nystatin (Cawson, 
1963; 1965; Budtz-Jorgensen and Bertram, 1970b; Van Reenen, 1973; Douglas 
and Walker, 1973; Nairn, 1975; Bergendal and Isacsson,1980; Bergendal, 1982;
68
Martin et al., 1986; Johnson et al., 1989) and amphotericin B (Ritchie et al.,
1969; Nairn, 1975; Olsen, 1975a;b; Budtz-Jorgensen et al., 1983a; Jegnathan et 
al., 1987) in the treatment of denture stomatitis. Some of these studies 
demonstrated that patients could be completely cured (Cawson, 1963; Ritchie et 
al., 1969; Budtz-Jorgensen and Bertram, 1970b; Nairn, 1975) whilst others 
showed that although clinically the majority of patients had improved, only a small 
number were completely clinically cured (Cawson, 1963; Budtz-Jorgensen and 
Bertram, 1970b; Bergendal, 1982; Budtz-Jorgensen et al., 1983a). In a direct 
comparison, nystatin and amphotericin B appeared to be equally efficacious 
(Nairn, 1975). High rates of relapse and recurrence following cessation of 
treatment with these drugs were a common finding (Budtz-Jorgensen and 
Bertram, 1970b; Nairn, 1975; Olsen, 1975a; Bergendal, 1982; Budtz-Jorgensen et 
al., 1983a). Possible reasons for this tendency to relapse include re-infection from 
exogenous sources as well as endogenous sites (Cawson, 1963; 1965; Bergendal 
and Isacsson, 1980). As mentioned earlier, the denture is an important source of 
re-infection (Budtz-Jorgensen and Bertram, 1970; Olsen, 1975a).
In most studies, although clinical improvement was usually accompanied 
by mycological improvement, the density of candidal colonisation quickly returned 
to pre-treatment levels on withdrawal of the drug (Ritchie et al., 1969; Budtz- 
Jorgensen and Bertram, 1970b; Olsen, 1975a; Bergendal and Isacsson, 1980; 
Johnson et a l, 1989). In patients followed up one year after treatment of denture 
stomatitis with either a combination of nystatin and new dentures or new dentures 
alone, nystatin was found to confer no long-term benefits (Bergendal, 1982).
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Antifungal therapy has been shown to improve subjective symptoms 
(Cawson, 1963; Budtz-Jorgensen and Bertram, 1970b; Olsen, 1975b) and other 
oral conditions (Cawson 1965; Budtz-Jorgensen and Bertram, 1970; Olsen,
1975b) associated with denture stomatitis. It has also been shown to lead to 
reversal of the histopathological (Budtz-Jorgensen, 1970) and immunological 
(Jegnathan et al., 1987) changes seen in the condition. Furthermore, Van Reenen 
(1973) found that nystatin inhibited the growth of some streptococci isolated from 
denture stomatitis patients.
Miconazole (Daktarin) is an imidazole-derived antifungal drug (Lombardi 
and Budtz-Jorgensen, 1993). It is fungistatic through the azoles’ property of 
changing membrane permeability (Scully et al., 1995), but also bacteriostatic for 
Gram-positive microorganisms, simultaneously blocking steroid and protein 
synthesis in microbial cell membranes (Lombardi and Budtz-Jorgensen, 1993). In 
the treatment of denture stomatitis, miconazole is used topically in the form of a 
2% gel, placed in contact with the fitting surface of the denture three times a day 
for 15 days (Lombardi and Budtz-Jorgensen, 1993). Topical miconazole gel, 
applied in this way, effectively reduced erythema in denture stomatitis patients and 
also resulted in decreased candidal colonisation of various oral sites (Watson et 
a/., 1982). Furthermore the effectiveness of miconazole against certain bacteria 
makes it useful for the treatment of angular cheilitis (Watson et al., 1982).
Ketoconazole was the first of the imidazole-derived agents to be 
developed (Lombardi and Budtz-Jorgensen, 1993) and the first to be shown 
capable of achieving therapeutic blood levels when given orally (Scully et al.,
1995). Systemically administered ketoconazole has been reported to be effective
in the treatment of denture stomatitis in one patient (Johnson and George, 1986). 
However, serious side-effects, including hepatotoxicity, have restricted its use 
(Lombardi and Budtz-Jorgensen, 1993; Scully etal., 1995).
Fluconazole is a fluorinated bis-triazole antifungal (Odds, 1996) that acts 
by inhibiting the cytochrome c-dependent demethylation step in fungal ergosterol 
production, essential in cell wall formation (Lewis et al., 1991). Fluconazole is 
well absorbed if taken orally and is widely distributed throughout body fluids, 
including saliva (Grant and Clissold, 1990). Fluconazole may reduce the 
adherence of Candida species to human buccal epithelial cells (Darwazeh et al., 
1991). Fluconazole was found to be efficacious in the treatment of denture 
stomatitis in an open, non-comparative study (Wragg et al., 1986) and in another 
placebo-controlled double blind trial (Budtz-Jorgensen et al., 1988). In the trial 
by Budtz-Jorgensen et al. (1988) fluconazole, at a dose of one 50mg capsule daily 
for 14 days, not only reduced palatal erythema and yeast colonisation, but also 
proved to be a safe, well-tolerated drug. The clinical and mycological relapse, 
which occurred in the majority of patients four weeks after treatment started, was 
attributed to possible reinfection from exogenous sources and to failure to 
eradicate yeasts from the denture plaque. Patients in this trial were not given 
denture hygiene advice and the authors acknowledged the importance of 
meticulous oral and denture hygiene in obtaining a more long-lasting cure of 
denture stomatitis after antifungal therapy. It was also concluded that a daily dose 
of fluconazole at 50mg for 2 weeks was not more efficient than topical treatment 
with antimycotic drugs for a similar treatment period. In contrast, however,
Pissell et al. (1993) found systemic fluconazole to be as effective as topical 
amphotericin B in patients who were given denture hygiene advice in addition to
antifungal therapy. In this study, as in others (Budtz-Jorgensen and Bertram, 
1 9 7 0 b; Nairn, 1975; Bergendal et al, 1979; Bergendal, 1982; Budtz-Jorgensen et 
al., 1983a; Budtz-Jorgensen et al., 1988), there was a high rate of clinical relapse 
and recurrence after therapy in both the amphotericin B and the fluconazole 
treatment groups.
Itraconazole is an orally active dioxalane tri-azole derivative which differs 
from fluconazole in several key areas (Odds, 1993a; 1996). It is a lipophilic 
molecule which achieves high and often persistent levels in skin and deep tissues.
It also has a much broader spectrum of activity than fluconazole, including 
Aspergillus species and less common Candida species. Itraconazole is available as 
50mg and lOOmg capsules. The most recent formulation to be described is a new 
cyclodextrin solution of itraconazole, which combines the effect of topical 
application to the oral mucosa and the systemic effects after absorption 
(Blatchford, 1990). Studies of itraconazole treatment so far have concentrated on 
patients who are greatly predisposed to the infection, for example those with 
AIDS (Blatchford, 1990). There have been no therapeutic trials of itraconazole 
among patients with denture stomatitis.
Lamb and Douglas (1988) treated ten patients, previously resistant to 
antifungal therapy, by means of a miconazole sustained drug-delivery device in the 
maxillary denture. Half the patients were cured. Those who were not cured had 
high levels of candidal colonisation prior to treatment and predisposing systemic 
factors. A single dose of miconazole varnish applied to the fitting surface of 
dentures has been found to be equally efficacious to miconazole gel (Budtz- 
Jorgensen and Carlino, 1994). Parvinen et al. (1994) also found a miconazole
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lacquer to be as effective as gel but suggested that repeated applications of the 
lacquer would be required to achieve a prolonged effect. Konsberg and Axell 
(1994) found a single application of miconazole lacquer to reduce the number of 
yeasts for a substantial period of time but suggested weekly re-application for 
most effectiveness. Furthermore, although miconazole lacquer was found to be a 
viable treatment of Candida-associated denture stomatitis in a cohort of Chinese 
patients (Dias et al., 1997), it was also concluded that to obtain lasting relief it 
was essential to apply the drug three times at weekly intervals and monitor 
treatment closely to detect recalcitrant infections requiring additional treatment 
sessions. Dias et al. (1997) found the major advantages of the miconazole lacquer 
to be its minimal dosage, compared with conventional formulations, and its 
application by a clinician, devoid of direct patient involvement.
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1.4. THE TRIAZOLES.
1.4.1. History of Use.
Fungal infections are a major cause of morbidity and mortality in 
immunocompromised individuals. For over 30 years amphotericin B has been 
considered the gold standard for the treatment of life-threatening fungal 
infections, but severe adverse reactions and treatment failures have obscured its 
status (Karyotakis and Anaissie, 1994). The introduction of ketoconazole 
provided an alternative to amphotericin B, but problems of resistance, 
hepatotoxicity, poor gastric absorption and failure to successfully treat fungal 
infections in the immunosuppressed have limited its use (Sugar, 1993). The need 
for safer and more effective systemic antifimgals led to the synthesis of the 
triazoles, fluconazole and itraconazole (Karyotakis and Anaissie, 1994). These 
agents are currently the most widely used of their class for the management of 
deep-seated fungal infections (Odds, 1996). Fluconazole is a well tolerated drug 
with an excellent safety profile (Osterloh, 1992). It has been used to treat 
superficial and systemic mycoses (Odds, 1993 a). Prolonged administration of 
fluconazole for prophylaxis has raised concerns about the emergence of resistance 
(Karyotakis and Anaissie, 1994). Itraconazole is safe and effective in the 
treatment of both superficial and systemic candidoses (Odds, 1993a; 1996). It has 
a broader spectrum of activity than fluconazole, including Aspergillus species and 
less common Candida species (Odds, 1993a).
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1.4.2. Mechanism of Action and Spectrum of Activity.
The azoles are fungistatic through their property of changing membrane 
permeability (Scully et al., 1995). They interfere with cytochrome P-450- 
dependent enzyme C-14a-demethylase, which is responsible for the conversion of 
lanosterol to ergosterol, the major component of the fungal cell membrane. The 
disruption of ergosterol synthesis causes functional and structural changes that 
render fungal cells more susceptible to osmotic and immune-mediated damage and 
result in deficient fungal cell adherence (Karyotakis and Anaissie, 1994).
Fluconazole, whilst active against most pathogenic yeasts, has limited 
activity, in vitro, against the moulds, including Aspergillus species. However, 
there is some evidence that higher doses may be effective in clearing aspergillus 
infections (Hay, 1991). Itraconazole’s spectrum of activity both in vitro and 
clinically is very broad (Odds, 1993a). However, neither triazole is active against 
C. krusei, C. glabrata, Fusarium species, and the zygomycetes. Other Candida 
species, such as C. parapsilosis, C. lusitaniae and C. gidllermondii, exhibit strain- 
dependent susceptibility (Karyotakis and Anaissie, 1994).
1.4.3. Fluconazole.
1.4.3.1. Chemistry.
Fluconazole is a triazole derivative, the important determinant of activity being 
the triazole moiety (Fig. 1.3). Fluconazole is unique among clinically available 
azole derivatives by being highly water-soluble. It is minimally protein-bound in
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the circulation (Odds, 1996). As a result it is distributed throughout body water. 
It is available as a capsule and as an aqueous solution for intravenous 
administration (Sugar, 1993).
Fig. 1.3. The structure of fluconazole.
OH
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1.4.3.2. Pharmacology.
Fluconazole, being very water soluble, has excellent absorption and is widely 
distributed throughout the body (Hay, 1991). High concentrations appear in CSF 
(50-100% serum concentrations) and peritoneal fluid (Odds, 1993a). Fluconazole 
is minimally metabolized and 80% of the administered dose is excreted unchanged 
in the urine (Karyotakis and Anaissie, 1994). The terminal half-life of fluconazole 
is approximately 24 hours. Serum concentrations increase sequentially with 
increasing dose (Hay, 1991) and, without a loading dose, steady state 
concentrations are reached in about five days. Optimal dosing depends on the 
indication, with doses ranging from 50mg to 400 mg given once daily (Sugar,
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1993). The half-life of fluconazole is markedly increased in patients with severely 
depressed glomerular filtration rates; hence the dose should be reduced in patients 
with renal impairment (Karyotakis and Anaissie, 1994).
1.4.3.3. Adverse Effects and Drug Interactions.
Fluconazole is a well tolerated drug (Osterloh, 1992). The main side-effect is 
gastrointestinal intolerance (Karyotakis and Anaissie, 1994; Odds, 1996). 
Headaches, dizziness, abdominal pain and pruritis may also occur (Karyotakis and 
Anaissie, 1994). Transient elevations of serum enzymes related to liver function 
occur frequently in AIDS patients treated with fluconazole but there are no effects 
on steroid metabolism related to adrenal or testicular function (Odds, 1996). Rare 
side-effects reported with fluconazole include anaphylaxis, Stevens-Johnson 
syndrome and thrombocytopenia (Sugar, 1993).
Fluconazole elevates or prolongs levels of phenytoin, cyclosporin, 
sulphonylurea and other oral hypoglycaemic agents such as chlorpropamide and 
tolbutamide (Odds, 1996). Potentiation of warfarin effects on prothrombin time 
have been noted (Sugar, 1993; Odds, 1996). Levels of ethinyl oestradiol are 
reduced in patients taking oral contraceptives (Odds, 1996). Rifampin has been 
reported to cause a modest reduction of fluconazole serum levels (Sugar, 1993; 
Odds, 1996).
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1.4.3.4. Clinical Efficacy.
The efficacy of fluconazole has been demonstrated in superficial fungal infections 
such as vaginal candidosis (Andersen et al., 1989) and in oropharyngeal 
candidosis in patients who are HIV positive (Dupont and Drouhet, 1988; DeWit 
etal., 1989). Oropharyngeal and oesophageal candidosis in the neutropenic 
patient have also been successfully treated with fluconazole (Sugar, 1993). Doses 
range from as low as 50mg daily, for superficial fungal infections, up to and 
exceeding 400mg daily for systemic candidal and cryptococcal infections 
(Osterloh, 1992). In the treatment of oral candidosis in patients with AIDS, 
although there is usually a rapid response to therapy there is also a high 
recurrence rate, usually within 30 days (Sugar, 1993). As a result, either 
maintenance therapy or intermittent therapy with fluconazole is essential to 
prevent relapse after cessation of treatment (Lewis et al., 1991). Fluconazole has 
been successfully used to treat chronic disseminated candidosis and, less 
convincingly, patients with candidaemia (Sugar, 1993). The efficacy of 
fluconazole in the treatment of Candida-associated denture stomatitis has been 
reviewed above (see Section 1.3.7.4).
1.4.3.5. Antifungal Prophylaxis.
The low toxicity of fluconazole has led to its use over long time intervals as a 
prophylactic agent in severely compromised patients, for example bone marrow 
transplant recipients and those with AIDS (Just-Niibling et al., 1991; Stevens et 
al-, 1991; Goodman et al., 1992). The poor in vitro activity of fluconazole against
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aspergilli is a possible disadvantage in the use of fluconazole as oral antifungal 
prophylaxis (Hay, 1991). Furthermore, there is concern about the emergence as 
pathogens of yeasts that are less virulent than C. albicans but which are resistant 
to fluconazole, for example C. krusei (Wingard et al., 1991; Goodman et al., 
1992).
1.4.4. Itraconazole.
1.4.4.1. Chemistry.
Itraconazole is a triazole derivative (Fig. 1.4). It is insoluble in aqueous media and 
is highly protein-bound in the bloodstream. Itraconazole is found concentrated in 
lipid tissues. It is dispensed as a lactose bead-encapsulated capsule and recently as 
a new liquid formulation using hydroxypropyl-|3-cyclodextrin, which offers more 
reliable absorption and near total bioavailability of the drug (Hostetler et al.,
1992). There is no intravenous preparation of itraconazole (Sugar, 1993).
Fig. 1.4. The structure of itraconazole.
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I.4.4.2. Pharmacology.
Itraconazole is highly lipophilic and essentially insoluble in aqueous solutions and 
at neutral pH (Sugar, 1993; Karyotakis and Anaissie, 1994). Conditions of low 
intragastric acidity interfere with the absorption of itraconazole. As a weak base, 
it requires low gastric pH and is better absorbed when administered with food 
(Karyotakis and Anaissie, 1994; Odds, 1996). A low pH also aids in maximising 
concentration of itraconazole in the blood (Sugar, 1993). Bradford et al (1991) 
have indicated that in cases of apparent failure of itraconazole therapy, 
measurement of serum concentrations of the drug may be helpful in determining 
the cause of the lack of response. Oral doses of 100-200mg itraconazole taken 
daily produce serum concentrations of 0.3mg/ml, one to three hours later (Hay, 
1991). However, repeated administration for two weeks results in a peak plasma 
concentration of around 2mg/ml (steady state) in healthy subjects. Furthermore, a 
loading dose (600mg/day for several days) may help to attain higher serum levels 
before the steady state is achieved (Karyotakis and Anaissie, 1994). Itraconazole 
is highly protein-bound to plasma proteins, and concentrations of itraconazole in 
body fluids, such as serum or CSF, are low (Sugar, 1993; Odds, 1996). However, 
when itraconazole is assayed in tissues, concentrations two to five times higher 
than those in blood are often found (Van Cutsem et al., 1987). As a result, 
itraconazole appears to reach potential sites of infection in concentrations that 
should provide an antifungal effect (Sugar, 1993). Itraconazole undergoes 
extensive metabolism in the liver (Karyotakis and Anaissie, 1994). At least one of 
the metabolites, hydroxyitraconazole, has an antifungal effect (Sugar, 1993; Odds, 
1996). Excretion of itraconazole and its metabolites is principally via bile (Odds, 
1996).
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1.4.4.3. Adverse Effects and Drug Interactions.
Itraconazole has an excellent safety profile (Odds, 1993a) causing only minor 
side-efifects, most of which are gastrointestinal in nature (Odds, 1993a; 1996). 
Headaches, dizziness, abdominal pain and pruritis may also occur (Karyotakis and 
Anaissie, 1994). Hepatotoxicity is not a serious problem with itraconazole (Odds, 
1993 a), although transient elevations of serum aminotransferases have been 
reported in some patients and itraconazole usage should be avoided in patients 
with liver disease (Odds, 1996). Itraconazole may occasionally interfere with 
steroid metabolism and can cause accumulation of substances with aldosterone­
like activity, capable of producing hypokalaemia, pedal oedema and hypertension 
(Karyotakis and Anaissie, 1994). These effects should not occur at normal 
dosages of itraconazole (Odds, 1996).
Itraconazole should not be used concomitantly with cyclosporin, digoxin, 
phenytoin and terfenadine to avoid increasing the serum levels of these drugs. 
Conversely, serum levels of itraconazole are lowered if it is administered 
concomitantly with rifampicin, rifabutin, antacids or H2 blocking agents. The 
anticoagulant effect of warfarin is prolonged and enhanced by itraconazole (Odds, 
1996).
1 -4.4.4. Clinical Efficacy.
Itraconazole is an effective agent for the treatment of both superficial and 
systemic mycoses (Odds, 1993a). Itraconazole’s broad spectrum of activity 
includes less common Candida species and Aspergillus species (Van Cutsem et
al., 1984; Van Cutsem et al., 1987). In a randomised comparative study with 
intravenous amphotericin B, itraconazole showed comparable activity with the 
latter in the treatment of fungal infection in neutropenic patients (Van t ’Wout et 
al., 1991). Studies of itraconazole treatment of oral candidosis have concentrated 
so far on patients who are greatly predisposed to the infection, for example those 
with AIDS (Blatchford, 1990). Itraconazole gave equally good clinical results 
when compared to ketoconazole in the treatment of oral and oesophageal 
candidosis in patients with HIV infection, although relapse rates were identical 
with both drugs (Smith et al., 1991). The new cyclodextrin solution of 
itraconazole (see 1.4.4.1.) has been used successfully among a group of AIDS 
patients with a history of failed treatment for oral candidosis using other azoles 
(Cartledge et al., 1994).
1.4.4.5. Antifungal Prophylaxis.
A combination of itraconazole and oral amphotericin B, when compared to oral 
amphotericin B alone, as a prophylactic measure in neutropenic patients with 
haematologic malignancies, reduced the incidence of C. albicans infection but 
made no difference to the incidence of aspergillosis, overall fungal infections or 
mortality. (Vreugdenhil et al., 1993). In two retrospective studies in neutropenic 
patients, prophylactic itraconazole was more effective than nystatin or 
ketoconazole and a combination of oral itraconazole and nasal amphotericin B 
effectively reduced the incidence and mortality of invasive aspergillosis compared 
vvith historical controls in patients with haematologic malignancies (Karyotakis 
and Anaissie, 1994).
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1.4.5. The Problem of Azole Resistance.
Therapeutically, azole resistance is a substantial problem (Denning, 1995). 
Fluconazole has been implicated in instances of emergent resistance more often 
than ketoconazole, and ketoconazole more often than itraconazole (Odds, 1993b). 
The first reports of fluconazole resistance in the context of AIDS did not emerge 
until 1990 (Fulton and Philips, 1990). C. krusei and C. glabrata are frequently 
cited as emergent colonizing flora during frequent or sustained clinical use of 
fluconazole in immunocompromised or debilitated patients and in treatment 
failures of diagnosed disease, both in disseminated infections and in mucosal 
candidal infections. Resistance to fluconazole in C. albicans is less common but 
does exist (Odds, 1993b). Evidence exists that strains of C. albicans are 
becoming more resistant to fluconazole, because of decreased cell wall 
permeability, when the drug is given in a low dosage and on a long-term basis to 
patients with AIDS for prophylaxis of oral candidosis (Dupont, 1995).
To date, there have been only anecdotal reports of itraconazole inducing 
resistance, but it has been suggested that this may reflect the much wider use of 
fluconazole (Milne, 1997). Barchiesi et al. (1994) have found a significant 
proportion of fluconazole-resistant C. albicans strains to be cross-resistant to 
itraconazole in vitro.
Three possible mechanisms o f resistance have been described (Odds,
1993b):
1) reduced permeability of the C. albicans membrane to azole 
antifungals
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2) mutation in the target fungal cytochrome P450 enzyme resulting in 
decreased binding affinity for the azole drugs
3) overproduction of the target cytochrome P450 enzyme.
The relative importance of each, and for which azole, is unknown (Denning,
1995). Stategies for the prevention of azole resistance include restraint in the use 
of these drugs, the avoidance of antifungal prophylaxis in AIDS patients, except 
when there are frequent episodes of oesophageal candidosis or for cryptococcal 
meningitis, and possibly the use of alternative antifungals to fluconazole, such as 
itraconazole formulated in cyclodextrin (Janssen) or the azole D0870 (Zeneca) 
(Denning, 1995). However, caution should be exercised if alternative antifungals 
to fluconazole are to be used in the longer term, as in cases where fluconazole- 
specific resistance has been demonstrated isolates have also shown a loss of 
sensitivity to itraconazole, although to a lesser degree (Johnson et al., 1995).
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1.5. AIMS.
Candida-associated denture stomatitis is common, affecting approximately 50% 
of denture wearers. Unfortunately, current treatments result in a high rate of 
recurrence (Budtz-Jorgensen, 1990). Until now, there have been no therapeutic 
trials of itraconazole among patients with denture stomatitis, despite the poor 
patient compliance with topical drugs and the rapid relapse reported following 
treatment with fluconazole (Budtz-Jorgensen et al., 1988; Bissell eta/., 1993).
The most recent formulation of itraconazole, the cyclodextrin solution, could 
prove advantageous in the armamentarium of denture stomatitis management by 
combining the effect of topical application to the mucosa and the systemic effects 
after absorption.
The objectives of this study were:
1. To determine by means of a single blind clinical trial the value of 
cyclodextrin solution of itraconazole at a dose of lOOmg twice daily in the 
treatment of Candida-associated denture stomatitis.
The trial design also encompassed:
• Determination o f  the safety o f and tolerance for itraconazole.
• Determination o f itraconazole sensitivity of yeasts isolated from the mouths of
patients before and after treatment.
• Measurement o f  itraconazole levels achieved in blood and saliva.
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2. To determine, by molecular typing of C. albicans species isolated before 
and after treatment, whether there had been recurrence of infection with the same 
strain(s), selection of particular strains or infection with new strains of C.albicans 
This may permit a fuller understanding of the reasons for any relapses following 
treatment.
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CHAPTER TWO 
MATERIALS AND METHODS
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2.1. PRELIMINARY INVESTIGATIONS.
2.1.1. Evaluation of the Erythema Meter.
Many diseases of the oral mucosa result in inflammation, manifesting clinically as 
an increase in mucosal erythema. Reduction in erythema, indicative of resolving 
inflammation, can therefore be used as an objective indicator of successful 
treatment. Clinical trials of antifiingal drugs have commonly used a reduction in 
erythema as an outcome measure. To date, however, the major difficulty has been 
the lack of an objective method for assessing erythema of the oral mucosa. 
Previous studies have relied on a subjective visual assessment (Bergendal and 
Isaacson, 1980; Bergendal, 1982; Johnson et al., 1989) or have used photographs 
(Olsen, 1975a; Budtz-Jorgensen, et a l 1988; Lai et al., 1992), but neither of 
these methods is ideal.
The Erythema meter (Fig. 2.1) was developed originally to measure 
cutaneous erythema induced by ultraviolet radiation (Diffey et al., 1984). The 
instrument is based on the principle that when white light, between 400nm and 
700nm, is reflected off a cutaneous or mucosal surface, haemaglobin in the 
vasculature selectively absorbs green light but has little effect on red. An 
‘erythema index’, defined as the logarithm of the ratio of red to green reflected 
light, can be determined. The difference between the ‘erythema index’ measured 
before and after treatment is related to reduced vasodilation following a reduction 
in the degree of inflammation.
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Figure 2.1. A photograph of the Erythema Meter - an electro-optical 
instrument for measuring oral mucosal erythema.
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The aims of the preliminary investigations were:
1 To evaluate the sensitivity and reproducibility of the Erythema meter for 
quantifying erythema of the palatal mucosa.
2. To determine the usefulness of the Erythema meter in a clinical trial situation.
2.1.1.1. Laboratory Study.
A series of non-clinical Erythema meter readings were taken from a check- 
standard used by graphic artists for colour reproduction. This check-standard 
(Fig.2.2) had a range of colours from pale pink to dark red. To the human eye 
these colours appeared similar to those of healthy and inflamed mucosa. The 
colours were composed of varying percentages of magenta, starting at 20% 
magenta for the palest pink shade and moving up to 100% magenta for the 
darkest red. The Erythema meter was used to record an erythema index for each 
shade on three separate occasions and the results averaged.
2.1.1.2. Clinical Investigations.
The protocol for the clinical study was approved by the local ethical review 
committee. All patients gave informed consent prior to participation.
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for colour reproduction.
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2.1.1.2.1. Patients.
Two groups of patients were studied. The first comprised 40 individuals with 
clinically healthy palatal mucosa, 20 of whom were dentate and 20 of whom wore 
complete dentures. The second group consisted of another 20 complete denture 
wearers, all of whom had clinical evidence of long-standing denture stomatitis.
The complete denture wearers were recruited from the Oral Medicine and 
Prosthodontic Departments of Glasgow Dental Hospital and School N.H. S.Trust, 
while the dentate participants were staff and students from Glasgow Dental 
Hospital and School N.H.S.Trust. Table 2.1 shows the sex and age distribution of 
the groups.
Table 2.1. Age and sex distribution for the three study groups.
n Mean age Male Female
 (ran g e)......................................
Healthy palatal 
mucosa
Non-denture 20 29.7(18-53) 9
controls
1 1
Denture controls 20 64.7(34-88) 10 10
Denture stomatitis 20 68.8(43-85) 7 13
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2.1.1.2.2. Baseline Investigations.
All patients were examined by the author. Following a full medical and dental 
history, the clinical assessment included an oral examination and both visual and 
objective assessments of erythema of the palatal mucosa.
The age and fit of dentures and existing denture hygiene practices were 
recorded for the complete denture wearers. Denture stomatitis, if present ,was 
classified as localised erythematous (Newton’s Type I), diffuse erythematous 
(Newton’s Type II) or hyperplastic granular (Newton’s Type III) (Newton,
1962).
Visual assessment of the degree of palatal erythema was recorded, from 
zero to three, according to Budtz-Jorgensen and Bertram (1970b).
Erythema meter readings were then taken from each side of the palate, 
repeated three times and averaged, as recommended by Dififey et al. (1984). This 
allowed the derivation of an ‘erythema index’. A removable attachment was fitted 
onto the end of the fibre optic cable to ensure the tip was positioned a standard 
distance above the mucosal surface. This attachment was heat-sterilised between 
patients. The sites measured were recorded on a diagram so that the readings 
could be repeated from exactly the same sites at the next visit.
Two weeks later the visual scores and the Erythema meter readings for 
the 40 patients with healthy palatal mucosa were repeated and recorded, to allow 
assessment of the reproducibility of the Erythema meter scores.
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2.1.1.3. Comparison of Fluconazole and Itraconazole in the Management of 
Denture Stomatitis.
2.1.1.3.1. Patients.
The twenty complete denture wearers with clinical evidence of long-standing 
denture stomatitis (see Section 2.1.1.2.1.) were enrolled in a clinical trial 
comparing the efficacy of fluconazole and itraconazole in the management of 
denture stomatitis.
The following groups of patients were excluded from the trial:
1. Female patients who were pregnant, lactating or of child-bearing age and not 
using reliable contraception.
2. Patients with impaired renal or hepatic function.
3 Those who had used an antifiingal agent within the preceding 10 days.
4 Those taking any drug listed in the British National Formulary (1996) as 
interacting with the azole group of antifungal drugs.
5. Those with a known sensitivity to the azole group of antifungal drugs.
6 Those intending to donate blood during or three weeks after the study period.
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2.1.1.3.2. Baseline Investigations.
The clinical history and investigations carried out were those described in Section
2.1.1.2.2. In addition, the denture fitting surfaces of the denture stomatitis 
patients were assessed visually and by scraping with a blunt instrument, then 
allocated a clinical denture cleanliness score of 0 to 4, depending on the amount 
of plaque visible on the denture fitting surface (Blair et al., 1995). Zero 
represented no visible plaque and no plaque adherent to a flat plastic instrument 
on light scraping of the denture fitting surface; 1, no visible plaque but matter was 
adherent to the instrument on light scraping; 2, deposits of plaque which were just 
visible without the need to confirm by scraping; 3, deposits of plaque which were 
clearly visible and 4, gross plaque deposits (Blair et al., 1995).
Venous blood was collected for routine haematological and biochemical 
investigations including a full blood count, serum ferritin, folate, vitamin B12 and a 
random blood glucose level.
Microbiological samples including imprint cultures (Arendorf and Walker, 
1979) from the palate and tongue, an oral rinse (Samaranayake et al., 1986a) and 
a denture disc specimen (Blair et al., 1995) were collected (see Section 2.2.3.4.1).
2.1.1.3.3. Treatment Protocols and Follow-up.
At baseline, all patients were instructed in denture hygiene measures and given an 
instruction leaflet containing relevant standardised information. Provision of 
specific antifungal medication was undertaken on an open basis. Ten consecutive
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patients were prescribed fluconazole capsules at a dose of 50mg once daily for 14 
days, and a further ten consecutive patients provided with itraconazole capsules at 
an oral dose of lOOmg once daily for 15 days. These dosages were those 
recommended in the British National Formulary (1996).
All patients were reviewed after 14 days, on completion of their course of 
antifungal medication, and the clinical and microbiological investigations 
described at baseline were repeated.
2.1.1.3.4. Microbiological Methods.
2.1.1.3.4.1. Specimen Processing.
Imprint cultures (Samaranayake et a/., 1986a) were inoculated sequentially onto 
plates of Sabouraud’s dextrose agar (Life Technologies, Paisley, Scotland) and 
CHROMagar* ('andida (Life Technologies, Paisley, Scotland) at the chairside.
After concentration, oral rinse specimens (Samaranayake et al., 1986a)
•  m2  j  * 3were inoculated by spiral plating onto blood agar (at dilutions of 10 and 10 ), 
Sabouraud’s dextrose agar and CHROMagarx Candida
Denture disc specimens (Blair et al., 1995) were collected by applying a 
pre-sterilised filter paper disc (Whatman Grade 1) to a standardised area of the 
denture fitting surface for 20 seconds The disc was immediately placed into 9ml 
sterile phosphate buffered saline (pH 7.4). On arrival at the laboratory the 
specimen was vortex mixed for 10 seconds and an aliquot tenfold diluted to 10
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Each dilution was spiral plated onto duplicate sets of blood agar and incubated for 
48 hours at 37°C both aerobically and anaerobically. Neat specimen was 
inoculated onto Sabouraud’s agar and CHROMagar Candida. Logarithmic 
conversion of the total anaerobic count produced a ‘denture cleanliness score’ 
(Blair et al., 1995).
All plates were incubated at 37°C for 48 hours.
2.1.1.3.4.2. Yeast Identification.
r. albicans was identified on the basis of germ tube production. A sucrose 
assimilation test was performed on germ tube positive yeasts to distinguish from 
C stellatoidea or C. tropica/is. Germ tube negative yeasts were identified by the 
API 32C test (bio-Merieux S A, Marcy-l’Etoile, France)(see Section 2.2.3.4.2).
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2.2. A CLINICAL TRIAL COMPARING THE EFFICACY OF A 
CYCLODEXTRIN SOLUTION OF ITRACONAZOLE AND 
ITRACONAZOLE CAPSULES IN THE MANAGEMENT OF CANDIDA- 
ASSOCIATED DENTURE STOMATITIS.
2.2.1. Study Design.
The study was a parallel design, single blind clinical trial which compared the 
effectiveness of denture hygiene instruction and treatment with the cyclodextrin 
solution of itraconazole against denture hygiene instruction and treatment with 
itraconazole capsules in the management of Ca/zJ/c/^-associated denture 
stomatitis.
The protocol for the clinical trial was approved by the local ethical review 
committee. All patients gave written informed consent to participate in the study 
(Appendix I).
2.2.2. Patients.
Patients were recruited from the Prosthodontic and Oral Medicine Departments of 
Glasgow Dental Hospital and School N.H.S. Trust Edentulous denture wearers 
with clinical evidence of denture stomatitis were examined for yeasts by swabbing 
the palatal mucosa and dorsum of the tongue Patient details were completed on a
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standard proforma (Appendix II). In the laboratory, the swabs were inoculated 
onto Sabouraud’s dextrose agar which was then incubated at 37°C for 48 hours.
Forty patients from whom yeasts were cultured at both sites and who 
fulfilled the other criteria were enrolled in the clinical trial. Nine were male and 
thirty-one were female with ages ranging from 29 to 81 years (mean age 62 
years). Table 2.2 shows the sex and age distribution of the two groups. Exclusion 
criteria were identical to those stated in Section 2 113 1
Table 2.2. Age and sex distribution for the two study groups.
n Mean age 
(range)
Male Female
( yclodextrin group 20 62.1(35-79) 6 14
I apsule group 20 65.2(29-81) 3 17
2.2.3. Baseline Investigations.
2-2.3.1. Clinical History’.
f linical details were recorded on a standard proforma (Appendix II). 
Demographic details were collected, together with a full medical and dental
99
history. In particular, local factors predisposing to oral candidosis were sought. 
These included continuous denture wearing, inadequate denture hygiene practices, 
smoking, use of steroid inhalers and oral dryness.
Similarly, systemic predisposing factors were identified, including relevant 
drug history, (steroids and other immunosuppressive medication, antibiotics and 
drugs inducing xerostomia), haematological or endocrine abnormalities and 
recognised immunodeficiency states.
2.2.3.2. Clinical Examination.
All patients were examined by the author. A complete oral examination was 
undertaken and the age and fit of dentures recorded. Mucosal changes suggestive 
of candidosis were noted. Denture stomatitis was classified visually as localised 
erythematous (Newton’s Type I), diffuse erythematous (Newton’s Type II) or 
hyperplastic granular (Newton’s Type III) (Newton, 1962).
Palatal erythema was visually assessed and awarded a score from 0 to 3, 
according to Budtz-Jorgensen and Bertram (1970a). Erythema meter readings 
were then taken from that area of the palate which appeared to be the most 
inflamed. The reading from this site was repeated three times and averaged, as 
recommended by Diffey et al. (1984). The site measured was recorded on a 
diagram (Appendix II) so that the readings could be repeated from exactly the 
same site at subsequent visits.
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The denture fitting surfaces were assessed visually and by scraping with a 
blunt instrument, then allocated a clinical denture cleanliness score of 0 to 4, 
depending on the amount of plaque visible on the denture fitting surface (Blair et 
a l 1995).
2.2.3.3. Haematology and Blood Chemistry.
The following investigations were undertaken for each patient at enrolment:
• full blood count
• serum ferritin
• serum folate
• vitamin B 1 2
• random blood glucose
• urea and electrolytes
• liver function tests
• C-reactive protein
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2.2.3.4. Microbiological Methods.
2.2.3.4.I. Specimen Collection and Primary Cultures.
• Imprint Cultures.
Imprint cultures (Arendorf and Walker, 1979) were collected from the hard 
palate, denture fitting surface and tongue. A modified version of the imprint 
culture technique was employed. Sterile foam pads were placed lightly onto the 
site to be sampled and then immediately inoculated at the chairside onto plates of 
Sabouraud’s dextrose agar followed by CHROMagar* Candida. After incubation 
at 37°C for 48 hours, yeast isolates were processed as described below.
• Oral Rinse.
An oral rinse (Samaranayake et al., 1986a) was collected from all patients. Each 
patient was asked to rinse the mouth for one minute with 9ml sterile phosphate 
buffered saline (pH 7.4) before returning the solution to the container provided. 
After concentration, by centrifugation at 3200 r.p.m. (Centaur) for 5 minutes 
(Samaranayake et al., 1986a), the supernatant was poured off and the oral rinse 
specimens were inoculated by spiral plating onto blood agar (at dilutions of 1 0  2 
and 10‘3), Sabouraud’s dextrose agar, CHROMagar* Candida and MacConkey 
agar. All plates were incubated at 37°C for 48 hours.
Staphylococcus aureus was identified by a commercially available 
coagulase test (Slidex Staph-Kit, bioMerieux SA, Marcy-l’Etoile, France) and (3- 
haemolytic streptococci were Lancefield grouped (bioMerieux SA, Basingstoke). 
Coliforms were tested as oxidase positive or negative using a paper strip for the
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detection of cytochrome oxidase (PYO-TEST, Medical Wire and Equipment 
Company (Bath) Limited). Oxidase negative coliforms were identified by the 
Analytical Profile Index (API 20E, bioMerieux SA, Marcy-l’Etoile, France) and 
oxidase positive coliforms by API 20NE (bioMerieux SA, Marcy-l’Etoile,
France). Yeasts were investigated as described below.
• Denture Disc Specimens.
Denture disc specimens (Blair et al., 1995) were collected from the fitting surface 
of the maxillary denture. A pre-sterilised filter paper disc (Whatman Grade 1) was 
applied to a standardised area of the denture fitting surface for 20 seconds. It was 
immediately placed into 9ml sterile phosphate buffered saline (pH 7.4). On arrival 
at the laboratory the specimen was vortex mixed for 1 0  seconds and an aliquot 
tenfold diluted to 10'4. Each dilution was spiral plated onto duplicate sets of blood 
agar and incubated for 48 hours at 37°C both aerobically and anaerobically. Neat 
specimen was inoculated onto selective media for yeasts and coliforms as 
described earlier.
Logarithmic conversion of the total anaerobic count provided a denture 
cleanliness score of relevance for patients with denture stomatitis. Isolates of 
coliforms, Staphylococcus aureus and P-haemolytic streptococci were identified 
as described above. Yeasts were analysed as described below.
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2.2.3.4.2. Selection of Yeasts from Primary Plates.
One colony of each morphological type on CHROMagar®’ Candida (Fig. 2.3) 
was plated for purity, identified and stored at -70°C. The proportion of each type 
on these plates was also recorded. For each patient, four further colonies were 
removed from the Sabouraud’s plates, selected at random from the specimens 
available. Each isolate was formally identified and stored at -70°C for further 
investigation.
2.2.3.4.3. Yeast Identification.
Although yeast species could be differentiated by their morphological appearance 
on CHROMagar* Candida, their identification was always confirmed by 
appropriate physiological testing.
C. albicans was initially identified by the green colouration of its colonies 
on CHROMagar Candida and this was confirmed by the production of germ 
tubes. A small portion of the yeast colony to be investigated was removed with a 
loop of wire, emulsified in 0 .5 ml serum in a tube and incubated at 37°C for 2 
hours. A drop of this mixture of serum and yeast was then removed, placed on a 
microscope slide and examined for the presence of germ tubes. If present, the 
yeast was identified as C. albicans. In the absence of germ tubes, the inoculated 
serum was reincubated for a further 60 minutes. If there was no evidence of germ 
tube production after this period of time, the isolate was classed as germ tube 
negative.
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A sucrose assimilation test was performed on germ tube positive yeasts to 
distinguish C. albicans from C. stellatoidea or C. tropicalis. Yeast identification 
agar was melted and allowed to cool to 45°C. One colony of the yeast to be 
investigated was emulsified in 5ml distilled water. Five drops of this mixture were 
then added to the molten agar, which was poured into a petri dish and allowed to 
set. Five discs, each saturated with a different carbohydrate (sucrose; lactose; 
trehallose; cellobiose; rafifmose) were placed onto the surface of the agar around 
the periphery of the plate. After incubation at 30°C for 24-48 hours, the plate was 
examined for growth around the discs to determine the assimilation profile.
Germ tube negative yeasts were identified using the ID 32C test 
(bioMerieux S A, Marcy-l’Etoile, France).
2.2.3.S. Oral Hygiene.
All participants were instructed on denture hygiene and given an instruction leaflet 
(Appendix III) containing relevant standardised advice This included instructions 
to clean dentures regularly after each meal using a soft brush and soap. Patients 
were also advised to remove their dentures at night for sleeping and immerse them 
overnight in luke-warm water containing an alkaline peroxide denture cleanser, 
such as Milton® or Steradent®.
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Figure 2.3. A photograph of a CHROMagar® Candida plate showing a 
mixed growth of C. albicans (green colonies) and C  glabrata 
(purple colonies).
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2.2.3.6. Azole Treatment.
The forty patients were randomised to receive either cyclodextrin solution of 
itraconazole (Sporanox Liquid®, Janssen Pharmaceuticals) at a dose of lOOmg 
twice daily for 15 days or itraconazole capsules (Sporanox®, Janssen 
Pharmaceuticals) at the same dosage, also for 15 days. These dosages were those 
recommended in the British National Formulary (1996). As the clinician 
examining the patients was blinded to the treatment code, the medication was 
dispensed by nursing staff in the Oral Medicine Department. Patients received a 
bag containing either itraconazole liquid or capsules along with printed 
instructions stating the dose to be taken and the appropriate time at which to take 
it (Appendix III). Itraconazole capsules were to be taken after food and 
cyclodextrin solution one hour before food. Patients in the cyclodextrin group 
were asked to remove their dentures and briefly swill the solution around their 
mouth before swallowing.
2.2.4. Assessment of Response.
Patients were reviewed after 15 days, on completion of their course of antifungal 
medication. Any patient who had failed to complete the course of medication was 
then excluded from the trial. Further reviews were undertaken at one and six 
months after treatment commenced.
At each review visit a full oral examination, including visual and objective 
assessment of any changes in the appearance of the palatal mucosa was made. An
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oral rinse, imprint cultures and denture disc specimen were also collected at each 
visit. The yeasts isolated were selected, identified, stored at -70°C and analysed as 
described above (see Section 2.2.3.4).
Blood was taken for a full blood count, liver function tests, urea and 
electrolytes and C-reactive protein measurement at the end of the 15 day study 
period. A further blood sample was taken at six months for a full blood count, 
serum ferritin, serum folate, vitamin B12 and a random blood glucose level.
An additional blood sample and at least 1 ml of whole saliva were collected 
at the end of the 14 day study period to enable measurement of itraconazole levels 
in serum and saliva Itraconazole concentrations were measured by means of 
reversed-phase high-performance liquid chromatography (HPLC) with a lower 
limit of detection of 10pg/L and coefficients of variation of 2 .2 - 7.8% over the 
concentration range of 20-1600pg/L (Warnock et a/., 1988). The standard curve 
was linear from 10 to 10,000pg/L. These measurements were made by the Public 
Health Laboratory Service Mycology Reference Laboratory in Bristol.
On completion of the antimycotic therapy patients were requested to 
complete a questionnaire (Appendix IV). This was designed to assess patient 
compliance and record the incidence of side-effects whilst enabling the clinician to 
remain blind to the treatment code until after the clinical trial.
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2.2.5. Additional Microbiological Methods.
2.2.5.1. Molecular Typing of Candida albicans Isolates Before and After 
Treatment.
2.2.5.1.1. DNA Extraction.
Pairs of isolates from those patients with C. albicans present at baseline and six 
months after treatment commenced,were removed from storage at -70°C and 
plated onto Sabouraud’s agar. The Sabouraud’s plates were incubated at 37°C for 
48 hours. DNA was extracted using a method similar to one based partly on that 
originally devised by Scherer and Stevens (1988), as described by Anthony et at. 
(1995). Growth from a Sabouraud’s plate was emulsified in 10ml YEPD broth 
(0.3 % yeast extract, 1 % mycopeptone, 2% dextrose) and incubated overnight at 
30°C in an orbital incubator. Cells from 1.5ml of the broth were pelleted in a 
centrifuge, the supernatant removed, and the cells washed by resuspending in 
lOOOpl 1M sorbitol. The cells were then pelleted in a centrifuge for 3 minutes, 
when the supernatant was removed and discarded. Cell walls were digested by re- 
suspending in 1M sorbitol plus 50mM K2HPO4 (pH 7.5) and adding to each tube 
3|_il (3-mercaptoethanol and 20p.l of freshly prepared 2 0 mg/ml lyticase 20 T (Sigma 
Chemical Company Limited, Dorset, UK) in 1M sorbitol and incubating at 37 C 
for 90 minutes. The resulting spheroblasts were pelleted by centrifugation (3 
minutes), the supernatant removed and lysed by adding 0.5ml GES reagent (30g 
guanidium thiocyanate dissolved at 65°C in 20ml 0.5mol/l EDTA at pH 8  and then 
2.5ml of 10% w/vol sarkosyl added, finally made up to 50ml with distilled water) 
(Pitcher et al., 1989). After 2 0  minutes at room temperature, samples were
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centrifuged again for 3 minutes and the supernatant was then removed into a new 
tube, leaving the protein pellet behind to be discarded. The supernatant volume 
was made up to 200pil with autoclaved distilled water. lOOpl phenol and lOOpl 
chloroform were added to the tube. This mixture was shaken well and centrifuged 
for a further 3 minutes. The top layer was then removed into a new tube and 
lOOpl of 5M potassium acetate and 0.5ml chloroform pentanol (24:1 V:V) was 
added. The mixture was centrifuged for 5 minutes, the top layer pipetted off into a 
new tube and the bottom layer discarded. The extracted DNA was precipitated 
with propan-2-ol, pelleted and resuspended in TE buffer (lOmM Tris and ImM 
EDTA, pH 7.5). RNA was digested with lpl of lOmg/ml RNAase A stock 
solution for 15 minutes at 37°C and the DNA re-precipitated in propan-2-ol, 
washed with 70% ethanol, then dissolved in 60pl of TE. The presence of DNA 
was confirmed by running samples on a 1 % agarose gel.
2.2.5.1.2. Restriction Enzyme Digestion.
Thirty microlitre aliquots of the DNA extract were restricted with EcoRI 
according to the manufacturer’s instructions (Boehringer Mannheim Biochemica). 
For example, for digestion of ten DNA samples, 40pl 10 x R3 buffer (Boehringer 
Mannheim), 8|lU 1 M spermidine and 30pl autoclaved distilled water were mixed 
together in an Eppendorf tube. This mixture was then aliquoted into ten new 
Eppendorf tubes (7.8pl per tube). Thirty microlitres of each DNA sample was 
added to each tube followed by 2.2pl of the enzyme EcoRI. The mixture was 
briefly vortex mixed, pulse spun to collect the liquid and placed in a water bath at
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37°C. After three hours an additional 1.5|nl of EcoRI was added to each tube to 
enhance the digestion. The digestion was continued at 37°C overnight. The 
restriction digests were then run on a 0 .8 % agarose gel at a constant 30v for 18 
hours in TBE buffer (Appendix V).
2.2.5.I.3. Southern Blotting.
Fragments of DNA separated by electrophoresis through an agarose gel were 
transferred to a nylon membrane (Boehringer Mannheim Biochemica) by Southern 
blotting. The method used was that of Sambrook etai (1989).
The gel was washed with three different solutions prior to the transfer 
process. Firstly, the gel was soaked in a pyrex dish containing 250ml 0.25M HC1 
for 5 minutes, with continuous shaking. The gel was then rinsed briefly in water. 
Next, the DNA was denatured by soaking the gel twice in 1,5M NaCl / 0.5M 
NaOH (Appendix V) for 15 minutes each time. Lastly, the DNA fragments were 
neutralised by soaking in 1.5M NaCL / 0.5M Tris (Appendix V) for 15 minutes. 
This process was also repeated. Each washing step was carried out in a pyrex dish 
at room temperature with constant rotational shaking. After each 15 minute stage, 
the solution was poured off and the gel washed briefly in distilled water before 
adding the next solution.
The top left hand comer was cut off the gel for orientation purposes. Six 
pieces of Whatman 3 mm chromatography paper were cut, allowing some overlap 
of the gel. One piece of positively charged nylon membrane (Boehringer
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Mannheim Biochemica) was cut to the same dimensions and the top left hand 
corner was removed. Care was taken to avoid contamination of the membrane. 
Both the nylon membrane and the Whatman paper were soaked in transfer buffer 
( 2 0  x SSC - Appendix V), until completely saturated. The restriction digests were 
capillary blotted onto the nylon membrane overnight (Sambrook et a/., 1989). The 
membrane was placed in an ultraviolet crosslinker for 1 minute, without prior 
washing, to ensure that the DNA was bound to it. The membrane was then 
washed briefly in distilled water before being left to airdry, DNA side up, on 
Whatman paper. It was then sealed in a plastic bag and stored at room 
temperature until hybridization.
2.2.5.1.4. EcoRI 27A Fragment Purification and Labelling.
The repeated sequence 27A originally described by Scherer and Stevens (1988) 
was provided, cloned in pUC18, plasmid number 824, by B B. Magee (University 
of Minnesota).
Plasmid DNA containing the 27A fragment was restriction digested using 
EcoRI and run in a 0.8% agarose gel. The top band containing the 27A was cut 
out of the gel and placed in a Spin-X column (Costar) on ice at -20 C for 30 
minutes. This was then centrifuged for 15 minutes at 13K (Eppendorf centrifuge 
5415C) to leave purified 27A DNA at the bottom of the tube. This template DNA 
was linearized and purified by adding equal volumes ( 1 :1 ) of phenol and 
chloroform. After shaking well, the mixture was centrifuged for 3 minutes. The
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top layer containing the DNA was transferred to a new tube, 500^ .1 chloroform 
added, mixed well and spun for a further 3 minutes. The top layer was then 
pipetted off into a new tube and the bottom layer discarded. The template DNA 
was re-precipitated with 0.1 volume of 3M sodium acetate and 2 volumes of 100% 
ethanol at -20°C overnight.
The re-precipitated DNA was centrifuged for 3 minutes and the 
supernatant discarded to leave a small pellet of DNA. The pellet was air-dried for 
approximately 5 minutes and then resuspended in 40pl of autoclaved distilled 
water. One microlitre of the suspension was run out in a 0 .8 % agarose gel to 
allow estimation of the yield of template DNA prior to labelling.
The template DNA (1 pg) was diluted to a total volume of 15 pi and 
denatured by heating for 1 0  minutes in a boiling water bath and quickly chilling on 
ice. Hexanucleotide mixture (2 pl oflOx concentration of hexanucleotide reaction 
mixture as supplied), 2pl dNTP mixture and 1 pi Klenow enzyme were added on 
ice to the denatured DNA. This was mixed, centrifuged briefly and incubated 
overnight at 37°C. EDTA (2pl; 0.2M; pH 8.0) was then added to stop the 
reaction. The labelled DNA was precipitated by adding 2.5pl 4M LiCl and 75pl 
pre-chilled ethanol and mixing well. It was then left for 30 minutes at 70 C before 
spinning in a centrifuge for 15 minutes. The supernatant was removed and the 
pellet washed with 50pl cold 70% ethanol. The DNA pellet was then briefly 
vacuum dried and dissolved in 50pl TE buffer (Boehringer Mannheim 
Biochemica, 1993a).
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I2.2.5.1.5. Prehybridization and Hybridization.
The nylon membrane was placed in a roller tube containing 20ml standard 
prehybridization solution (Appendix V) and prehybridized at 6 8 °C for 4  hours. 
The prehybridization solution was then discarded and hybridization solution 
(Appendix V) containing the DIG-labelled probe was added and the probe 
allowed to hybridize at 6 8 °C overnight (Boehringer Mannheim Biochemica, 
1993b).
Following the overnight hybridization, the membrane was removed from 
the roller tube and placed in a plastic lunch box. Stringency washes were then 
carried out. This involved two 5 minute washes in 2 x SSC, 0.1% SDS 
(Appendix V) at room temperature and two 15 minute washes in 0 . 1  SSC, 0 .1% 
SDS (Appendix V) at 6 8 °C, under constant agitation on a rotashaker (Boehringer 
Mannheim Biochemica, 1993b).
2.2.5.1.6. Detection of DIG-Labelled Probe.
1 he membrane was rinsed briefly (1-5 minutes) in maleic acid buffer (buffer 1 - 
Appendix V) before incubating for 30 minutes in 1 0 0 ml blocking solution (buffer 
2, 1 x concentration - Appendix V). Anti-DIG-AP conjugate was diluted in buffer
2  to 75mU/ml ( 1 :1 0 0 0 0 ) in blocking solution (lx concentration) and the 
membrane was incubated for 30 minutes in 2 0 ml of this antibody solution. 
Unbound antibody was removed by washing twice with 10 0 ml maleic acid buffer 
(buffer 1 ). Equilibration was carried out for 2-5 minutes in 2 0 ml detection buffei
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(buffer 3 - Appendix V). The membrane was then incubated for 5 minutes in 10ml 
freshly prepared colour substrate solution (Appendix V), sealed in a box in the 
dark. Colour precipitate started to form within a few minutes and was complete 
after 12-16 hours. The reaction was stopped by washing the membrane with 50ml 
distilled water for 5 minutes and the membrane was photographed for 
documentation (Boehringer Mannheim Biochemica, 1993c).
2.2.5.2. Itraconazole Sensitivity Testing.
The sensitivity to itraconazole of all the C. albicans species isolated at 
baseline was measured by a broth microdilution assay. The buffers and stock 
solutions required for this method were made up as described in Appendix V.
C. albicans isolates taken from each patient at baseline were removed 
from storage at -70°C. Each isolate was plated onto Sabouraud’s dextrose agar 
and incubated at 37°C for 48 hours.
Following incubation, five colonies were taken from the purity plate, 
emulsified in 5 ml sterile distilled water and diluted to a concentration of 1 in 1 0  by 
adding 0.5 ml of this suspension to 4.5ml RPMI broth (Appendix V). This 
suspension was used for the yeast counts using a Neubauer haemocytometer.
A multichannel pipette with a setting of lOOpl was used to add RPMI 
broth to columns one and three, through to column 12, of a 96-well flat-bottomed 
microtitre plate (Alpha Laboratories). Column two of the microtitre plate was left 
empty. One hundred microlitres of the stock itraconazole solution (32 mg/1 -
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Appendix V) was added to columns one, two and three. Again using the 
multichannel pipette, 1 0 0 p.l was transferred from column three to column four and 
this step was repeated from column four to column five and so on, up to column 
11 (medium control). Lastly, 100(nl of the yeast suspension was added to all wells 
except column one (inoculum free control). A control strain (C.g/abrata NCPF 
3931) was set up in row one of every microtitre plate. The control strain was kept 
refrigerated on Sabouraud’s dextrose agar. Single colonies were subcultured 
every two weeks. The microtitre plate was incubated at 28°C for 48 hours.
An ELISA multiscan plate reader was used to interpret the results. It was 
set to 450nm and the blank was Bl. The MIC was the lowest drug concentration 
at which the growth of the organism was reduced by 50% of the drug free control 
well (column 1 2 ).
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2.3. STATISTICAL ANALYSIS.
The data were analysed using the Minitab Statistical Programme, Release 1 1  for 
Windows.
It was decided that a level of significance of p < 0.05 would be appropriate. 
Parametric statistical tests, such as two-sample-t-tests, were judged to be suitable 
for both within group and between group comparisons. Treatment effects of each 
formulation of itraconazole and the effect of time were analysed by Repeated 
Measures Analysis of Variance. Analysis of any changes between baseline and 
subsequent visits, for variables such as mean Erythema meter indices, was by 
Analysis of Covariance. CV?/-squared tests were used to compare the mycological 
response of trial participants who received new dentures with those who did not 
and to compare the frequency of zero and non-zero saliva itraconazole 
concentrations in each treatment group
Other analyses were made on a purely descriptive basis.
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CHAPTER THREE 
RESULTS
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3.1. RESULTS OF PRELIMINARY INVESTIGATIONS.
3.1.1. Evaluation of the Erythema Meter .
3.1.1.1. Laboratory Study.
Table 3.1 shows the mean erythema indices as they corresponded to the varying 
percentages of magenta in the colour card standards. These standards gave a 
range of erythema index readings from 44 for the palest pink strip (20% magenta ) 
to 285 for the darkest red strip (100% magenta). Fig. 3.1 is a graphical 
representation of the same data and shows that the erythema index increases 
steadily by about 40-50 units each time the proportion of magenta increases by 
1 0%. This steady proportional rise continues until the Erythema meter records an 
index of 270, after which the graph levels off.
Table 3.1. Non-clinical erythema indices corresponding to the percentage 
of magenta in the colour card standards.
Percentage of magenta Erythema meter index
2 0 4 4
30 8 6
40 123
50 174
60 2 1 0
70 258
80 280
90 281
1 0 0 285
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3.1.1.2. Clinical Study.
The mean age of dentures worn in each of the denture-wearing groups was seven 
years. In general, maxillary dentures were retentive but ill-fitting. The most 
common form of denture stomatitis, seen in 14 of the patients, was Newton's 
Type II. One patient had Newton's Type I and 5 patients had Newton’s Type III 
denture stomatitis. At the initial visit, 11 of 2 0  denture wearers with healthy 
palatal mucosa and four of 2 0  denture stomatitis patients admitted removing their 
dentures for sleeping.
For the 40 patients with healthy palatal mucosa, the clinical erythema 
scores ranged from 0  (no inflammation) to 1 (mild inflammation), whereas the 
scores for the denture stomatitis patients ranged from 2  (moderate inflammation) 
to 3 (severe inflammation) (Table 3 .2 ).
Table 3.2. Clinical visual erythema scores for patients with healthy 
palatal mucosa and those with denture stomatitis.
Clinical erythema 
score
Healthy palatal 
mucosa (n=40)
Denture 
stomatitis (n=20)
0 35 0
1 5 3
2 0 1 0
3 0 7
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Table 3.3 shows the median erythema index derived from the Erythema 
meter readings for all patients at the initial visit. The 40 patients with healthy 
mucosa were re-assessed after two weeks. The mean erythema indices of each 
patient, at the initial and the follow-up visits, are plotted in Fig. 3.2. The points lie 
on or very close to the line of equality in the majority of cases, having changed 
very little from one visit to the next. A components of variance analysis allowed 
the standard variation of the erythema index across patients to be estimated at 8  .8 , 
while the standard deviation within patients was 3.2. This gave a reproducibility 
coefficient of 8 8 %.
Table 3.3. Median erythema indices and range recorded at initial visit.
n Median erythema 
index
Range
Healthy non-denture wearers 2 0 1 2 2-38
Healthy denture wearers 2 0 5 0-29
Denture stomatitis patients 2 0 95 36-117
To compare the objectivity of the Erythema meter with the more 
subjective visual erythema scores, the latter were plotted against the mean 
erythema index for each patient at that visit (Fig. 3.3). Visual erythema scores of 
zero (no inflammation) corresponded to low erythema indices of less than 2 0 , 
whilst scores of 3  (severe inflammation) corresponded to high erythema indices 
of greater than 100. There was some overlap when comparing clinical erythema 
scores of 1 (mild inflammation) and 2  (moderate inflammation) with the 
corresponding erythema index for that patient.
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3.1.2. A Pilot Study Comparing Fluconazole and Itraconazole in 
the Treatment of Denture Stomatitis.
3.I.2.I. Clinical Investigations.
Newton's Type II denture stomatitis affected seven patients in both the 
itraconazole and the fluconazole groups respectively. One patient in the 
fluconazole group had Newton's Type I denture stomatitis and 5 patients in total 
had Type III denture stomatitis, three in the itraconazole group and two in the 
fluconazole group.
The median erythema indices recorded at baseline and on completion of 
the relevant course of antifungal treatment are given in Table 3 .4 . There was a 
reduction in erythema with both fluconazole and itraconazole. While this 
difference appears greater for the fluconazole group, the median score at the 
beginning of the study was lower for those on the itraconazole arm, with 
correspondingly less room for improvement with treatment. Erythema meter 
scores of between zero and 38 have been recorded for those with healthy mucosa 
(Table 3.3).
Table 3.4. Median erythema indices before and after antifungal 
treatment.
Before After Difference Range of
 differen ces
Fluconazole (n=lO) 1 0 0  48 52 9-71
Itraconazole (n=10) 74 43 31 7-57
The mean erythema indices for each patient, at the initial and the follow- 
up visits, have been plotted for those in the fluconazole and itraconazole groups in 
figure 3.4. In most cases the points plotted lie above the line of equality, 
indicating a reduction in erythema following the course of antifungal therapy. One 
patient in the fluconazole group and two in the itraconazole group showed little 
change in their erythema indices between visits.
At the initial visit, only four of the 20 patients admitted removing their 
dentures for sleeping. However, all patients responded to the advice given and by 
visit 2 were removing their dentures at night for sleeping. However, analysis of 
the clinical visual denture cleanliness scores revealed a variable picture (Figs. 3.5 
and 3 .6). In the fluconazole group, four patients showed improvement in their 
denture cleanliness scores, with the scores reducing from one or three to zero in 
all four cases. The remaining patients had the same amount of plaque present on 
their denture fitting surface from one visit to the next, except for one patient 
whose score increased at the review. In the itraconazole group, five patients 
showed varying degrees of improvement in their denture cleanliness scores, with 
the remaining five patients showing no change. Results from the objective denture 
disc method were in agreement with the visual scores and are described in Section
3.1.2.2.
126
Fi
gu
re
 
3.
4.
 T
he
 
me
an
 
Er
yth
em
a 
m
ete
r 
in
di
ce
s 
for
 
ea
ch
 
pa
tie
nt
 i
n 
the
 
flu
co
na
zo
le
 
an
d 
itr
ac
on
az
ol
e 
gr
ou
ps
 
at 
the
 
in
iti
al
 a
nd
 
fo
llo
w
-u
p 
vi
sit
s. 
Po
in
ts 
ab
ov
e 
the
 
lin
e 
of 
eq
ua
lit
y 
in
di
ca
te
 
a 
re
du
ct
io
n 
in 
er
yt
he
m
a 
an
d 
th
er
ef
or
e 
cl
in
ic
al
 i
m
pr
ov
em
en
t.
oaeotjas-
■
00
© ©©•'*©oo©©f S
I  j i s j a  -  x a p u i  n u 4 B i fh < J 3
127
M
ea
n 
Er
yt
he
m
a 
M
ete
r 
In
de
x 
- V
isi
t 
2
Fi
gu
re
 
3.
5.
 C
lin
ic
al
 v
isu
al
 d
en
tu
re
 
cl
ea
nl
in
es
s 
sc
or
es
 f
or 
pa
tie
nt
s 
in 
the
 
flu
co
na
zo
le
 
gr
ou
p 
be
fo
re
 
an
d 
af
te
r
tr
ea
tm
en
t.
4>aa < □ ■
3 J 0 3 S  s s a u i | U B a | 3  a j n | U 9 Q  l B 3 ! u H 3
128
Fl
uc
on
az
ol
e 
gr
ou
p
Fi
gu
re
 
3.
6.
 C
lin
ic
al
 v
isu
al
 d
en
tu
re
 
cl
ea
nl
in
es
s 
sc
or
es
 
for
 
pa
tie
nt
s 
in 
the
 
itr
ac
on
az
ol
e 
gr
ou
p 
be
fo
re
 
an
d 
af
te
r
tr
ea
tm
en
t.
9J CCQ < □ ■
3 J 0 3 S  S S 3 U I |U B 3 |3  a J n |U 3 Q  I B 3 I U I O
129
It
ra
co
na
zo
le
 
gr
ou
p
3 .I.2 .2 . Microbiological Investigations.
A wide range of yeast species was isolated from the mouths of the denture 
stomatitis patients before treatment (Table 3.5). C. albicans was the most 
common isolate, present in samples from all 20 patients, with C. glabrata the 
second most commonly isolated species .
Table 3.5. The species of yeast isolated from patients with denture 
stomatitis before treatment.
Study group Species isolated
C.
albicans
C.
glabrata
c. c.
tropicalis parapsilosis
Sacch.
cerevisiae
C.
guillermondii
Fluconazole 
(n = 10)
10 5 1 1 2 0
Itraconazole 
(n = 10)
10 1 1 0 1 1
Total 20 6 2 1 3 1
Following antifungal therapy, patients were classified as having responded 
to treatment if they were mycologically cured or if there was a reduction in yeast 
count (Table 3.6). A total mycological cure was achieved in five of the 20 
patients, one in the fluconazole group and four in the itraconazole group. Eight of 
the 10 patients in the fluconazole group had reduced yeast counts by the second 
visit. A reduction in yeast count also occurred in three of the 10 patients treated 
with itraconazole. However, one patient in the fluconazole group and three in the 
itraconazole group had increased yeast counts after treatment. C. albicans was 
eradicated completely in four patients after treatment with fluconazole and in six
130
patients after treatment with itraconazole. When C. glabrata was one of the 
original yeast species it persisted, in all cases, after antifungal therapy.
Table 3. 6. The mycological response to treatment in each patient group.
Fluconazole Itraconazole
......................................................(n..= .1.0)................ (n = 10)........
Mycological cure 1 4
Reduced yeast count 8 3
Increased yeast count 1 3
Coliforms were isolated from seven patients, four in the fluconazole group 
and three in the itraconazole group. S. aureus was isolated from one patient and 
Group B B haemolytic streptococci from another in the itraconazole group. No 
further investigations were carried out on these organisms.
The objective microbiological 'denture cleanliness scores' measured before 
and after the two week course of antifungal medication are illustrated in Figs. 3.7 
and 3.8. These data indicate that denture cleanliness did not improve for the 
majority of the participants.
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3.1.2.3. Haematological Investigations.
Six patients, three patients in each treatment group, were iron-deficient (serum 
ferritin <25ng/ml) at baseline and did not receive replacement iron therapy until 
after their antifungal treatment was completed. Despite this underlying haematinic 
deficiency, all six demonstrated reduced erythema after antifungal treatment and 
although none of these patients were mycologically cured, four had reduced yeast 
counts and had therefore responded to treatment.
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3.2. RESULTS OF A CLINICAL TRIAL COMPARING THE EFFICACY 
OF CYCLODEXTRIN SOLUTION OF ITRACONAZOLE AND 
ITRACONAZOLE CAPSULES IN THE MANAGEMENT OF CANDIDA- 
ASSOCIATED  DENTURE STOMATITIS.
3.2.1. Clinical Investigations.
The mean age of the patients' dentures was 9.9 years (range 0.2-27 years) in the 
cyclodextrin group and 10.5 years (range 0.3-30 years) in the capsule group. 
Sixty-two per cent of maxillary dentures in this study had retentive bases but 52% 
were unstable laterally or antero-posteriorly. Twenty-two per cent had under­
extended bases and 12% had worn occlusal surfaces. The most common form of 
denture stomatitis seen was Newton’s Type II, which affected seventeen patients 
in both the cyclodextrin and capsule groups respectively. Six patients in total had 
Newton’s Type III denture stomatitis, three in each group. Type I denture 
stomatitis was not found in this study population. The majority of patients, 32 of 
40 enrolled in the clinical trial, had attended the Dental Hospital for the provision 
of new complete dentures and were unaware of their palatal inflammation prior to 
the screening appointment. A further five of the 40 patients enrolled at baseline 
complained of oral dryness and three complained of a sore, burning tongue.
Two patients in the cyclodextrin group and two in the capsule group failed 
to complete the course of itraconazole. These patients were excluded from all 
efficacy analyses. Another two patients in the capsule group each missed one 
appointment during the trial - one at four weeks and the other at six months after
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treatment commenced. However, results obtained from these patients were 
included in the efficacy analyses.
The mean reduction in Erythema meter indices recorded at each visit 
following antifungal therapy are given in Table 3.7. Using Repeated Measures 
Analysis of Variance on the reductions in mean Erythema Meter index from 
baseline, a significant reduction in erythema was found (p = 0.002) but there was 
no significant (p = 0.31) treatment effect with respect to the visit at which the 
mean Erythema Meter index was recorded. The cyclodextrin solution of 
itraconazole resulted in a constant additional reduction in palatal erythema over 
itraconazole capsules of an average of 10.1 units (95% confidence interval of 3.6, 
16.4).
Table 3.7. Mean reductions in Erythema meter indices following 
antifungal therapy.
Mean Reduction in Erythema Index (range)
Visit 2 3 4
Cyclodextrin group 43.9(6-93) 54.7(26-100) 5 4 . 6  (-4-136)
S.D. 24.6 S.D. 22.6 S.D. 38.9
n =  18 n=  18 n =  18
Capsules group 36.6 (20-74) 36.1 (-30-77) 50.6 (-11-91)
S.D. 16.8 S.D. 27.3 S.D. 26.5
n = 18 n=  17 n =  17
The mean Erythema meter indices for each patient, at each visit, have been 
plotted for those in the cyclodextrin and capsule groups (Figs. 3.9 and 3.10).
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Figure 3.9. Mean Erythema Meter Indices (EMI) across visits for
patients in the cyclodextrin itraconazole group.
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Figure 3.10. Mean Erythema Meter Indices (EMI) across visits
for patients in the itraconazole capsule group.
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Patients in the cyclodextrin group had a higher mean level of erythema at 
baseline than those in the capsule group. Consequently, when calculations were 
adjusted for the higher pre-treatment Erythema meter indices of the cyclodextrin 
group, the appropriate Repeated Measures Analysis, now incorporating ‘Baseline 
Erythema Meter Index as a covariate, eliminated the significant treatment 
difference (p = 0.38) referred to above.
At the initial visit, only five of the 20 patients in each treatment group 
admitted removing their dentures for sleeping. By the review appointment six 
months after treatment commenced, 25 (13 cyclodextrin patients and 12 capsule 
patients) of the 36 patients who completed the trial were removing their dentures 
at night for sleeping. However, analysis of clinical visual denture cleanliness 
scores recorded throughout the clinical trial revealed little change between 
baseline and subsequent visits (Table 3 .8). Although the majority of patients in 
each treatment group improved their scores by one or two points throughout the 
clinical trial, six patients in the cyclodextrin group and four in the capsule group 
had higher plaque scores at some of the post-treatment visits than at enrolment.
Table 3.8. Median Reductions in Clinical Visual Denture Cleanliness 
Scores. 
Median Reduction in Clinical Denture 
Cleanliness Scores (range)
Visit 2 3 4
Cyclodextrin group 1 (-1 to 3) 1.5 (-2 to 4) 1.5 (-2 to 4)
n =18 n =18 n =18
Capsules group 1 (0 to 3) 0 (-2 to 3) 2 ( - l t o 4 )
n =18 n = 17 n = 17
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Six patients in the cyclodextrin group and nine in the capsule group 
received new dentures whilst enrolled in the clinical trial. These dentures were 
provided between four weeks and six months after treatment commenced. Table 
3 .9 summarises the mycological response of trial participants, six months after 
treatment commenced, in relation to whether they received new dentures or not 
whilst enrolled in the study. From this table it can be seen that there is some 
evidence of a higher rate of mycological cure in those patients who did receive 
new dentures, in contrast to those who continued to wear their existing dentures.
Table 3.9 The mycological response six months after treatment
commenced of patients in each treatment group in relation to 
the provision of new complete dentures.
New
dentures
No new 
dentures
p-value
Cyclodextrin
group
mycologically
cured
3 1
not mycologically 
cured
3 11 }0.131
Capsule group mycologically
cured
6 1
not mycologically 
cured
3 7 }0.137
When the mycological results for both treatment groups were pooled, a 
C7?/-squared test of these data revealed a significantly higher chance of a patient in 
this study remaining mycologically cured six months after treatment commenced if 
new dentures were provided following antifungal therapy (p = 0.020) (Table 
3.10).
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Table 3.10. A comparison of the mycological cure rates of patients who 
received new dentures and those who did not, irrespective of 
treatment group, using a C/ri-squared test (p = 0.020).
New dentures No New dentures Total
Mycologically cured 9 2 11
Not mycologically cured 6 18 24
Total 15 20 35
3.2.2. Microbiological Investigations.
A wide range of yeast species was isolated from the mouths of the denture 
stomatitis patients before treatment (Table 3.11). C. albicans was the most 
common isolate, present in samples from all 40 patients. C. glabrata was the 
second most commonly isolated species. It was found in 12 patients at baseline 
and persisted, post-treatment, in all but two of these cases - one from each 
treatment group.
Table 3.11. The species of yeast isolated from patients with denture 
stomatitis before treatment.
Study " Species isolated
group
C C. C. C. C. Sacch. C.
albicans glabrata tropicalis Jtruseiparapsilosis w
Cyclodextrin 20 5 1 0 0
(n=18)
1Capsules 20 7 0 1
(n=18)
1 1Total 40 12 1
141
Following antifungal therapy, patients were classified as having responded 
to treatment if they were mycologically cured or if there was a reduction in yeast 
count (Table 3.12). A total mycological cure was achieved in 17 of the 36 patients 
on completion of treatment (Visit 2). Four weeks after treatment commenced, of 
the 17 mycologically cured patients, 13 (eight in the cyclodextrin group and five 
in the capsule group) remained yeast free and seven of these patients (three 
cyclodextrin and four capsule) were still mycologically cured six months after 
treatment commenced. Reduced yeast counts were found, on completion of 
treatment, in seven patients in the cyclodextrin group and 11 in the capsule group. 
Four weeks after treatment commenced, four cyclodextrin patients and eight 
capsule patients had yeast counts lower than they had been at baseline and the 
same was found in eight cyclodextrin patients and seven capsule patients six 
months after treatment started. No patients had an increased yeast count on 
completion of the two week course of antifungal therapy, suggesting good patient 
compliance with both preparations of itraconazole. However, some patients, in 
each of the treatment groups, had higher yeast counts by four weeks and six 
months after treatment started than had been found prior to treatment (Table 
3.12).
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Table 3.12. The mycological response to treatment in each patient group.
Cyclodextrin group Capsule group
Visit 2
n =  18
3
n =  18
4
n =  18
2
n =  18
3
n = 17
4
n = 17
Mycological
cure
10 11 4 7 6 8
Reduced 
yeast count
7 4 8 11 8 7
Increased 
yeast count
0 3 6 0 3 2
No change 1 0 0 0 0 0
Coliforms were isolated from 16 of 36 patients who completed the clinical 
trial - seven in the cyclodextrin group and nine in the capsule group. S. aureus 
was isolated from only two patients throughout the trial. Following identification 
of these organisms, the number of colonies in each sample was noted but no 
further microbiological investigations were carried out. No B haemolytic 
streptococci were isolated from this patient population.
Repeated Measures Analyses of the median reductions in objective 
microbiological 'denture cleanliness scores' measured from baseline for each 
treatment group are illustrated in figure 3.11. These data indicate that denture 
cleanliness in both treatment groups improved very slightly but significantly 
(p = 0.01), by an average value of 0.3 (95% confidence interval of 0.1, 0.5).
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3.2.3. Haematological Investigations.
Eight patients, three in the cyclodextrin group and five in the capsule group, were 
iron-deficient (serum ferritin <25ng/ml) at baseline. All received appropriate 
investigation and replacement iron therapy and only one patient remained iron- 
deficient six months after treatment commenced. Despite this underlying 
haematinic deficiency at baseline, all eight demonstrated reduced erythema after 
antifungal treatment and three (two patients on cyclodextrin solution of 
itraconazole and one on itraconazole capsules) were mycologically cured on 
completion of treatment.
Figure 3.12 is a box-plot diagram comparing the total yeast concentration 
at baseline of patients with iron deficiency and those with normal serum ferritin 
levels, irrespective of treatment group. From this diagram it can be seen that 
patients with iron deficiency at baseline had, overall, a slightly lower yeast 
concentration than those with normal blood results. Flowever, a two sample t-test 
(Table 3.13) was used to compare the mean total yeast concentrations of the two 
groups at baseline. This analysis revealed that although patients with iron 
deficiency did have slightly lower yeast concentrations at baseline than those with 
normal serum ferritin levels, this proved not to be statistically significant (p=0.19).
Table 3.13. A two sample t-test to compare the differences in total baseline 
yeast concentration in those patients with iron deficiency and 
those with normal serum ferritin (p = 0.19 n.s.).
n Mean Yeast 
Concentration
S.D. SE Mean
Normal serum ferritin 28 3.13 1.31 0.25
Iron deficient 8 2.36 1.40 0.49
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Figure 3.12. A comparison of the total yeast concentration found in
denture stomatitis patients with iron deficiency at baseline 
and those with normal blood results.
Iron
Deficient
Not Iran 
Deficient
Total Yeast Concentration at Baseline 
(cfu/ml)
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Twelve patients, four in the cyclodextrin group and eight in the capsule 
group, had high blood sugar levels (random blood glucose level > 6.0mmol/L) at 
enrolment. One of these patients failed to complete the course of itraconazole and 
was excluded from the trial. Despite corrective measures, six of the remaining 
eleven patients still had raised blood sugar levels six months after treatment 
commenced. However, all of the 11 patients had reduced erythema indices 
following antifimgal therapy and six were mycologically cured on completion of 
treatment. Furthermore, two of these patients remained mycologically cured for 
the duration of the clinical trial.
Figure 3 .13 is a box-plot diagram comparing the total yeast concentration 
at baseline of patients with raised blood glucose levels and those with normal 
blood glucose levels. From this diagram it can be seen that there was little 
difference in the total baseline yeast concentrations between the two groups. 
Consequently a two sample t-test found no significant difference between the 
baseline yeast concentrations of the two groups (p = 0.99 n.s.) (Table 3.14).
Table 3.14. A two sample t-test to compare the differences in total baseline 
yeast concentration in those patients with raised blood glucose 
and those with normal blood glucose levels (p = 0.99 n.s.).
n Mean Yeast 
Concentration
S.D. SE Mean
Normal blood glucose 11 2.95 1.59 0.48
Raised blood glucose 25 2.96 1.26 0.25
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Figure 3.13. A comparison of the total yeast concentration found in
denture stomatitis patients with raised blood glucose levels at 
baseline and those with normal blood glucose levels.
Normal
Blood
Glucose
Raised
Blood
Glucose
Total Yeast Concentration at Baseline 
(cfu/ml)
148
There were no adverse changes in haematologic indices, liver function 
tests or urea and electrolyte measurements throughout the trial. C-reactive protein 
measurements were found to be normal (<10mg/L) at baseline and on completion 
of treatment in 21 of 36 trial participants. Nine patients had raised C-reactive 
protein levels at baseline but normal levels on completion of treatment. Of the 
remaining six patients, all had persistently higher than normal values of C-reactive 
protein before and after antifungal therapy.
3.2.4. Questionnaire.
Questionnaires from 18 patients in each treatment group who had completed the 
course of itraconazole were assessed. Only two patients in the cyclodextrin group 
and one in the capsule group found the time at which they had to take their 
medication inconvenient. With the exception of three patients in the cyclodextrin 
group and one in the capsule group, the study participants found their particular 
formulation of itraconazole pleasant to take. However, twelve patients in the 
cyclodextrin group complained of gastro-intestinal side-effects such as diarrhoea 
and stomach cramps. None of the patients who had been taking itraconazole 
capsules reported any side-effects. Lastly, 15 of the cyclodextrin patients and nine 
of the capsule patients said that their mouths “felt better following the course of 
antimycotic treatment.
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3.2.5. Itraconazole Levels.
Table 3.15 shows the results for serum and saliva levels measured for patients in 
each of the two study groups on completion of the 15 day course of treatment. 
The median serum itraconazole level in the cyclodextrin group was 0.74mg/L 
(interquartile range 0.46 to 1.18) compared to 0.61mg/L (interquartile range 0.37 
to 0.93) in the capsule group. Using a two sample t-test, no significant difference 
was found in the serum itraconazole concentrations between the two formulations 
(p = 0.39). However, when considering the saliva itraconazole concentrations, the 
high incidence of zero values in the capsule group is very obvious (Table 3 .15).
Table 3.15. The serum and saliva itraconazole levels for each patient in 
each treatment group.
Cyclodextrin solution 
(n “  18)
Capsules 
(n -  18)
Serum(mg/1) Saliva(mg/1) Serum(mg/1) Saliva(mg/1)
1.08 0.16 0.37 0.00
0.75 0.00 0.83 0.00
0.00 0.00 1.42 0.00
1.20 0.00 0.87 0.00
0.56 0.68 0.45 0.00
1.03 0.48 1.23 0.00
0.34 0.00 0.31 0.00
1.03 1.50 0.93 0.00
0.68 0.17 0.71 0.00
1.26 0.07 0.21 0.00
1.17 0.69 0.91 0.00
0.28 1.04 1.24 0.00
0.00 0.21 0.50 0.00
0.68 0.00 0.51 1.68
1.50 0.05 0.39 7.40
0.73 0.06 0.34 0.00
1.48 0.53 0.39 0.00
0.50 0.02 1.09 0.02
Median 0.74 Median 0.12 Median 0.61 Median 0.00
Interquartile Interquartile Interquartile Interquartile
range 0.46, 1.18 range 0.00, 0.53, range 0.37, 0.93 range 0.00 0.00,
A confirmation of the difference in saliva concentration achieved in each 
of the groups was obtained by comparing the frequency of zero and non-zero 
values on each treatment using a C/77-squared test (Table 3.16). This provided a 
p-value of less than 0.001, representing a clear and significant difference in the 
proportion of patients in the cyclodextrin group with detectable itraconazole 
levels in their saliva on completion of treatment, compared to those in the 
itraconazole capsule group.
Table 3.16. A comparison of the frequency of zero and non-zero saliva
concentrations of itraconazole in each treatment group using a 
Chi-squared test (p < 0.001).
zero non-zero
Cyclodextrin (n=18) 5 13
Capsules (n=18) 15 3
The serum and saliva itraconazole levels for the cyclodextrin group only 
were then analysed in order to test whether there was any correlation between 
these two concentrations for this preparation of itraconazole. Figure 3.14 shows 
little evidence of any relationship (p = 0.704) between the serum and saliva levels 
of those patients in the cyclodextrin group.
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Figure 3.14. The relationship of saliva and serum itraconazole 
concentrations for patients in the cyclodextrin group
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The relationship between the serum itraconazole levels and the mean 
reductions in Erythema meter index for patients in both treatment groups on 
completion of treatment (Visit 2) is shown in figure 3 .15. This plot shows a 
significant (p = 0.033), moderately positive relationship (95% confidence interval 
of 0.03, 0.61) between the serum itraconazole concentrations and the mean 
reductions in Erythema meter index recorded at visit 2 for patients in both of the 
treatment groups. The sample correlation coefficients were 0.370 for the 
cyclodextrin group and 0.302 for the itraconazole capsule group, revealing that, 
on completion of treatment, the reductions in palatal inflammation, when related 
to the serum itraconazole levels, were very similar for both forms of itraconazole.
Figure 3.16 shows a comparison of the serum itraconazole levels of 
mycologically cured patients and non-mycologically cured patients on completion 
of the course of antimycotic therapy (Visit 2). As can be seen from the graph, 
there is a large overlap between the serum itraconazole levels measured for both 
those patients who were free of yeasts at Visit 2 and those who were not 
mycologically cured. However, the serum itraconazole levels of the mycologically 
cured patients were greater than 0.6mg/L in all but three cases, whereas the 
majority of the non-mycologically cured patients had serum itraconazole levels of 
less than 0.5mg/L (Fig. 3.16). A two sample t- test (Table 3.17) was performed to 
assess the significance of these higher drug levels. As a result it was found that the 
slightly higher serum itraconazole levels seen in the patients who were 
mycologically cured at Visit 2 were not significantly different, on average, from 
those not cured at Visit 2 (p = 0.28 n.s.).
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Table 3.17. A two sample t-test to assess the significance of the higher 
serum itraconazole drug levels found in mycologically cured 
patients compared to non-mycologically cured patients
(p = 0.28 n.s.).
n Mean Serum 
Concentration
S.D. SE Mean
Non-mycologically cured 19 0.663 mg/L 0.461 0.12
Mycologically cured 17 0.818 mg/L 0.370 0.083
3.2.6. Itraconazole Sensitivities.
One baseline C. albicans isolate from each patient who completed the clinical trial 
was removed from storage at -70°C for itraconazole sensitivity testing. All C. 
albicans isolates tested proved to be highly sensitive to itraconazole. MIC values 
ranged from 0.06mg/L to 0.5mg/L.
3.2.7. Smoking and Candida-associated Denture Stomatitis.
Thirteen of the study participants, nine in the cyclodextrin group and four in the 
capsule group, were cigarette smokers. As a result of the small numbers, analyses 
were made on the results from these 13 patients as a single group, irrespective of 
their treatment formulation.
The effect of smoking on the reduction in mean Erythema meter index was 
considered first of all. Figures 3.17, 3.18 and 3.19 show, respectively, the range of
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Figure 3.17. A box-plot comparing the baseline mean Erythema Meter
Indices (EMI) of smokers versus non-smokers, irrespective of 
treatment group.
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Figure 3.18. A box-plot comparing the reduction in mean Erythema Meter 
Indices (EMI) on completion of treatment (Visit 2) of smokers 
versus non-smokers, irrespective of treatment group.
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Figure 3.19. A box-plot comparing the reduction in mean Erythema Meter 
Indices (EMI) six months after treatment commenced (Visit 4) 
of smokers versus non-smokers, irrespective of treatment 
group.
NanSmoker
Smoker
0 50 100 150
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mean erythema indices at baseline and reductions in mean erythema indices at two 
weeks (Visit 2) and six months (Visit 4) after treatment commenced. At baseline 
(Fig. 3 .17), the non-smoking group had higher levels of erythema than the 
smokers. Following antifungal therapy at Visit 2 (Fig. 3.18), and also six months 
after treatment commenced (Fig. 3.19), the non-smokers had greater reductions in 
their mean erythema indices than the smokers. However, two-sample t-tests of the 
differences in erythema at baseline or the differences in mean reductions in 
erythema at subsequent visits of smokers against non-smokers did not prove 
significant (Table 3.18).
Table 3.18. Two sample t-tests of the differences in erythema at baseline 
and the differences in mean reductions in erythema following 
antifungal therapy in smokers versus non-smokers.
n Mean S.D. S.E. Mean p-value
Baseline Smokers 13 120.6 20.7 5.7
Non-smokers 23 121.5 22.7 4.7 }0.91
Visit 2 Smokers 13 34.2 18.2 5.0
Non-smokers 23 43.7 22.2 4.6 }0.18
Visit 4 Smokers 12 45.8 31.6 9.1
Non-smokers 23 56.3 33.9 7.1 }0.37
Secondly, the effect of smoking on the chance of achieving a mycological 
cure following antifungal therapy was analysed. A Fisher Exact test was used 
because of the small numbers of trial patients who smoked. Although the p-value 
of the Fisher Exact test of 0.10 did not quite prove significant, it suggested,
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although not conclusively, that smokers in this study had less chance of a long 
term (ie. 12 weeks after treatment commenced) mycological cure.
3.2.7. Molecular Typing of C  albicans Isolates. 
3.2.7.1. DNA Extraction.
Eighteen of 36 patients who completed the clinical trial had C. albicans present at 
baseline and six months after treatment commenced. Genomic DNA was 
extracted from 36 stored C. albicans isolates in total, two isolates from each of 
the 18 patients, one which had been collected at baseline and another collected six 
months after treatment commenced. A one microlitre aliquot of each DNA sample 
was run on a 1% agarose gel to estimate the size of yeast DNA fragments 
extracted (Fig. 3.20 ). The majority of the DNA extracted was found to be in the 
region of 23.1 kilobases.
3.2.7.2. Restriction Enzyme Digestion.
Following overnight digestion with the enzyme EcoRl, a 30pl aliquot of each 
DNA sample was run out on a 0.8% agarose gel. Figure 3.21 shows a 
representative sample of the digested C. albicans DNA extracts. The first and last 
lanes in the gel contain the base pair marker ^Hind III-EcoRl and the remaining 
lanes contain the DNA samples.
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Figure 3.20. A photograph of an ethidium bromide-stained 1% agarose gel. 
Lanes 1 to 13 each contain a one microlitre aliquot of 
extracted yeast DNA. Lane 14 contains six microlitres of the 
molecular base pair marker A,Hind III.
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Figure 3.21. A photograph of an ethidium bromide-stained 0.8% agarose 
gel. Lanes 1 and 20 contain the molecular base pair marker 
TlHind III-EcoRl. Lanes 2 to 19 contain 30 microlitre aliquots 
of digested yeast DNA from a representative sample of trial 
patients.
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3.2.7.3. Southern Blotting and Hybridization.
DNA was transferred from a 0.8% agarose gel to a nylon membrane (Boehringer 
Mannheim) by Southern blotting. Hybridization of the 27 A probe to the DNA 
samples cut with EcoRI gave differentiation of the strains of C. albicans (Figs.
3.22 and 3.23). The lanes labelled ‘M’ in figures 3.22 and 3.23 show the base pair 
marker MTind III-EcoRl. The sizes of the marker fragments are shown on the 
right. Lanes 1 to 12 in figure 3.22 and lanes 1 to 18 in figure 3.23 represent 
samples taken from six and nine patients respectively. Each pair of lanes 
represents the DNA of yeasts isolated from the same patient at baseline (first lane 
of any pair) and six months (second lane of any pair) after treatment commenced. 
Use of the C. albicans 27 A repetitive element probe revealed only minor 
differences in band patterns between lane pairs indicating that, in any one patient, 
the C  albicans strains isolated prior to itraconazole therapy and six months after 
treatment commenced were the same strain. These differences in band pattern 
were subtle when compared to the major differences seen among strains from 
different patients. For example, in figure 3.22 lanes 9 and 10 are C. albicans 
isolates taken from the same patient at baseline (lane 9) and six months after 
treatment commenced (lane 10). The band patterns of these two isolates are 
almost identical and were considered to be the same strain. However, comparison 
of isolates taken from different patients, for example, lanes 5, 9 and 11 in figure
3.22 and lanes 1, 3 and 17 in figure 3.23, reveals a significantly different band 
pattern in each lane implying that different strains of C. albicans have been
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Figure 3.22. A scanned image of a Southern blot showing the 
C. albicans 27A  repetitive element probe hybridized to EcoRl 
digested C. albicans DNA.
The lanes ‘M’ at either side of the blot show the base pair marker 
X Hind III / EcoRl. Lanes 1 to 12 show a representative sample of 
digested DNA from C. albicans isolates taken from six of the 
study patients. Each pair of lanes represents C. albicans DNA 
extracted from isolates from the same patient. In any pair of lanes, 
the first lane represents digested DNA from yeasts isolated at 
baseline and the second lane represents DNA from yeasts isolated 
six months after treatment commenced. Lane 2 failed to hybridize 
completely.
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Figure 3.23. A scanned image of a Southern blot showing 
the C. albicans 27A repetitive element probe hybridized to 
EcoRl digested C. albicans DNA.
The lanes ‘M’ at either side of the blot show the base pair marker 
X Hind III / EcoRl. Lanes 1 to 18 show a representative sample of 
digested DNA from C. albicans isolates taken from nine of the 
study patients. Each pair of lanes represents C. albicans DNA 
extracted from isolates from the same patient. In any pair of lanes, 
the first lane represents digested DNA from yeasts isolated at 
baseline and the second lane represents DNA from yeasts isolated 
six months after treatment commenced. Lane 7 failed to hybridize 
well.
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isolated from each of these patients. Among this group of eighteen patients, 
thirteen completely different strains (arbitrarily labelled A to M) of C. albicans 
were found. Of these thirteen strains, four were found to be carried by more than 
one patient. The different genotypes of C. albicans isolated from eighteen study 
patients who had C. albicans present at baseline and six months after treatment 
commenced are illustrated in Table 3.19.
Table 3.19. The range of C. albicans strains isolated from this study 
population.
Strain A B C D E F G H I J K L M
Patient 2
19
20
6 7 8 10 16 23 24
34
26
40
29 33
37
35 38
Lanes 2 (Fig. 3.22) and 7 (Fig. 3.23) failed to hybridize well.
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CHAPTER FOUR 
DISCUSSION
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Denture stomatitis is recognised as a multifactorial disease (Budtz-Jorgensen, 
1974). Whilst yeasts are known to play an important role in many cases, the value 
of antifungal medication in treatment is unclear. Walker et al (1981) showed that 
mechanical cleansing of dentures was as effective as topical treatment with 
amphotericin B in treating Candida-associated denture stomatitis, and concluded 
that routine prescription of antimycotic drugs was unnecessary. However, 
although treatment should be directed primarily towards reducing levels of 
denture plaque (Arendorf and Walker, 1979), not all patients follow denture 
hygiene advice, as seen in this study. Overall, the results show a significant benefit 
of using antifungal medication as an adjunct to other measures. Antifungal 
treatment may also be indicated for patients who are at risk of disseminated 
infection (Warnock, 1992).
Of the systemic antifungals, itraconazole is the most recent addition to the 
orally-active triazole derivative agents. It has a very broad spectrum of activity 
(Odds, 1993a), but to date there have been no therapeutic trials of itraconazole in 
the treatment of denture stomatitis. Previous studies (Osterloh, 1992) of 
fluconazole treatment of Candida-associated denture stomatitis have shown a 
significant initial reduction in erythema and yeast cell concentration, although high 
rates of relapse have also been reported (Bissell et al., 1993). Itraconazole is an 
effective agent for the treatment of both superficial and systemic mycoses (Smith 
et al., 1991; Van t ’Wout etal ,  1991; Odds, 1993a). The new cyclodextnn 
solution of itraconazole has been used successfully among a group of AIDS
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patients with a history of failed treatment for oral candidosis using other azoles 
(Cartledge et al., 1994).
Preliminary investigations were carried out prior to commencing the main 
clinical trial. These aimed to evaluate the sensitivity and reproducibility of an 
electro-optical instrument, the Erythema meter, as an objective means of assessing 
erythema of the palatal mucosa. Until this study, use of the Erythema meter had 
been mainly confined to the skin, where objective data were obtained following 
experimentally induced erythematous lesions (Farr & Diffey, 1984). The 
instrument had also been used to record intra-oral erythema in one patient with 
stomatitis as a result of intolerance to bovine products (Ferguson et al, 1987).
Erythema meter readings taken from the check-standard used by graphic 
artists for colour reproduction permitted determination of the range of redness 
that the instrument could resolve. These non-clinical investigations showed the 
Erythema meter to be a very sensitive and reproducible means of differentiating 
varying shades of red, up to an erythema index reading of approximately 270. 
Above this level the instrument had difficulty in discriminating between stronger 
shades of red. However, as the clinical investigations have indicated, this does not 
pose a problem for measurement of mucosal erythema in vivo, since inflamed 
mucosa does not result in readings this high.
To determine the range of erythema indices that would be found intra- 
orally in both health and disease, a series of clinical experiments was performed, 
involving 40 patients with healthy palatal mucosa and 20 with denture stomatitis. 
The healthy denture wearers and denture stomatitis groups were well age- 
matched, although as would be expected, the non-denture wearing group had a
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much lower mean age. Both the healthy denture wearing group and the non­
denture wearers were well sex matched but there was a predominance of female 
patients in the denture stomatitis group. This will be discussed in relation to the 
pilot clinical trial of fluconazole versus itraconazole. Patients with healthy palatal 
mucosa gave a range of erythema indices of below 40, whereas the erythema 
indices for patients with denture stomatitis lay within a much higher range (46 to 
117).
As a result of comparing the objective erythema indices with the more 
subjective visual scores, it was clear that the clinician could quite easily distinguish 
visually no inflammation, or even mild inflammation, from severe. However, there 
was some difficulty when discriminating mild inflammation from moderate, or 
moderate from severe. Such discrepancies pose a major problem in clinical trials, 
when an accurate end-point is essential. Use of the Erythema meter increases 
objectivity since degrees of inflammation can now be related to Erythema meter 
indices. For example, absence of inflammation of the palatal mucosa corresponds 
to an erythema index of less than 20, mild inflammation gives an index of 20 to 
40, moderate 40 to 80 and severe inflammation corresponds to an index of greater 
than 80.
In addition to this, the study was also designed to assess the sensitivity and 
reproducibility of the instrument. The reproducibility coefficient of 88% is 
sufficiently exacting for clinical trial use. The Erythema meter proved to be quick 
and easy to use intra-orally. It was well tolerated by all patients. This highly 
sensitive and reproducible method of measuring oral mucosal erythema has many 
potential applications for both clinical research and diagnostic purposes. For
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example, the instrument is currently being used in a study to assess the effect on 
the palatal mucosa of a new light-cured acrylic used in the base plates of upper 
removable orthodontic appliances. Adaptation of the Erythema meter to improve 
the portability of the instrument and reduce the size of the tip of the fibre optic 
cable, to facilitate easy use at any intra-oral site, could extend the use of the 
instrument in other dental specialities, such as Oral Medicine, Oral Surgery and 
Periodontology.
To test the usefulness of the Erythema meter in a clinical trial situation and 
to pilot the study design, a clinical trial was conducted, on an open basis, among 
20 patients to examine the efficacy of itraconazole and fluconazole capsules in the 
treatment of denture stomatitis. All patients had long-standing denture stomatitis 
and were prescribed antifimgals on the basis of both a clinical and mycological 
diagnosis. It should be noted that the fluconazole and itraconazole denture 
stomatitis groups, although well matched for age, were not well sex-matched. 
There was a predominance of females, as may be expected from the epidemiology 
of this condition (Budtz-Jorgensen, 1974). However, there was no difference 
between the sexes regarding compliance with the two antifungal agents or denture 
hygiene advice.
The tri-azoles are generally well tolerated antimycotic drugs (Osterloh, 
1992; Bissell et al., 1993; Odds, 1993a; Karyotakis and Anaissie, 1994). In the 
pilot study all patients completed their prescribed course of either fluconazole or 
itraconazole capsules and no adverse side-eflfects were reported.
The reduction in erythema after treatment with fluconazole was greater 
than the reduction seen in those patients treated with itraconazole, though it
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should be noted that the erythema indices in the fluconazole group were higher to 
start with. The latter is a reflection of the small numbers in the pilot study. 
However, in both groups the median Erythema meter indices remained higher 
after antifungal treatment than the indices found in patients with clinically healthy 
palatal mucosa.
Patients who were mycologically cured or had a reduced yeast count at 
the end of their course of antifungal treatment were classed as having responded 
to treatment. Using these criteria, both itraconazole and fluconazole produced 
similar results, with nine patients in the fluconazole group and seven in the 
itraconazole group responding to their respective treatments (Table 3.6). 
Although the total mycological cure rates were low, these patients had improved 
clinically and it can be concluded that itraconazole and fluconazole do reduce 
inflammation in denture stomatitis.
Some workers have reported that although fluconazole has a relatively 
narrow spectrum of activity compared to previous azole derivatives (Odds,
1993 a), itraconazole shows a high potency against all the commonly encountered 
pathogenic Candida species (Espinol-Ingrofif e/ al., 1984; Van Cutsem et al., 
1987; Lombardi et a l , 1989; Van Cutsem, 1989; Osterloh, 1992). Other studies, 
however, have reported that neither fluconazole nor itraconazole are active 
against C. glabrata, C. krusei and Fusarium species (Odds, 1993b; Karyotakis 
and Anaissie, 1994). This may explain why, in the pilot study, when C. glabrata 
was one of the yeasts isolated at baseline it persisted, in all cases, after 
antimycotic therapy.
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One patient in the fluconazole group and three in the itraconazole group 
had increased yeast counts on completion of treatment (Table 3.6). As Candida 
glabrata was the species isolated from three out of four of these patients 
following treatment, the increased yeast count could be attributed to the reduced 
azole sensitivity of this species (Odds, 1993b; Karyotakis and Anaissie, 1994). 
However, the isolation of C. albicans in two of the patients with increased yeast 
counts is more difficult to explain. This may be the result of poor patient 
compliance either with the drug or, more likely, with denture hygiene procedures.
Of the five patients who were mycologically cured, three were colonised 
by C. albicans alone and the remaining two patients had a mixed growth of C. 
albicans and C. guillermondii in one case and C. albicans, C. parapsilosis and 
Sacch. cerevisiae in the other. C. albicans was present in samples from all 20 
patients before treatment but was not always eradicated completely by antifungal 
medication, persisting in six patients on completion of a course of fluconazole and 
four patients after treatment with itraconazole.
The pilot study ended after a review appointment which coincided with the 
completion of the two week course of antifungal therapy and no data were 
obtained to allow assessment of the rate of re-establishment of oral yeasts in this 
study population, an aspect which received attention in the main clinical trial.
The relationship between denture cleanliness and inflammation in denture 
stomatitis is well established (Walker et al., 1981). As part of the overall 
management of denture stomatitis in this pilot study, patients were advised to 
remove their dentures for sleeping and to immerse them overnight in an alkaline 
peroxide cleanser. Patients were also asked to clean their dentures regularly after
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each meal with a soft brush and soap. Although every patient followed the advice 
to remove their dentures at night, analysis of the clinical denture cleanliness scores 
relating to the amount of plaque visible on the denture fitting surfaces before and 
after treatment indicated that most patients were not complying with the 
additional advice. Furthermore, the standard of denture cleanliness was quantified 
by a microbiological assay technique devised by Blair et al. (1995). This 
confirmed the lack of improvement in denture hygiene for many of the patients 
over the two week trial period. Interestingly, two of the three patients whose 
erythema indices showed little change from one visit to the next, in spite of 
treatment with antifungal medication, had higher microbiological denture 
cleanliness scores at the second visit. The persistence of significant amounts of 
plaque on the denture fitting surfaces in many patients at the second visit may help 
to account for the higher median erythema index recorded post-treatment in this 
group compared to the median erythema index that was previously determined for 
denture wearers with healthy palatal mucosa (Cross et al., 1998).
Itraconazole and fluconazole produced similar results in the pilot study. 
Both drugs were found to reduce palatal inflammation in patients with denture 
stomatitis although they rarely resulted in a mycological cure. The hrythema 
meter proved to be a valuable means of objectively measuring changes in 
erythema of the palatal mucosa. The design of the main clinical trial was modified 
slightly as a result of the pilot study. For example, in the latter study Erythema 
meter readings were taken from two sites on either side of the palate in an attempt 
to obtain a level of redness for the whole of the palate. However, analysis of the 
preliminary results suggested that these repeated measurements offered no
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advantage and so only one site (that which appeared most inflamed on visual 
examination) was recorded with the Erythema meter in the main clinical trial. Also 
as a result of the pilot study, itraconazole appeared to be of comparable efficacy 
to fluconazole in the treatment of denture stomatitis but as it had received 
relatively little attention in relation to treatment of oral candidosis in 
immunocompetent hosts, it was felt that this drug merited further study. In 
addition, the recent introduction of the new cyclodextrin solution of itraconazole 
meant that a clinical trial of these two forms of itraconazole in the management of 
denture stomatitis would be timely. In particular, it was postulated that the new 
cyclodextrin solution of itraconazole may provide a major therapeutic advantage 
over traditional treatment of oral candidosis as it combines the effect of topical 
application to the mucosa and systemic effects after absorption (Blatchford,
1990).
A randomised single blind clinical trial was, therefore, conducted among 
40 patients to examine the efficacy of the cyclodextrin solution of itraconazole 
and itraconazole capsules in the treatment of denture stomatitis. All patients had 
long-standing denture stomatitis and were prescribed antifungals on the basis of 
both a clinical and mycological diagnosis. The two treatment groups, were well 
matched for age and sex, but as in the pilot study there was a predominance of 
females. However, as before, no difference was found between the sexes 
regarding compliance with the two antifungal agents or denture hygiene advice.
A questionnaire was used in the clinical trial to help assess patient 
compliance and the incidence of side-effects in each treatment group. Both forms 
of itraconazole were similar as regards ease of use and patient compliance. Only
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four of the 40 patients enrolled in the study, two from each treatment group, 
failed to complete the two week course of itraconazole. The two patients in the 
cyclodextrin group who failed to complete the course found they could not 
tolerate the solution, the taste of which they both described as ‘sickly’. The two 
patients excluded from the capsule group did not give any particular reason for 
failing to complete their course of medication. An important difference between 
the two forms of itraconazole was seen in the incidence of gastro-intestinal side- 
effects. Two-thirds of the patients using the cyclodextrin liquid preparation 
complained of diarrhoea, stomach cramps or nausea whilst taking the course of 
itraconazole compared to the capsule group who did not complain of any 
problems. The symptoms experienced by patients in the cyclodextrin group were 
transient and resolved on completion of the course of itraconazole. A study 
carried out for Janssen-Cilag (1996) has also reported an increased stool 
frequency, loose stools and abdominal cramps in nine of 12 volunteers taking 
200mg cyclodextrin solution twice daily for fifteen days (ie. double the dosage 
prescribed in the denture stomatitis trial). These abnormalities were not observed 
with the capsule formulation of itraconazole. P-cyclodextrin is a chemically 
modified cylinder-shaped oligosaccharide starch derivative, which when combined 
with the otherwise insoluble itraconazole molecule increases the solubility of the 
latter in aqueous media. The gastro-intestinal side-effects noted in relation to the 
liquid preparation have been attributed to an osmotic effect of high levels of 
hydroxy-propyl-P-cyclodextrin in the gut following administration of the 
cyclodextrin solution of itraconazole (Vandewoude et al., 1997). None of the 
denture stomatitis patients failed to complete their course of cyclodextrin solution
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as a result of the side-effects. However, since the response to treatment was 
similar with both preparations, the itraconazole capsules would be preferred to the 
cyclodextrin solution of itraconazole for treatment of denture stomatitis.
Denture stomatitis is generally regarded as a symptomless condition 
(Arendorf and Walker, 1987) although some studies have recorded oral 
complaints in 28% to 70% of cases (Ritchie et al., 1969; Budtz-Jorgensen and 
Bertram, 1970a; Olsen, 1975a; Dorey etal ., 1985). In this study only 22% of 
patients complained of oral symptoms at baseline. These patients complained 
either of oral dryness or a painful burning tongue. However, 64% of the patients 
who completed the clinical trial, 15 of 18 patients in the cyclodextrin group and 
eight of 18 patients in the capsule group, reported that their mouths felt better on 
completion of the course of antimycotic treatment. The higher level of subjective 
improvement reported by the cyclodextrin group is possibly related to the fact that 
this is a ‘mouthwash’ formulation which may be associated with general oral 
health and a feeling of oral cleanliness, in addition to the fact that the cyclodextrin 
solution of itraconazole has a topical as well as systemic effect.
The reduction in erythema after treatment with the cyclodextrin solution 
of itraconazole appeared greater than the reduction seen in those patients treated 
with itraconazole capsules. However, it should be noted that the erythema indices 
in the cyclodextrin group were higher to start with and when appropriate 
corrections were made to account for this, there was no statistically significant 
difference between the two preparations. This problem was encountered in the 
pilot study, where the itraconazole capsule group had greater levels of erythema 
at baseline than the fluconazole group. It seems difficult to avoid such loading in
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studies of this design where patients are recruited from various clinics and 
randomly assigned to a particular treatment group. In both groups the median 
Erythema meter indices remained higher after antifungal treatment than the 
indices found in patients with clinically healthy palatal mucosa (Cross et al.,
1998), though with time they may reduce further. The presence of residual 
erythema regardless of the preparation of itraconazole used emphasises the 
multifactorial nature of denture stomatitis (Budtz-Jorgensen, 1974).
Patients who were mycologically cured or had a reduced yeast count at 
the end of their course of antifungal treatment were classed as having responded 
to treatment. Using these criteria, both forms of itraconazole produced similar 
results, with 17 patients in the cyclodextrin itraconazole group and 18 in the 
itraconazole capsule group responding at the end of each treatment course (Table 
3 .12). Although one patient in the cyclodextrin group had no change in yeast 
count on completion of the antifungal therapy, all patients in each treatment group 
had improved clinically by this stage in the trial and it can be concluded that both 
preparations of itraconazole reduced inflammation in denture stomatitis. This is an 
obvious benefit, as more accurate impressions may then be taken of the less 
inflamed tissues, enabling the provision of new dentures, an important step in the 
long-term management of denture stomatitis. In this study, patients who received 
new dentures during the trial had a significantly greater chance (p = 0.020) of 
remaining mycologically cured six months after treatment commenced than those 
patients who continued to wear their existing dentures following the antimycotic 
therapy.
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As found in the pilot study, when C. glabrata was one of the yeasts 
isolated at baseline from either the cyclodextrin group or the itraconazole capsule 
group, it persisted, in all but two cases, after antimycotic therapy. C. krusei, 
although isolated from only one patient at baseline, was also present in that 
patient s samples at each post-treatment visit. These data reflect the relative 
resistance of these two species to itraconazole.
Eight patients in the cyclodextrin group and four in the capsule group had 
increased yeast counts at either four weeks, six months or at both four weeks and 
six months after treatment commenced. Six of these twelve patients were regular 
smokers which may have been a contributory factor (Arendorf and Walker, 1980; 
Cumming et al., 1990) or it may be the result of poor patient compliance with 
denture hygiene procedures, since five of the twelve (four of whom were non- 
smokers) had poorer levels of denture cleanliness at four weeks or six months 
after treatment commenced.
Of the 17 patients who were mycologically cured on completion of 
treatment, 12 were colonised by C.albicans alone. Two of the remaining five 
patients had a mixed growth of C. albicans and C. glabrata, two had C. albicans 
and Sacch. cerevisiae and one had C. albicans and C. guillermondii C. albicans 
was present in samples from all 40 patients before treatment but was not always 
eradicated completely by antifungal medication, persisting in five patients on 
completion of a course of cyclodextrin solution and seven patients after treatment 
with itraconazole capsules. However, although yeasts may not have been 
completely eradicated in some patients, on completion of therapy yeast counts
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were reduced in all patients except one in the cyclodextrin group, whose yeast 
count remained unchanged between baseline and the end of treatment.
Progressive recolonisation of the mucosa and the denture fitting surface by 
yeasts and the consequent recurrence of denture stomatitis after completion of 
antifungal treatment has been reported (Bergendal et al., 1979; Budtz-Jorgensen 
et al., 1983a; Bissell et al., 1993; Karyotakis and Anaissie, 1994). In the present 
study, seven patients remained mycologically cured after completing the course of 
antifungal therapy until the end of the trial. A further patient who was free of 
yeasts four weeks after treatment commenced remained so six months later. 
However, 50% of patients who had been mycologically cured at two or four 
weeks after treatment commenced were recolonised by yeasts at six months. 
Genetic typing of C. albicans strains isolated from these patients at baseline and ' 
six months after treatment has shown that, in the majority of cases, the same strain 
of C. albicans was present before treatment as at the end of the clinical trial. This 
will be discussed in more detail below.
Seventy per cent of patients followed the advice to remove their dentures 
at night. However, the clinical denture cleanliness scores showed that in many 
cases the level of denture hygiene did not improve, despite written and verbal 
instructions. The standard of denture cleanliness was quantified by an objective 
microbiological assay technique (Blair et al., 1995). These data also showed only 
a small improvement, though overall it was significantly better than at baseline. 
These findings were similar to those seen in the pilot study. This suggests that 
treatment of denture stomatitis by educating patients to improve their denture 
hygiene without adjunctive antifungal therapy is unrealistic.
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Baseline haematological investigations of the denture stomatitis patients 
revealed eight patients with iron deficiency and 12 patients with a raised blood 
sugar level. Although these haematinic abnormalities did not adversely affect the 
patients’ response to antifungal therapy, the relatively high proportion of patients 
in this study population with some underlying haematological problem highlights 
the importance of the routine screening of patients with denture stomatitis for 
such problems. For example, two patients had elevated blood glucose levels at 
baseline of 14mmol/L and 16.5mmol/L respectively. As a direct result of their 
denture stomatitis and subsequent enrolment in this clinical trial, these patients 
were diagnosed with maturity onset diabetes mellitus. Consequently, corrective 
measures were started before other more serious signs of this condition became 
apparent.
In a study by Jennings and MacDonald (1990), the density of candidal 
colonisation in denture stomatitis patients with haematological deficiencies was 
found to be lower than that found in denture stomatitis patients with normal blood 
results. Mucosal atrophy is commonly associated with iron deficiency and so 
patients with such a deficiency may be expected to have clinically obvious palatal 
inflammation with lower yeast concentrations than those with normal blood 
results. In this study the only form of haematological deficiency discovered at 
baseline was iron deficiency, affecting eight patients. Although the number of 
patients with low serum ferritin levels (ie. <25ng/ml) was small, this group of trial 
paticipants was found to have slightly lower yeast concentrations at baseline than 
those patients with normal serum ferritin levels. However, the difference in yeast 
concentration between these two groups was found not to be statistically
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significant (p -  0.19 n.s.), possibly due to the small number of patients involved. 
A similar analysis carried out on those patients with elevated blood glucose levels 
(ie. >6.0mmol/L) at baseline found this group of patients to have similar yeast 
concentrations to patients with normal blood sugar levels (p = 0.99 n.s.).
C-reactive protein measurement is a useful indicator of the presence of 
underlying inflammatory disease and the response to treatment. As a result, C- 
reactive protein levels would be expected to fall following the administration of a 
course of antifungal therapy. In this clinical trial, only nine of the 36 trial 
participants had such a response. However, 58% of the study patients had normal 
C-reactive protein levels both before and after antifungal therapy. This may 
suggest that the area of inflammation associated with denture stomatitis is too 
small to be reflected in the C-reactive protein measurement and that perhaps the 
patients who did have elevated C-reactive protein levels had some other 
underlying disease process in addition to their denture stomatitis. In fact, the 
medical histories of those patients with elevated C-reactive protein levels did 
record a range of inflammatory conditions including chronic bronchitis, ulcerative 
colitis and osteoarthrosis.
The solubility and subsequent absorption of itraconazole following oral 
administration of the capsule formulation is dependent on gastric acidity, the 
bioavailability of the itraconazole being reduced in the fasting state or under 
conditions of hypochlorhydia. One study involving healthy volunteers found the 
bioavailability of itraconazole to be significantly reduced when the gastric pH was 
increased by administration of ranitidine but also showed that this effect could be 
counteracted by the co-administration of an acidic cola beverage (Lange et al.,
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1997). In contrast to the capsules, the cyclodextrin solution of itraconazole is 
more bioavailable when taken optimally with or before food (Janssen-Cilag,
1996). To ensure optimal bioavailability of each formulation of itraconazole in this 
clinical trial, patients were requested to take the cyclodextrin solution of 
itraconazole one hour before food and the itraconazole capsules with food. 
However, it is claimed that the cyclodextrin solution of itraconazole offers 
improved solubility over itraconazole capsules resulting in improved absorption 
and enhanced bioavailability (Janssen-Cilag, 1996). To investigate this claim, 
patients from each treatment group in this clinical trial provided serum and whole 
saliva samples on completion of the 15 day course of itraconazole. Serum and 
saliva itraconazole concentrations were then measured using reversed-phase high- 
performance liquid chromatography (HPLC). No significant difference was found 
in the serum itraconazole concentrations achieved in patients from the two 
treatment groups. The reduction in palatal inflammation resulting from the 
itraconazole therapy was found to be very similar for both formulations of the 
medication. The serum itraconazole levels for those patients who were 
mycologically cured on completion of treatment were then compared to the levels 
found in those patients from whom yeasts could still be isolated. These patients 
were grouped according to their mycological response, irrespective of treatment 
group, as it was now apparent that both formulations of itraconazole had similar 
efficacy in the treatment of denture stomatitis. Some overlap was found between 
the serum itraconazole levels of the mycologically cured and non-mycologically 
cured patients in this trial. However, patients who were free of yeasts on 
completion of treatment did have slightly higher levels of serum itraconazole,
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although this proved not to be statistically significant (p = 0.28 n.s.).
Nevertheless, it is interesting to note that the majority of mycologically cured 
patients in this clinical trial had serum itraconazole levels of greater than 0.6mg/L 
whereas most of the non-mycologically cured patients had serum itraconazole 
levels of 0.5mg/L and less. In contrast to this, Cartledge et al. (1997) found 
higher serum drug concentrations and better clinical response rates with the 
cyclodextrin solution of itraconazole than with itraconazole capsules in AIDS 
patients. The bioavailability of itraconazole capsules in immunocompromised 
patient groups is variable and known to be lower than in non­
immunocompromised indivduals, largely resulting from low gastric acidity or 
chemotherapy-induced gastro-intestinal toxicity associated with patients in the 
former group (Janssen-Cilag, 1996). Cartledge et al. (1997) also suggested that a 
serum itraconazole concentration of less than l.Omg/L on day seven was 
predictive of therapeutic failure. Therapeutic success was achieved with much 
lower serum itraconazole concentrations in the denture stomatitis patients. This 
may reflect the immuno-competent status of the patients enrolled in this study or 
the multifactorial aetiology of denture stomatitis.
C. albicans species isolated from trial participants at baseline all proved to 
be sensitive to itraconazole. The MIC values (range 0.06 - 0.5mg/L) related well 
to the serum itraconazole levels discussed above.
Patients in the cyclodextrin group had significantly higher (p < 0.001) 
levels of itraconazole in their saliva, compared to patients in the itraconazole 
capsule group, the majority of whom had no itraconazole detectable in their saliva 
at all. Only two patients in the capsule group had unusually high salivary
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itraconazole levels. These results were so aberrant that they must be attributed to 
laboratory or sampling error. The detection of itraconazole in the saliva of 
patients treated with the cyclodextrin formulation suggests an additional topical 
effect of cyclodextrin which would provide an obvious advantage of this 
preparation in the treatment of oropharyngeal candidosis. However, in this study, 
despite the significantly higher salivary itraconazole concentrations achieved with 
the cyclodextrin solution of itraconazole, the advantage of a topical effect was not 
apparent as both formulations were equally effective in the management of 
denture stomatitis in terms of mycological response and reduction in erythema.
When the serum and saliva itraconazole levels of the group on the 
cyclodextrin preparation were considered, no relationship was found (p = 0.704). 
This implies that the presence of itraconazole in the saliva following 
administration of the cyclodextrin solution is due to persistence of the drug 
following direct contact with the buccal mucosa to which itraconazole adheres 
and is subsequently released (Janssen-Cilag, 1996), rather than due to systemic 
absorption followed by secretion of itraconazole into saliva. This is confirmed by 
the fact that no active metabolite has been found in saliva (Janssen-Cilag, 1996).
The association between tobacco smoking and an increased prevalence of 
denture stomatitis has been reported previously (Hand and Whitehill, 1986, 
Cumming et al., 1990). In this study the proportion of trial participants who were 
cigarette smokers was quite small (13 out of 36 patients). However, analysis of 
the results from these patients, considered as a group irrespective of their 
treatment formulation, revealed some interesting facts. For example, at baseline, 
the smokers had lower levels of erythema than the non-smokers. This could be
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due to the vasoconstrictive action of nicotine affecting the blood vessels of the 
palatal mucosa and resulting in lower levels of palatal erythema. However, 
perhaps because of the small numbers, these differences in erythema at baseline 
and the differences in mean reductions in erythema at subsequent visits of smokers 
versus non-smokers did not prove to be statistically significant.
Smoking is known to be a major risk factor for periodontal disease 
(Haber, 1994) and would appear to have an adverse effect on the outcome of 
periodontal treatment (Preber and Bergstrom, 1985; Preber and Bergstrom,
1990). Interestingly, the results from this clinical trial, although not fully 
conclusive, suggest that denture stomatitis patients in this study who were 
cigarette smokers had less chance of a long-term mycological cure than their non­
smoking counterparts. Thus part of the overall management of Candida- 
associated denture stomatitis, as in periodontal disease, must include counselling 
for those patients who smoke in order to help them to stop.
One of the aims of this study was to determine, by molecular typing of C  
albicans species isolated before and after treatment, whether there had been a 
recurrence of infection with the same strain, selection of particular strains or 
infection with new strains of C. albicans. In the past it was difficult to answer this 
type of question as strain comparisons were based on phenotypes rather than 
genotypes, with the assumption that the underlying genetic differences that 
produced the phenotypic changes were the same in different isolates (Scherer and 
Stevens, 1988).The advent of recombinant DNA technology has meant that 
genetic assessments of strain relatedness are now possible, overcoming the risk of 
grouping together genetically unrelated strains with similar phenotypes and
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separating related strains with different phenotypes. One of the most effective of 
these techniques has been Southern blot hybridization with DNA probes 
containing moderately repetitive sequences (Hellstein et al., 1993). The C. 
albicans middle repetitive 27A sequence was chosen as this has been shown to be 
a very sensitive method of analysing restriction digested DNA samples (Magee et 
al., 1992). EcoRl was chosen as the enzyme for the digestion of the DNA as this 
has been suggested as the enzyme of choice for the 27A probe (Magee et al., 
1992; Anthony et al., 1995).
For every patient enrolled in the trial, at least five yeast isolates per visit 
had been stored at -70°C for further investigation. Although C. albicans was not 
the only species isolated from this study population it is considered to be the main 
pathogen in oral candidosis and, as corresponding species-specific repeat 
sequence probes have not been developed for other Candida species (Sullivan et 
al., 1993), it was decided to concentrate only on C. albicans for the molecular 
investigations. In this study there were 18 patients from whom C. albicans was 
isolated six months after treatment commenced as well as at baseline. Two 
isolates from each patient, one collected at baseline and one six months after 
treatment commenced, were removed from storage. Although some studies have 
found that the majority of C. albicans isolates from different sites within the same 
oral cavity have been found to belong to the same genetic group (Mathaba et al., 
1995), other studies have reported that some patients may carry more than one 
strain of C. albicans (Anthony et al., 1995). In this study, as far as possible, the 
isolate collected six months after treatment commenced was from the same intra­
oral site as the baseline isolate with which it was to be compared. This was to
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overcome the chance of sampling error’ which may have given the impression 
that a different strain was present at the six month review than at baseline, when 
actually multiple strains may have been present at different intra-oral sites for 
much of the time.
The genetic typing of C. albicans isolates proved to be a very time- 
consuming procedure. From the extraction of DNA to the end stage of detection 
of the 27 A probe at least seven days would be required to complete ten samples. 
If a sufficient yield of DNA were not obtained in the first instance, this would lead 
to poor digestion and incomplete or uninterpretable hybridizations. The labelled 
27A probe was stored at -20°C and could be re-used confidently up to six times, 
after which the signals became very faint and difficult to interpret. Even when 
optimal conditions had been achieved and the method followed to the letter, there 
was no guarantee that every sample would hybridize to the same degree.
Examples of poor hybridizations can be seen in lane two of figure 3.22 and lane 
seven of figure 3.23.
In this study, 13 different strains of C. albicans were isolated from the 18 
patients. This genetic diversity is similar to that found in other studies of C. 
albicans strains isolated from the oral cavities of non-immunocompromised 
individuals (Hellstein et al., 1993; Mathaba et al., 1995). For each volunteer with 
a mycological relapse, the strain of C. albicans isolated six months after 
itraconazole treatment commenced was considered to be genetically the same as 
the original strain isolated at baseline. In the study by Mathaba et al. (1995) the C. 
albicans strains isolated from the dentures during the primary infection were the 
same as those isolated during the secondary infection, following a course of
189
antifungal therapy, in nine out of 11 patients. This implies that the presence of C. 
albicans in these patients is typically due to a recolonisation of the original 
infecting strain rather than re-infection with a different strain. The primary 
reservoir of Candida species in healthy individuals is generally considered to be 
the gastro-intestinal tract (MacFarlane, 1990). Consequently, the patient’s denture 
must be considered a potential source of re-infection, a view shared by other 
authors (Budtz-Jorgensen and Bertram, 1970b; Nairn, 1975; Bissell et al., 1993). 
This further supports the conclusion that the provision of new dentures is an 
important factor in the long- term resolution of denture stomatitis.
The variety of genotypes identified in this study, as in the study by 
Mathaba et al (1995), suggests that no one particular virulent strain of C. 
albicans is associated with denture stomatitis. However, it would be interesting to 
compare the genotypes of C. albicans isolates from denture wearers with healthy 
palatal mucosa and those from denture wearers with denture stomatitis, in an 
attempt to determine whether commensal strains of C. albicans are capable of 
causing an infection or whether, in the transition from a healthy to an infected 
mouth, there is strain substitution.
Itraconazole is clearly a very effective drug for use in the treatment of 
denture stomatitis. Both the new cyclodextrin solution of itraconazole and 
itraconazole capsules produced similar reductions in palatal erythema and yeast 
colonisation in this clinical study. However, the high incidence of gastro-intestinal 
complications with the cyclodextrin solution of itraconazole and its significantly 
higher cost compared to the capsule formulation, suggest that the latter is more 
appropriate for management of denture stomatitis.
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Conclusions.
The following conclusions have been drawn from the results of this study:
1. The Erythema meter is a useful instrument for measuring oral mucosal 
erythema in a clinical trial situation. It is quick and easy to use and is well 
tolerated by patients.
2. Fluconazole and itraconazole capsules have similar efficacy in the treatment of 
denture stomatitis. Both antifungal agents reduced palatal erythema but rarely 
resulted in a mycological cure. Neither drug is associated with any serious side- 
effect.
3. Itraconazole capsules and the cyclodextrin solution of itraconazole have similar 
efficacy in the treatment of denture stomatitis. However, the high incidence of 
gastro-intestinal side-eflfects associated with the cyclodextrin formulation of 
itraconazole contra-indicates its use in the management of out-patient oral 
candidosis. The high cost of the cyclodextrin formulation, at twice the cost of 
itraconazole capsules, further limits its use in the management of this condition.
4. The establishment and maintenance of good denture hygiene habits, including 
the removal of dentures for sleeping, are important in the long-term resolution of 
denture stomatitis. However, despite careful instruction, not all patients achieve
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acceptable levels of denture hygiene and so denture hygiene advice alone is not an 
acceptable means of managing denture stomatitis.
5. Cigarette smoking may reduce the chance of patients with denture stomatitis 
achieving a long-term mycological cure following itraconazole therapy.
6. Denture stomatitis may be an early indication of some underlying haematinic 
deficiency or elevated blood glucose level. All patients presenting with denture 
stomatitis should be routinely screened haematologically and biochemically.
7. The patient’s denture must be considered a potential source of re-colonisation. 
As a result, the provision of new complete dentures soon after completion of a 
course of antifungal therapy greatly improves the chance of a long-term 
mycological cure and resolution of the condition.
8. The strain of C  albicans isolated from denture stomatitis patients six months 
after antifungal therapy commenced is likely to be the same as the original strain 
isolated at baseline. This implies that a recurrence of denture stomatitis is due to a 
re-colonisation by the original infecting strain, rather than re-infection with a
different strain.
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9. To obtain long-term clinical success in the treatment of Candida-2iSsoc\2LtQ<\ 
denture stomatitis the multifactorial aetiology of denture stomatitis must be borne 
in mind. As a result, the management of Candida-associated denture stomatitis 
should include:
i) Routine haematological and biochemical screening.
ii) Itraconazole capsules - lOOmg twice daily for 15 days, taken with food.
iii) Comprehensive denture hygiene instructions, provided in a written form.
The importance of following this advice in relation to treatment success 
should be stressed.
iv) Denture stomatitis patients who smoke should be strongly advised to give 
up the habit. The reduced chances of successful treatment for those who 
continue to smoke should be emphasised.
v) Once the health of the palatal mucosa has been restored, impressions 
should be taken for the provision of new complete dentures.
vi) Patients should be reviewed regularly to screen for any evidence of relapse 
and to encourage the maintenance of good denture hygiene habits.
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APPENDIX I 
Patient Consent Form
GLASGOW DENTAL HOSPITAL AND SCHOOL 
PATIENT INFORMATION SHEET
A COMPARATIVE TRIAL OF ITRACONAZOLE TABLETS (SPORANOX) WITH A 
MOUTHWASH FORM OF ITRACONAZOLE (CYCLODEXTRIN) FOR TREATMENT OF 
DENTURE STOMATITIS.
I .......................................  Of
freely and voluntarily agree to participate in a clinical research study entitled "A 
comparative trial of itraconazole tablets (Sporanox) with a mouthwash form of 
itraconazole (cyclodextrin) for treatment of denture stomatitis".
I have read the accompanying information sheet. The nature and purpose of the
study have been explained to me by ................................................ I have had the
opportunity to ask questions and I understand fully what is proposed.
I recognise that I may receive no benefit from the study. I accept that there may 
be other risks associated with the procedure which are not directly attributed to 
negligence on the part of those undertaking the procedure.
I understand that I am free to withdraw my consent at any time without prejudice 
to me or my dental care.
I have been assured that any information obtained from me will not be disclosed 
without my permission to any other party in any manner which will reveal my 
identity.
Signature ................................................................................................................
Date ................................................................................................................
I confirm that I, ...............................................................   have explained the
nature and purpose of the clinical research study and the procedure in respect of 
which consent has been given by the above named.
Signature ................................................................................................................
Date
APPENDIX II 
Patient Details Forms
CYCLODEXTRIN TRIAL.
Screening Visit.
PATIENT DETAILS
Name Hospital Number
D O B
Medical History relevant / not relevant
(see medical history sheet)
Smoker / Non-smoker
CLINICAL EXAMINATION.
Dentures Age
Fit
Oral Mucosa
Removed for sleeping 
Denture Stomatitis
Microbiology
Y / N
Localised | |
Diffuse | |
Hyperplastic
granular
Swab a) palate
b)tongue
□
Signature Date
Enrol Y / N
CYCLODEXTRIN TRIAL.
Visit 1 - Enrolment.
PATIENT DETAILS
Name____________________ _ Hospital Number
D O B ______________  Study Number
CLINICAL EXAMINATION.
Denture Cleanliness Score (clinical) ___________
Palatal Mucosa i) Visual Examination (circle)
0 No inflammation (pink and healthy)
1 Slight inflammation (pinkish-red)
2 Moderate inflammation (red)
3 Severe inflammation (florid redness)
Erythema Meter Reading
1. 2. 3.
HAEMATOLOGY & BLOOD CHEMISTRY
FBC Serum Fe Serum Folate V itB12 Random glc Us&Es LFTs CRP
□ □ □ □ □
IMMUNOLOGY
lOmls Whole Saliva □
lOmls Venous Blood | |
MICROBIOLOGY
i) Imprint Culture a) Palate
ii) Oral Rinse□
Signature
b) Tongue c) Denture
iii) Denture Disc□
Date
PATIENT DETAILS
Nam e_________
D O B .
CYCLODEXTRIN TRIAL.
Visit 2 - Completion of Course of Antifungals .
Hospital Number 
Study Number
Date and Time of Last Dose of Antifungals
CLINICAL EXAMINATION.
Denture Cleanliness Score (clinical)
Palatal Mucosa
HAEMATOLOGY
ii)
Visual Examination (circle)
0 No inflammation
1 Slight inflammation
2 Moderate inflammation
3 Severe inflammation 
Erythema Meter Reading
1. 2 .
(pink and healthy) 
(pinkish-red)
(red)
(florid redness)
 & BLOOD CHEMISTRY
FBC Us&Es LFTs C-reactive protein
□ □ □
IMMUNOLOGY
lOmls Whole Saliva 
lOmls Venous Blood | |
MICROBIOLOGY
i) Imprint Culture a) Palate
ii) Oral Rinse□
Signature______ __________
DRUG LEVELS
Saliva 
Serum
Time ________
b) Tongue c) Denture
iii) Denture Disc□
Date ___
□
□
CYCLODEXTRIN TRIAL.
Visit 3 - Four Weeks After Antifungal Treatment Commenced .
PATIENT DETAILS
Name
D O B .
Hospital Number 
Study Number
CLINICAL EXAMINATION.
Denture Cleanliness Score (clinical)______ ___________
Palatal Mucosa i) Visual Examination (circle)
0 No inflammation
1 Slight inflammation
2 Moderate inflammation
3 Severe inflammation
ii) Erythema Meter Reading
1 . 2 .
IMMUNOLOGY
1 Omls Whole Saliva □
lOmls Venous Blood | |
MICROBIOLOGY
i) Imprint Culture a) Palate
ii) Oral Rinse□
(pink and healthy) 
(pinkish-red)
(red)
(florid redness)
b) Tongue c) Denture
iii) Denture Disc□
Signature Date
CYCLODEXTRIN TRIAL.
Visit 4 - Six Months After Antifungal Treatment Commenced
PATIENT DETAILS
Name
D O B
Hospital Number 
Study Number
CLINICAL EXAMINATION.
Denture Cleanliness Score (clinical) ___________
Palatal Mucosa i) Visual Examination (circle)
0 No inflammation
healthy)
redness)
1 Slight inflammation
2 Moderate inflammation
3 Severe inflammation
ii) Erythema Meter Reading
1. 2 .
HAEMATOLOGY & BLOOD CHEMISTRY
FBC Serum Fe Serum Folate V itB12 Random glc
i □ □ □ □
IMMUNOLOG Y
lOmls Whole □  Saliva
lOmls Venous | | Blood
MICROBIOLOGY
i) Imprint Culture a) Palate b) Tongue
(pink and
(pinkish-red)
(red)
(florid
c) Denture
ii) Oral Rinse □
Signature___
iii) Denture Disc □
Date
APPENDIX III 
Patient Information Sheets
A C o m p a r a t iv e  T r i a l  Of I t r a c o n a z o l e  T a b l e t s  ( S p o r a n o x )  W i t h  A 
M o u t h w a s h  F o r m  Of I t r a c o n a z o l e  ( C y c l o d e x t r i n )  F o r  T r e a t m e n t  Of
D e n t u r e  St o m a t it is .
You have been given two boxes of the Itraconazole tablets (Sporanox). This course 
will last two weeks.
Please take two tablets daily - the first should be taken just after breakfast
and the second just after your evening meal.
It is important to complete the course.
If you require further advice please contact Dr. J. Bagg on (0141) 211 9741 (daytime) 
or(0141)357 5802 (evenings).
Thank you for your help in this study.
A C o m p a r a t iv e  T r i a l  Of I t r a c o n a z o l e  T a b l e t s  ( S p o r a n o x )  W i t h  A 
M o u t h w a s h  F o r m  Of I t r a c o n a z o l e  ( C y c l o d e x t r i n )  F o r  T r e a t m e n t  Of
D e n t u r e  St o m a t it is .
You have been given two bottles of the mouthwash form of itraconazole 
(Cyclodextrin). This course will last two weeks.
Please take lOmls of this liquid twice daily on an empty stomach - take the first 
dose approximately 1 hour before breakfast and the second approximately 1 
hour before your evening meal.
Please remove your dentures before taking the medicine and swish it around 
your mouth before swallowing it.
It is important to complete the course.
If you require further advice please contact Dr. J. Bagg on (0141) 211 9741 (daytime) 
o r (0141) 357 5802 (evening).
Thank you for your help in this study.
GLASGOW DENTAL HOSPITAL AND SCHOOL 
PATIENT INFORMATION SHEET
A COMPARATIVE TRIAL OF ITRACONAZOLE TABLETS (SPORANOX) WITH A 
MOUTHWASH FORM OF ITRACONAZOLE (CYCLODEXTRIN) FOR TREATMENT OF 
DENTURE STOMATITIS.
C a r e  o f  y o u r  d e n t u r e s .
Your dentures may accumulate food debris, stain and tartar so keeping them clean 
is important.
You should clean them regularly after each meal using a SOFT BRUSH and 
SOAP
Your dentures should be IMMERSED overnight in LUKE-WARM WATER 
containing a tablet (or powder) of an alkaline peroxide denture cleanser such as 
Milton or Steradent.
Do NOT WEAR YOUR DENTURES OVERNIGHT.
APPENDIX IV 
Questionnaire
GLASGOW DENTAL HOSPITAL AND SCHOOL 
QUESTIONNAIRE
A COMPARATIVE TRIAL OF ITRACONAZOLE TABLETS (SPORANOX) WITH A 
MOUTHWASH FORM OF ITRACONAZOLE (CYCLODEXTRIN) FOR TREATMENT OF 
DENTURE STOMATITIS.
N a m e ______________ St u d y  N u m b e r
1. Which form of itraconazole did you take? tablets / mouthwash
(please circle)
2. Did you complete the course? Yes / No
(please circle)
3. Did you find the time of day you were asked to take the medicine convenient?
Yes / No
(please circle)
If inconvenient, please state why.
4. Was your medicine pleasant to take? Not at all / Quite / Very
(please circle)
If unpleasant, please state why.
5. Did you suffer any of the following side-effects whilst taking the medicine?
stomach cramps Yes / No
diarrhoea Yes / No
sickness Yes / No
other problems_____________________
6. Did your mouth feel better after taking the medicine? No / Same / Yes
(please circle)
Thank you very much for your help in this study.
APPENDIX V 
Buffers, Solutions and Media
Buffers, Solutions and Media
Denaturation Solution 1000ml
5M NaOH 100ml
5M NaCl 300ml
Autoclaved Distilled Water 600ml
Neutralisation Solution 1000ml
lM TrisHCl 500ml
Na Cl (solid) 175.4g
Autoclaved Distilled Water to make up to 1000ml
Buffer 1
NaCl 150mmol/l
Maleic acid 100mmol/l, pH 7.5
Adjusted with solid or concentrated NaOH 
Autoclaved
Blocking Reagent
Blocking Reagent is dissolved in buffer 1 to a final concentration of 10% (w/v) 
with shaking and heating in a microwave oven. The blocking Reagent must be 
heated while it dissolves in the maleic acid buffer (buffer 1). Boiling will cause the 
reagent to coagulate, so care should be taken to avoid boiling.
Autoclave.
Store at room temperature, +4°C or - 20 °C.
Buffer 2
Blocking Reagent stock solution diluted 1:10 in buffer 1 
(final concentration = 1% blocking reagent)
Buffer 3
Tris-HCl
NaCl
MgCl2
TE Buffer
Tris HC1 
EDTA
100mmol/l 
100mmol/l 
50mmol/l
10mmol/l 
1 mmol/1
10 x TBE Stock Solution
Tris Base 
Boric Acid 
EDTA
108g
55g
7.46g
Made up to 1 litre with autoclaved distilled water
20 x SSC
3M NaCl
300mM Sodium citrate
350.4g 
176.5g
Autoclaved Distilled Water to make up to 2000ml 
Standard Hybridization Buffer
5 x SSC
0.1% sodium-lauroylsarcosine
0.02% SDS
1% Blocking Reagent from 1% blocking reagent stock solution 
Stringency Washes
I 2 x SSC 
0.1% SDS
II 0.1 x SSC 
0.1% SDS
Colour Substrate Solution
45 pi NBT solution and 3 5 pi X-Phosphate in 10ml Buffer 3. 
Use directly.
1% Agarose Gel
Agarose 2g
1 x TBE 200ml
Ethidium Bromide 35pl
CHROMagar* Candida
Peptone 10.0g/l
Special chromogenic mix 22.0g/l 
Chloramphenicol 0.5g/l
Agar 15. 0g/l
MOPS Buffer
MOPS 34.53g
Glucose 20.00g
Dissolved in 1 litre distilled water 
pH adjusted to 7.0
RPMI
RPMI powder 1 bottle
MOPS buffer 1 litre
Itraconazole Stock Solution
Itraconazole powder 1 Omg
DMSO 1ml
RPMI 9ml
Heat to 60°C to dissolve
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